[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Medicina Uk Ltd\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":271},{"warningLetters":4,"total":270},[5,33,56,74,94,111,128,142,162,185,209,228,249],{"id":6,"raw":7,"subject":12,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":28,"issuing_office":11,"recipient_name":29,"body_fetched_at":30,"delivery_method":31,"recipient_title":20,"reference_number":20,"action_taken_date":32,"medical_device_id":20,"response_letter_date":20},2483,[8,9,10,11,12,13,14,13],"\u003Ctime datetime=\"2022-08-30T13:20:00Z\">08\u002F30\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-03T04:00:00Z\">08\u002F03\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fusa-medical-llc-631500-08032022\">USA Medical LLC\u003C\u002Fa>","Center for Devices and Radiological Health","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device","","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fusa-medical-llc-631500-02062023\">\u003Ctime datetime=\"2023-02-09T05:00:00Z\">02\u002F09\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Damon H. Roberts\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FOwner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>USA Medical LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1220 Texan Trail, Suite 205\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Grapevine\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>76051-4164\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:damon@USAMedicalllc.com\"> damon@USAMedicalllc.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 631500\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 3, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Roberts:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at USA Medical LLC (USA Medical), located at 1220 Texan Trail, Suite 205, Grapevine, TX from February 28 through March 15, 2022. During the inspection, FDA investigators determined that your firm is a medical device manufacturer and distributor of SARS-CoV-2 Antigen Rapid Test kits distributed under the names SARS-COV-2 Antigen Rapid Test, \u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID-19 Ag Rapid Test\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> (hereafter, collectively referred to as “COVID-19 Tests”). Based on our review, your COVID-19 Tests are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that the COVID-19 Tests have been distributed in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, these products are adulterated within the meaning of section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>Your products are also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because labeling distributed with these products included statements that the products are authorized for use under an Emergency Use Authorization (EUA). These statements create a false impression that your products have been approved or authorized for emergency use by FDA and are misleading. As discussed above, none of your COVID-19 Test Kits have been approved, cleared, or authorized for emergency use by FDA.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed products that are intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent the distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fa>. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that these COVID-19 Tests are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, in manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We note that you have not responded to the Form FDA 483, List of Inspectional Observations issued to your firm initially on March 15, 2022, and, again in annotated form, on March 17, 2022. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish procedures for acceptance activities, as required by 21 CFR § 820.80(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm distributed at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> SARS-CoV-2 Antigen Rapid Test kits from 9\u002F30\u002F2021 – 2\u002F24\u002F2022 without establishing procedures for incoming product and finished device acceptance activities to ensure the device(s) conform to specified requirements and meet acceptance criteria, and acceptance records are maintained.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR § 820.90(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures to ensure that nonconforming product is identified, documented, evaluated, segregated, and dispositioned. As you repackage and relabel tests and you do not have an authorized Emergency Use Authorization for those products, you do not have procedures regarding these nonconforming products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR § 820.160(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established and maintained procedures for the control and distribution of your SARS-CoV-2 Antigen Rapid Qualitative Test system to ensure only devices approved for release are distributed, and that purchase orders are reviewed to ensure that ambiguities and errors are resolved before devices are released for distribution. You distributed more than \u003Cstrong>(b)(4)\u003C\u002Fstrong> test kits from 9\u002F30\u002F2021 - 2\u002F24\u002F2022 to customers in the United States and did not review and approve the products prior to release\u002Fdistribution.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR § 820.50.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for evaluation of suppliers, including the quality requirements that must be met by suppliers, to ensure that received products and services conform to specified requirements. The firm did not evaluate the manufacturers of the SARS-CoV-2 Antigen Rapid Test kits based on their ability to meet specified requirements, including quality requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to establish procedures for corrective and preventative action, as required by 21 CFR § 820.100(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for implementing and documenting corrective and preventive action, including requirements for: 1) analyzing quality data sources; 2) investigating the cause of nonconformities; 3) identifying the actions needed to prevent occurrence or recurrence of nonconformities; 4) ensuring actions implemented are effective; 5) documenting changes in methods and procedures; 6) disseminating information related to quality problems to appropriate individuals; and 7) submitting relevant information on quality problems for management review.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR § 820.198(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for complaint handling and documentation to ensure that complaints are: 1) processed in a uniform and timely manner, 2) oral complaints are documented upon receipt, 3) complaints are evaluated to determine if the reported event is required to be submitted to the FDA as a Medical Device Report.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to establish procedures to control environmental conditions as required by 21 CFR § 820.70(c).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures to control environmental conditions to ensure that the SARS-CoV-2 Antigen Rapid Test products (raw materials and finished devices) are stored within the required temperature range(s) and monitored to ensure that any deviations are noted and addressed. Your firm was found to be storing test kits in its loading dock and administrative areas without procedures\u002Frequirements\u002Fmonitoring. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> kit has defined storage requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8. Failure to establish and maintain adequate procedures to ensure that mix-ups, damage, deterioration, contamination, or other adverse effects to product do not occur during handling as required by 21 CFR § 820.140.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, \u003Cstrong>(b)(4)\u003C\u002Fstrong> boxes containing \u003Cstrong>(b)(4)\u003C\u002Fstrong> Diagnostic Kit SARS-CoV-2 Antigen Rapid Test kits (no batch\u002Flot number identification) of products returned on 2\u002F16\u002F2022 in the common administrative area were observed that had not been identified, documented, or segregated as returned product.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>9. Failure to establish procedures for quality audits as required by 21 CFR § 820.22.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for quality audits to ensure that the quality system complies with the quality system requirements and to determine the effectiveness of the quality system. Quality audits have not been performed since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>10. Failure to establish procedures for management review as required by 21 CFR § 820.20(c).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for management review of the suitability and effectiveness of the quality system. Management reviews have not been conducted since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>11. Failure to establish procedures for training and identifying training needs as required by 21 CFR § 820.25(b).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established training procedures to identify training needs and to ensure that all personnel are trained to adequately perform their responsibilities. Training records are not maintained.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>12. Failure to establish a policy, and objectives for, and commitment to, quality as required by 21 CFR § 820.20(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your Management with executive responsibility has not established it policy and objectives for, and commitment to, quality.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your COVID-19 Tests are misbranded under Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Failure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations. Other federal agencies may take your compliance history into account when considering the award of contracts. Should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices such devices will not be approved until the violations have been corrected. Should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-%20fdas-decision-not-issue-certain-export-certificates-devices\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-fdas-decision-not-issue-certain-export-certificates-devices\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Note, there are two response time frames specified. You should take immediate action to address any violations relating to your firm’s sale or distribution of the COVID-19 Test Kits and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>Please also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter related to Quality Systems and MDR reporting. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\u003C\u002Fp>\n\n\u003Cp>This response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at oradevices3firmresponse@fda.hhs.gov. Please identify your response with CMS Case # 631500.\u003C\u002Fp>\n\n\u003Cp>If you have questions about the contents of this letter, please contact Compliance Officer Raymond W. Brullo at 949-608-2918, or via email at raymond.brullo@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to correct any violations and bring your products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nTimothy T. Stenzel, M.D., Ph.D. Director\u003Cbr>\nOHT7: Office of In Vitro Diagnostics\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 3\u003Cbr>\nOffice of Regulatory Affairs\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The “\u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID‐19 Ag Rapid Test” distributed by your firm appears to be the \u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID‐19 Ag Rapid Test manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. On \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FDA reissued an Emergency Use Authorization (EUA) pursuant to section 564 of the Act, 21 U.S.C § 360bbb‐3, to permit emergency use of \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>COVID‐19 Ag Rapid Test. The test is indicated for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, that meet the requirements to perform high complexity, moderate complexity, or waived tests and in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. However, the EUA does not authorize the distribution of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID‐19 Rapid Test for use outside of these specified settings.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID‐19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID‐19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential%E2%80%90actions\u002Fproclamation%E2%80%90declaring%E2%80%90national%E2%80%90%20emergency-concerning%E2%80%90novel%E2%80%90coronavirus%E2%80%90disease%E2%80%90covid%E2%80%9019%E2%80%90outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential‐actions\u002Fproclamation‐declaring‐national‐ emergency-concerning‐novel‐coronavirus‐disease‐covid‐19‐outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Accessible at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nDamon H. Roberts\n\nRecipient Title\n\nPresident\u002FOwner\n\nUSA Medical LLC\n\n1220 Texan Trail, Suite 205\n\nGrapevine, TX 76051-4164\n\nUnited States\n\ndamon@USAMedicalllc.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS # 631500\n\nAugust 3, 2022\n\nDear Mr. Roberts:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at USA Medical LLC (USA Medical), located at 1220 Texan Trail, Suite 205, Grapevine, TX from February 28 through March 15, 2022. During the inspection, FDA investigators determined that your firm is a medical device manufacturer and distributor of SARS-CoV-2 Antigen Rapid Test kits distributed under the names SARS-COV-2 Antigen Rapid Test, (b)(4) COVID-19 Ag Rapid Test1 (hereafter, collectively referred to as “COVID-19 Tests”). Based on our review, your COVID-19 Tests are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-192 in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nOur inspection revealed that the COVID-19 Tests have been distributed in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, these products are adulterated within the meaning of section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nYour products are also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because labeling distributed with these products included statements that the products are authorized for use under an Emergency Use Authorization (EUA). These statements create a false impression that your products have been approved or authorized for emergency use by FDA and are misleading. As discussed above, none of your COVID-19 Test Kits have been approved, cleared, or authorized for emergency use by FDA.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.3 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.4 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed products that are intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent the distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”5 provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\n\nOur inspection also revealed that these COVID-19 Tests are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, in manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We note that you have not responded to the Form FDA 483, List of Inspectional Observations issued to your firm initially on March 15, 2022, and, again in annotated form, on March 17, 2022. These violations include, but are not limited to, the following:\n\n1. Failure to establish procedures for acceptance activities, as required by 21 CFR § 820.80(a).\n\nSpecifically, your firm distributed at least (b)(4) SARS-CoV-2 Antigen Rapid Test kits from 9\u002F30\u002F2021 – 2\u002F24\u002F2022 without establishing procedures for incoming product and finished device acceptance activities to ensure the device(s) conform to specified requirements and meet acceptance criteria, and acceptance records are maintained.\n\n2. Failure to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR § 820.90(a).\n\nSpecifically, your firm has not established procedures to ensure that nonconforming product is identified, documented, evaluated, segregated, and dispositioned. As you repackage and relabel tests and you do not have an authorized Emergency Use Authorization for those products, you do not have procedures regarding these nonconforming products.\n\n3. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR § 820.160(a).\n\nSpecifically, your firm has not established and maintained procedures for the control and distribution of your SARS-CoV-2 Antigen Rapid Qualitative Test system to ensure only devices approved for release are distributed, and that purchase orders are reviewed to ensure that ambiguities and errors are resolved before devices are released for distribution. You distributed more than (b)(4) test kits from 9\u002F30\u002F2021 - 2\u002F24\u002F2022 to customers in the United States and did not review and approve the products prior to release\u002Fdistribution.\n\n4. Failure to establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR § 820.50.\n\nSpecifically, your firm has not established procedures for evaluation of suppliers, including the quality requirements that must be met by suppliers, to ensure that received products and services conform to specified requirements. The firm did not evaluate the manufacturers of the SARS-CoV-2 Antigen Rapid Test kits based on their ability to meet specified requirements, including quality requirements.\n\n5. Failure to establish procedures for corrective and preventative action, as required by 21 CFR § 820.100(a).\n\nSpecifically, your firm has not established procedures for implementing and documenting corrective and preventive action, including requirements for: 1) analyzing quality data sources; 2) investigating the cause of nonconformities; 3) identifying the actions needed to prevent occurrence or recurrence of nonconformities; 4) ensuring actions implemented are effective; 5) documenting changes in methods and procedures; 6) disseminating information related to quality problems to appropriate individuals; and 7) submitting relevant information on quality problems for management review.\n\n6. Failure to establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR § 820.198(a).\n\nSpecifically, your firm has not established procedures for complaint handling and documentation to ensure that complaints are: 1) processed in a uniform and timely manner, 2) oral complaints are documented upon receipt, 3) complaints are evaluated to determine if the reported event is required to be submitted to the FDA as a Medical Device Report.\n\n7. Failure to establish procedures to control environmental conditions as required by 21 CFR § 820.70(c).\n\nSpecifically, your firm has not established procedures to control environmental conditions to ensure that the SARS-CoV-2 Antigen Rapid Test products (raw materials and finished devices) are stored within the required temperature range(s) and monitored to ensure that any deviations are noted and addressed. Your firm was found to be storing test kits in its loading dock and administrative areas without procedures\u002Frequirements\u002Fmonitoring. The (b)(4) kit has defined storage requirements.\n\n8. Failure to establish and maintain adequate procedures to ensure that mix-ups, damage, deterioration, contamination, or other adverse effects to product do not occur during handling as required by 21 CFR § 820.140.\n\nSpecifically, (b)(4) boxes containing (b)(4) Diagnostic Kit SARS-CoV-2 Antigen Rapid Test kits (no batch\u002Flot number identification) of products returned on 2\u002F16\u002F2022 in the common administrative area were observed that had not been identified, documented, or segregated as returned product.\n\n9. Failure to establish procedures for quality audits as required by 21 CFR § 820.22.\n\nSpecifically, your firm has not established procedures for quality audits to ensure that the quality system complies with the quality system requirements and to determine the effectiveness of the quality system. Quality audits have not been performed since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\n\n10. Failure to establish procedures for management review as required by 21 CFR § 820.20(c).\n\nSpecifically, your firm has not established procedures for management review of the suitability and effectiveness of the quality system. Management reviews have not been conducted since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\n\n11. Failure to establish procedures for training and identifying training needs as required by 21 CFR § 820.25(b).\n\nSpecifically, your firm has not established training procedures to identify training needs and to ensure that all personnel are trained to adequately perform their responsibilities. Training records are not maintained.\n\n12. Failure to establish a policy, and objectives for, and commitment to, quality as required by 21 CFR § 820.20(a).\n\nSpecifically, your Management with executive responsibility has not established it policy and objectives for, and commitment to, quality.\n\nOur inspection also revealed that your COVID-19 Tests are misbranded under Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting.\n\nFailure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\n\nSpecifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements.\n\nYour firm should take prompt action to address any violations. Other federal agencies may take your compliance history into account when considering the award of contracts. Should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices such devices will not be approved until the violations have been corrected. Should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-fdas-decision-not-issue-certain-export-certificates-devices.\n\nNote, there are two response time frames specified. You should take immediate action to address any violations relating to your firm’s sale or distribution of the COVID-19 Test Kits and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\n\nFDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nPlease also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter related to Quality Systems and MDR reporting. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\n\nThis response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at oradevices3firmresponse@fda.hhs.gov. Please identify your response with CMS Case # 631500.\n\nIf you have questions about the contents of this letter, please contact Compliance Officer Raymond W. Brullo at 949-608-2918, or via email at raymond.brullo@fda.hhs.gov\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to correct any violations and bring your products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, M.D., Ph.D. Director\n\nOHT7: Office of In Vitro Diagnostics\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 3\n\nOffice of Regulatory Affairs\n\n___________________________\n\n1 The “(b)(4) COVID‐19 Ag Rapid Test” distributed by your firm appears to be the (b)(4) COVID‐19 Ag Rapid Test manufactured by (b)(4). On (b)(4), FDA reissued an Emergency Use Authorization (EUA) pursuant to section 564 of the Act, 21 U.S.C § 360bbb‐3, to permit emergency use of (b)(4) COVID‐19 Ag Rapid Test. The test is indicated for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, that meet the requirements to perform high complexity, moderate complexity, or waived tests and in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. However, the EUA does not authorize the distribution of the (b)(4) COVID‐19 Rapid Test for use outside of these specified settings.\n\n2 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID‐19).\n\n3 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n4 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID‐19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential‐actions\u002Fproclamation‐declaring‐national‐ emergency-concerning‐novel‐coronavirus‐disease‐covid‐19‐outbreak\u002F.\n\n5 Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload.","USA Medical LLC","usa-medical-llc-631500-08032022","2026-08-18T06:42:29.145918+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fusa-medical-llc-631500-08032022","2026-10-26T08:10:18.402099+00:00","Warning Letter","Closed Out","2022-08-30","631500","Medical Devices","2023-02-09","Damon H. Roberts","2026-08-20T01:37:57.067+00:00","VIA Electronic Mail","2022-08-03",{"id":34,"raw":35,"subject":40,"body_html":41,"body_text":42,"firm_name":43,"letter_id":44,"created_at":45,"fei_number":20,"letter_url":46,"updated_at":47,"action_type":23,"case_status":48,"posted_date":49,"marcs_cms_no":50,"product_type":51,"closeout_date":20,"issuing_office":39,"recipient_name":52,"body_fetched_at":53,"delivery_method":54,"recipient_title":20,"reference_number":20,"action_taken_date":55,"medical_device_id":20,"response_letter_date":20},22010,[36,37,38,39,40,13,13,13],"\u003Ctime datetime=\"2026-10-27T04:00:00Z\">10\u002F27\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-23T04:00:00Z\">10\u002F23\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbest-chinese-medicines-llc-738556-10232026\">Best Chinese Medicines LLC\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Unapproved New Drugs","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Gretchen Synclaire\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Best Chinese Medicines LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>102 Shawnee Dr\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lake Kiowa\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>76240\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@bestchinesemedicines.com\"> support@bestchinesemedicines.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 23, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference Number: 738556\u003C\u002Fp>\u003Cp>To Gretchen Synclaire:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website, https:\u002F\u002Fbestchinesemedicines.com, and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of your website https:\u002F\u002Fbestchinesemedicines.com in September 2026. Based on our review, “Dissolve Mass Stasis Breaker,” “Gynostemma Leaf (Penta) Jiao Gu Lan,” “Wenxin Keli,” “Lianhua Qingwen Capsules,” and “Duhuo Jisheng Wan” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>This review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Based on a review of your website, “Dissolve Mass Stasis Breaker,” “Gynostemma Leaf (Penta) Jiao Gu Lan,” “Wenxin Keli,” “Lianhua Qingwen Capsules,” and “Duhuo Jisheng Wan” are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>Dissolve Mass Stasis Breaker\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fbestchinesemedicines.com\u002Fproducts\u002Fdissolve-mass-stasis-breaker-liquid-extract-tincture\u002F:\u003C\u002Fp>\u003Cul>\u003Cli>“Dissolve Mass (Stasis Breaker) helps dissipate nodules, palpable masses, and tumors by strongly invigorate [sic] the circulation of blood, qi, &amp; lymph.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Gynostemma Leaf (Penta) Jiao Gu Lan\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fbestchinesemedicines.com\u002Fproducts\u002Fjiao-gu-lan-liquid-extract-tincture\u002F:\u003C\u002Fp>\u003Cul>\u003Cli>“Lowers LDL cholesterol, raises HDL cholesterol”\u003C\u002Fli>\u003Cli>“Controls blood pressure”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>On your blog post “How to Reduce Hypertension (Blood Pressure) with Chinese Medicine” on your website https:\u002F\u002Fbestchinesemedicines.com\u002Fblog\u002Fhow-to-reduce-blood-pressure-with-chinese-medicine\u002F, where you direct consumers to your “Gynostemma Leaf (Penta) Jiao Gu Lan” webpage https:\u002F\u002Fbestchinesemedicines.com\u002Fproducts\u002Fjiao-gu-lan-liquid-extract-tincture\u002F:\u003C\u002Fp>\u003Cul>\u003Cli>“Chinese Herbal Medicine for Hypertension (High Blood Pressure)\u003Cbr>Chinese herbal medicine has no shortage of high blood pressure formulas. . . . Jiaogulan is an adaptogenic herb that is used to restore healthy blood pressure, manage blood sugar, reduce ‘bad’ cholesterol, and slow the signs of aging.(Examine.com). Along with improving heart health, Jiaogulan also reduces stress and soothes the mind.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Wenxin Keli\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fbestchinesemedicines.com\u002Fproducts\u002Fwenxin-keli-by-buchang\u002F:\u003C\u002Fp>\u003Cul>\u003Cli>“Wenxin Keli for arrhythmias, restless heart palpitations, shortness of breath and fatigue, dizziness and palpitations, chest pain and oppression, ventricular contractions, atrial premature beats and other cardiovascular disease.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Lianhua Qingwen Capsules\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fbestchinesemedicines.com\u002Fproducts\u002Flianhua-qingwen-capsules\u002F:\u003C\u002Fp>\u003Cul>\u003Cli>“Lianhua Qingwen has become a popular treatment for symptoms related to Covid-19.”\u003C\u002Fli>\u003Cli>“Lianhua Qingwen gained widespread popularity because it became known as a convenient, easy-to-use herbal formula often kept on hand during cold and flu season and periods of increased respiratory concerns.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Duhuo Jisheng Wan\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fbestchinesemedicines.com\u002Fproducts\u002Fduhuo-jisheng-wan-solitary-hermit-min-kang\u002F:\u003C\u002Fp>\u003Cul>\u003Cli>“Take Du Huo Ji Sheng Wan if you experience the following symptoms:\u003Cbr>• Lower back pain\u003Cbr>• joint pain\u003Cbr>• rheumatoid arthritis\u003Cbr>• pain accompanied with numbness\u003Cbr>• weakness, and\u002For stiffness”\u003C\u002Fli>\u003Cli>“This is a popular formula for those suffering from:\u003Cbr>• Diabetic Neuropathy\u003Cbr>• Osteoarthritis”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>“Dissolve Mass Stasis Breaker,” “Gynostemma Leaf (Penta) Jiao Gu Lan,” “Wenxin Keli,” “Lianhua Qingwen Capsules,” and “Duhuo Jisheng Wan” are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration. Identify your response with reference number “738556” in the subject line of the email.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.fda.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>cc:\u003Cbr>Gretchen Synclaire\u003Cbr>Econic Ventures Corporation\u003Cbr>102 Shawnee Dr,\u003Cbr>Lake Kiowa, TX 76240\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nGretchen Synclaire\n\nRecipient Title\n\nDirector\n\nBest Chinese Medicines LLC\n\n102 Shawnee Dr\n\nLake Kiowa, TX 76240\n\nUnited States\n\nsupport@bestchinesemedicines.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nOctober 23, 2026\nWARNING LETTER\nReference Number: 738556\nTo Gretchen Synclaire:\nThis warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website, https:\u002F\u002Fbestchinesemedicines.com, and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\nFDA Review\nViolations were identified and documented during a review of your website https:\u002F\u002Fbestchinesemedicines.com in September 2026. Based on our review, “Dissolve Mass Stasis Breaker,” “Gynostemma Leaf (Penta) Jiao Gu Lan,” “Wenxin Keli,” “Lianhua Qingwen Capsules,” and “Duhuo Jisheng Wan” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nThis review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nUnapproved New Drug Violations\nBased on a review of your website, “Dissolve Mass Stasis Breaker,” “Gynostemma Leaf (Penta) Jiao Gu Lan,” “Wenxin Keli,” “Lianhua Qingwen Capsules,” and “Duhuo Jisheng Wan” are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\nDissolve Mass Stasis Breaker\nOn the webpage https:\u002F\u002Fbestchinesemedicines.com\u002Fproducts\u002Fdissolve-mass-stasis-breaker-liquid-extract-tincture\u002F:\n“Dissolve Mass (Stasis Breaker) helps dissipate nodules, palpable masses, and tumors by strongly invigorate [sic] the circulation of blood, qi, & lymph.”\nGynostemma Leaf (Penta) Jiao Gu Lan\nOn the webpage https:\u002F\u002Fbestchinesemedicines.com\u002Fproducts\u002Fjiao-gu-lan-liquid-extract-tincture\u002F:\n“Lowers LDL cholesterol, raises HDL cholesterol”\n“Controls blood pressure”\nOn your blog post “How to Reduce Hypertension (Blood Pressure) with Chinese Medicine” on your website https:\u002F\u002Fbestchinesemedicines.com\u002Fblog\u002Fhow-to-reduce-blood-pressure-with-chinese-medicine\u002F, where you direct consumers to your “Gynostemma Leaf (Penta) Jiao Gu Lan” webpage https:\u002F\u002Fbestchinesemedicines.com\u002Fproducts\u002Fjiao-gu-lan-liquid-extract-tincture\u002F:\n“Chinese Herbal Medicine for Hypertension (High Blood Pressure)\nChinese herbal medicine has no shortage of high blood pressure formulas. . . . Jiaogulan is an adaptogenic herb that is used to restore healthy blood pressure, manage blood sugar, reduce ‘bad’ cholesterol, and slow the signs of aging.(Examine.com). Along with improving heart health, Jiaogulan also reduces stress and soothes the mind.”\nWenxin Keli\nOn the webpage https:\u002F\u002Fbestchinesemedicines.com\u002Fproducts\u002Fwenxin-keli-by-buchang\u002F:\n“Wenxin Keli for arrhythmias, restless heart palpitations, shortness of breath and fatigue, dizziness and palpitations, chest pain and oppression, ventricular contractions, atrial premature beats and other cardiovascular disease.”\nLianhua Qingwen Capsules\nOn the webpage https:\u002F\u002Fbestchinesemedicines.com\u002Fproducts\u002Flianhua-qingwen-capsules\u002F:\n“Lianhua Qingwen has become a popular treatment for symptoms related to Covid-19.”\n“Lianhua Qingwen gained widespread popularity because it became known as a convenient, easy-to-use herbal formula often kept on hand during cold and flu season and periods of increased respiratory concerns.”\nDuhuo Jisheng Wan\nOn the webpage https:\u002F\u002Fbestchinesemedicines.com\u002Fproducts\u002Fduhuo-jisheng-wan-solitary-hermit-min-kang\u002F:\n“Take Du Huo Ji Sheng Wan if you experience the following symptoms:\n• Lower back pain\n• joint pain\n• rheumatoid arthritis\n• pain accompanied with numbness\n• weakness, and\u002For stiffness”\n“This is a popular formula for those suffering from:\n• Diabetic Neuropathy\n• Osteoarthritis”\n“Dissolve Mass Stasis Breaker,” “Gynostemma Leaf (Penta) Jiao Gu Lan,” “Wenxin Keli,” “Lianhua Qingwen Capsules,” and “Duhuo Jisheng Wan” are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nSend your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration. Identify your response with reference number “738556” in the subject line of the email.\nPlease note FDA posts warning letters on www.fda.gov.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\ncc:\nGretchen Synclaire\nEconic Ventures Corporation\n102 Shawnee Dr,\nLake Kiowa, TX 76240","Best Chinese Medicines LLC","best-chinese-medicines-llc-738556-10232026","2026-11-03T01:02:17.615107+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbest-chinese-medicines-llc-738556-10232026","2026-11-17T01:02:03.701861+00:00","Issued","2026-10-27","738556","Drugs","Gretchen Synclaire","2026-11-03T01:02:32.738+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2026-10-23",{"id":57,"raw":58,"subject":62,"body_html":63,"body_text":64,"firm_name":65,"letter_id":66,"created_at":67,"fei_number":20,"letter_url":68,"updated_at":69,"action_type":23,"case_status":48,"posted_date":70,"marcs_cms_no":71,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":72,"body_fetched_at":73,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":70,"medical_device_id":20,"response_letter_date":20},1361,[59,60,61,11,62,13,13,13],"\u003Ctime datetime=\"2024-07-18T18:00:00Z\">07\u002F18\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-07-18T04:00:00Z\">07\u002F18\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjiangsu-caina-medical-co-ltd-687033-07182024\">Jiangsu Caina Medical Co., Ltd\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jun Lu Board\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chairman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Jiangsu Caina Medical Co., Ltd\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 23 Huanxi Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Zhutang Town\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jiangyin City\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jiangsu Sheng\u003C\u002Fspan>,\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Jun Lu,\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located at No. 23 Huanxi Road Zhutang Town, Jiangyin City, Jiangsu, China on March 11 through March 23, 2024, an investigator from the United States&nbsp;Food and Drug Administration (FDA) determined that your firm manufactures various medical devices including Sterile Luer Lock Syringes without Needles and Sterile Enteral&nbsp;Syringes. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of&nbsp;disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>The inspection revealed that these devices are adulterated under section 501(h) of the Act, 21 U.S.C. § 351(h), because the methods used in, or the facilities or controls used for, their&nbsp;manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of&nbsp;Federal Regulations (CFR), Part 820.\u003C\u002Fp>\n\n\u003Cp>We received responses from Jun Lu dated April 16, 2024, May 15, 2024, and June 15, 2024, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of&nbsp;Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the&nbsp;following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Quality System Regulation Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately establish and maintain procedures for corrective and preventive action (CAPA) as required by 21 CFR 820.100(a).\u003C\u002Fp>\n\n\u003Cp>a. Specifically, your firm did not ensure sources of quality data were analyzed to identify existing and potential causes of nonconforming product, or other quality&nbsp;problems, as required by 21 CFR 820.100(a)(1).\u003C\u002Fp>\n\n\u003Cp>Your firm manufactured Sterile Luer Lock Syringes without Needles cleared under K113091 and Sterile Enteral Syringes cleared under K190502, under the brand name&nbsp;“Monoject”, for distribution by Cardinal Health in the US beginning on\u002Fabout June 2023. FDA discovered during its inspection that starting in July 2023, your firm&nbsp;received at least 41 US market complaints related to syringe pump incompatibility and\u002For incorrect volume detection for these syringes. However, your firm did not&nbsp;adequately analyze these complaints to determine if a CAPA should be initiated.\u003C\u002Fp>\n\n\u003Cp>b. Your firm failed to investigate the cause of nonconformities relating to product, processes, and the quality system, as required by 21 CFR 820.100(a)(2).\u003C\u002Fp>\n\n\u003Cp>For example, FDA discovered during its inspection that your firm conducted an investigation into complaint 20230705 for syringe pump incompatibility for the&nbsp;Cardinal Health branded Luer Lock syringes on July 27, 2023. Your investigation confirmed pump incompatibility was an issue in that it found that 20mL Cardinal&nbsp;Health branded Monoject syringes were not recognized by Medfusion pumps while the same syringes were recognized by Alaris pumps. The complaint additionally&nbsp;noted that for recognized syringes, the healthcare provider was unable to calibrate the syringe prior to use with the pump, and shared concerns related to inaccurate dosing\u003Cbr>\nof anesthesia medication. However, your firm failed to evaluate the inaccurate dosing issues and did not consider delivery accuracy and volume detection as part of this&nbsp;investigation. The complaint was closed without opening a CAPA. While FDA acknowledges that a CAPA for the issue was opened on August 28, 2023, it appears&nbsp;that this CAPA was opened only after additional complaints were received, and not in response to complaint 20230705 when it was received by your firm.\u003C\u002Fp>\n\n\u003Cp>A similar investigation was also conducted for complaint 20231008 for Cardinal Health branded Monoject Enteral syringes on October 23, 2023, related to syringe&nbsp;incompatibility with the Medela feeding pump in the Neonatal intensive care unit (NICU). Your firm conducted testing to show that the 35mL Monoject Enteral&nbsp;syringe could be recognized by Perfusor, Alaris, and Medfusion pumps; however, the Medela feeding pump that was the subject of the complaint was not evaluated. The&nbsp;complaint stated that the customer was previously using the “Covidien brand” and “[t]oday they received the Cardinal brand and they do not work. They look similar&nbsp;but are a different diameter. They do not work in the pumps” and noted concerns with the Cardinal brand “leaving no work around to feed the NICU infants.” Your firm did&nbsp;not investigate failure of the syringes with the Medela feeding pump or the alleged syringe nonconformity indicating the diameter of the two syringes labeled Monoject&nbsp;were different. The complaint was closed without opening a CAPA.\u003C\u002Fp>\n\n\u003Cp>A Class I recall to remove the Monoject Luer lock and Enteral sterile syringes manufactured by your firm under K113091 and K190502 was initiated by Cardinal&nbsp;Health on December 28, 2023 following an earlier Class 1 recall for the Monoject Luer lock syringes Cardinal Health initiated on September 20, 2023, due to recognition and&nbsp;compatibility issues with syringe pumps. As part of this recall activity, FDA also issued a Letter to Healthcare Providers to advise that Cardinal Health Monoject syringes, when used with syringe pumps or patient-controlled analgesia (PCA) pumps, may result in&nbsp;recognition, compatibility, and pump performance issues such as overdose, underdose, delay in therapy, and delays in occlusion alarms. Based on FDA’s inspectional findings,&nbsp;it appears that your firm’s failure to thoroughly analyze and investigate complaint data for these syringes may have contributed to a delay in recognition that the risk of&nbsp;incompatibility applied to additional sizes of Cardinal Health Monoject syringes.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses and concluded that they are not adequate. Your response included revised CAPA and complaint handling procedures, but you have not&nbsp;provided evidence to support that the new procedures have been implemented, or that they are effective. Your response states that a retrospective review of complaints from&nbsp;2019-2024 was performed which resulted in opening 12 new CAPAs, but documentation of the complaint analysis and investigations that resulted in opening these CAPAs was&nbsp;not provided.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain procedures for validating the device design, including risk analysis, as required by 21 CFR 820.30(g).\u003C\u002Fp>\n\n\u003Cp>Specifically, your Risk Management Report for Disposable Syringes without Needles, RMR-ZSQ02, Ver. B0, dated December 30, 2022, and effective when your firm began&nbsp;manufacturing these devices for Cardinal Health under the brand name “Monoject”, did not include the hazard of use in an infusion pump. Your firm updated this report (Ver C0)&nbsp;on November 10, 2023, to include the hazard of “The syringe is connected to pump”, with an assigned risk level of 4 (which your firm considers acceptable), a severity level of&nbsp;S2 “serious” and a probability level of P2 “Very few happened”, even though your firm had received dozens of syringe pump incompatibility complaints of which at least 11&nbsp;were MDR reportable events related to over-delivery of medication in critical care patients. Your firm was also aware that the use of these syringes in infusion pumps\u003Cbr>\nresulted in the initiation of a Class I recall by Cardinal Health because these Cardinal Health Monoject syringes, when used with syringe pumps, may result in pump&nbsp;performance issues such as overdose, underdose, delay in therapy, and delays in occlusion alarms. Your updated risk analysis determinations in Version C0 do not seem&nbsp;appropriate given your firm’s awareness of complaints, MDRs and the Class 1 recall associated with the hazard of use in an infusion pump for these syringes.\u003C\u002Fp>\n\n\u003Cp>Your firm also failed to verify that the risk control measures identified in Version C0 for this hazard were implemented or effective. Your firm lists “Identify professional use or&nbsp;Rx only on the labels and IFU” as the risk control measure for the hazard of the use in pumps. However, no instructions for use, or IFU, were provided with these devices.\u003C\u002Fp>\n\n\u003Cp>Further, though the device labels do contain an Rx symbol, FDA is not aware of any information provided to date from your firm that explains whether the inclusion of an Rx&nbsp;symbol without an IFU for these devices is an effective risk control measure with respect to the hazard of use in an infusion pump for these devices.\u003C\u002Fp>\n\n\u003Cp>Syringe infusion pumps are used to deliver precise doses of high-risk medications to vulnerable patient populations including infusions in neonates and delivery of anesthesia&nbsp;drugs during surgery. Your risk analysis process should be able to continually identify, evaluate, control, and monitor the risks associated with the use of your device.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses and concluded that they are not adequate. Your response provided an Updated Risk Assessment Report for sterile single use syringes that&nbsp;now includes as the risk control action for pump use “IFU states that the syringes should be used manually.” Your response also states that you have reviewed your US syringe&nbsp;SKUs (CAINA US SKU LIST-labeling IFU Check) and evaluated if the labeling of these products complies with the applicable risk analysis. Products without compliant labeling&nbsp;have been identified and shipment has been stopped until updated instructions can be included. The products identified as needing updated instructions all refer to K113091&nbsp;and are sold under the brands Vesco, McKesson, Monoject, One-Care, Wellmed, Ceros, Avanos, Caina, Resilient, and Henry Schein. The Revised Package Label for Cardinal&nbsp;Health Monoject syringes has been provided which includes additional warnings not to use in pumps on the outer labeling. However, the risk severity level and probability level&nbsp;of the pump use hazard in your risk analysis has not changed. For the other 45 SKUs identified in the response as needing updated labels or IFUs, no updated labeling has&nbsp;been provided.\u003C\u002Fp>\n\n\u003Cp>In addition, we offer the following comment regarding Observation 1 on the FDA 483, along with our review of your responses as they pertain to this citation:\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;Failure to submit a report to the FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that&nbsp;reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that your firm markets would be likely to cause or contribute to a death or&nbsp;serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\u003C\u002Fp>\n\n\u003Cp>For example, the information included for Complaint Nos. 20230909, 20230910, 20231001, 20231003, 20231012, 20231102, 20231202, 20231204, 20240101 and&nbsp;20240102 reasonably suggests that your firm’s syringes malfunctioned (i.e., compatibility issues, leaks, contamination, and ruptures) while in use. Your firm initiated recall Z-0112-2024 and recalls Z-1937-2024, Z-0146-2024 to Z-0150-2024 for the same referenced malfunctions. Per the Preamble, in the Medical Devices; Medical User&nbsp;Facility and Manufacturer Reporting, Certification and Registration; Final Rule, 60 Fed. Reg. 63585 (Dec. 11, 1995), Comment 12, a malfunction is reportable if the manufacturer&nbsp;takes or would be required to take an action under sections 518 or 519(g) of the act as a result of the malfunction of the device or other similar devices. There is no information&nbsp;included for the complaints that rules out that the referenced malfunctions would not be likely to cause or contribute to a death or serious injury if they were to recur. As such,&nbsp;each of the referenced complaints represents a reportable malfunction, as defined in 21 CFR 803.3. However, your firm failed to submit MDRs for each of the referenced&nbsp;complaints.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s responses dated April 16, 2024, and May 15, 2024, cannot be determined at this time. In the response dated April 16, 2024, your firm states that you&nbsp;are conducting a retrospective review of complaints received from 2019 to the present, including both US and non-US products, using your updated MDR procedure. However,&nbsp;your firm has not provided documentation or evidence indicating the completeness of the planned corrective actions, as they are still ongoing. The response dated May 15, 2024,&nbsp;did not include any information.\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>•\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;In addition, FDA discovered during its inspection that once the outer packaging of these devices is removed the only remaining labeling on the syringe barrel is “Monoject.” FDA&nbsp;is aware of at least one example from complaint 20230705, received by your firm on July 27, 2023, which stated that “Once the package is open the staff cannot tell them apart&nbsp;because Covidien and Cardinal Health is not written on the syringe to identify it.” and “BD and Monoject syringes are the only ones approved for the OR due to compatibility&nbsp;with Anesthesia syringe pumps.” FDA does not have any information to date from your firm regarding whether the sole use of term “Monoject” printed directly on these devices&nbsp;reduces the probability that these devices will be used in infusion pumps, given that healthcare professionals who are trained to use syringe infusion pumps may recognize&nbsp;that “Monoject” syringes are listed in the compatible syringe libraries of most infusion pumps and may not be able to distinguish between what “Monoject” syringes are&nbsp;appropriate for use with a particular type of infusion pump when no other differentiating information is provided.\u003C\u002Fp>\n\n\u003Cp>Given the serious nature of the violations of the Act, sterile and non-sterile syringes manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21&nbsp;U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA has taken steps to refuse entry of these devices into the United States, known as “detention without physical&nbsp;examination,” until these violations are addressed. In order to remove the devices from detention, your firm should provide a written response to this Warning Letter as described below&nbsp;and address the violation(s) described in this letter. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the&nbsp;appropriate corrections and\u002For corrective actions have been made.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should&nbsp;FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the&nbsp;violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an&nbsp;explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must&nbsp;address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those&nbsp;activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be&nbsp;completed. Please provide a translation of documentation not in English to facilitate our review.&nbsp;We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been&nbsp;made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office&nbsp;of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993.&nbsp;\u003Cstrong>Refer to CMS case #687033 when replying\u003C\u002Fstrong>. If you have any questions about the contents of this letter, please contact: Shruti Mistry at Shruti.Mistry@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws&nbsp;and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of&nbsp;serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address&nbsp;any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nKellie B. Kelm, Ph.D.\u003Cbr>\nActing Director\u003Cbr>\nOHT 3: Office of GastroRenal, ObGyn,\u003Cbr>\nGeneral Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CC:\u003Cbr>\nOfficial correspondent:\u003C\u002Fstrong>\u003Cbr>\nJun Lu at jun.lu@cainamed.com\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>US AGENT:\u003C\u002Fstrong>\u003Cbr>\nMarco Mu\u003Cbr>\nMid-Link International Co., Ltd,\u003Cbr>\n2219 Rimlang Drive\u003Cbr>\nSuite 301\u003Cbr>\nBellingham, WA US 98226\u003Cbr>\nEmail: us.agent@mid-link.net\u003Cbr>\nPhone: (702) 209-5185\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJun Lu Board\n\nRecipient Title\n\nChairman\n\nJiangsu Caina Medical Co., Ltd\n\nNo. 23 Huanxi Road\n\nZhutang Town\n\nJiangyin City\n\nJiangsu Sheng,\n\nChina\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nDear Mr. Jun Lu,\n\nDuring an inspection of your firm located at No. 23 Huanxi Road Zhutang Town, Jiangyin City, Jiangsu, China on March 11 through March 23, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures various medical devices including Sterile Luer Lock Syringes without Needles and Sterile Enteral Syringes. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nThe inspection revealed that these devices are adulterated under section 501(h) of the Act, 21 U.S.C. § 351(h), because the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\n\nWe received responses from Jun Lu dated April 16, 2024, May 15, 2024, and June 15, 2024, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\nQuality System Regulation Violations\n\n1. Failure to adequately establish and maintain procedures for corrective and preventive action (CAPA) as required by 21 CFR 820.100(a).\n\na. Specifically, your firm did not ensure sources of quality data were analyzed to identify existing and potential causes of nonconforming product, or other quality problems, as required by 21 CFR 820.100(a)(1).\n\nYour firm manufactured Sterile Luer Lock Syringes without Needles cleared under K113091 and Sterile Enteral Syringes cleared under K190502, under the brand name “Monoject”, for distribution by Cardinal Health in the US beginning on\u002Fabout June 2023. FDA discovered during its inspection that starting in July 2023, your firm received at least 41 US market complaints related to syringe pump incompatibility and\u002For incorrect volume detection for these syringes. However, your firm did not adequately analyze these complaints to determine if a CAPA should be initiated.\n\nb. Your firm failed to investigate the cause of nonconformities relating to product, processes, and the quality system, as required by 21 CFR 820.100(a)(2).\n\nFor example, FDA discovered during its inspection that your firm conducted an investigation into complaint 20230705 for syringe pump incompatibility for the Cardinal Health branded Luer Lock syringes on July 27, 2023. Your investigation confirmed pump incompatibility was an issue in that it found that 20mL Cardinal Health branded Monoject syringes were not recognized by Medfusion pumps while the same syringes were recognized by Alaris pumps. The complaint additionally noted that for recognized syringes, the healthcare provider was unable to calibrate the syringe prior to use with the pump, and shared concerns related to inaccurate dosing\n\nof anesthesia medication. However, your firm failed to evaluate the inaccurate dosing issues and did not consider delivery accuracy and volume detection as part of this investigation. The complaint was closed without opening a CAPA. While FDA acknowledges that a CAPA for the issue was opened on August 28, 2023, it appears that this CAPA was opened only after additional complaints were received, and not in response to complaint 20230705 when it was received by your firm.\n\nA similar investigation was also conducted for complaint 20231008 for Cardinal Health branded Monoject Enteral syringes on October 23, 2023, related to syringe incompatibility with the Medela feeding pump in the Neonatal intensive care unit (NICU). Your firm conducted testing to show that the 35mL Monoject Enteral syringe could be recognized by Perfusor, Alaris, and Medfusion pumps; however, the Medela feeding pump that was the subject of the complaint was not evaluated. The complaint stated that the customer was previously using the “Covidien brand” and “[t]oday they received the Cardinal brand and they do not work. They look similar but are a different diameter. They do not work in the pumps” and noted concerns with the Cardinal brand “leaving no work around to feed the NICU infants.” Your firm did not investigate failure of the syringes with the Medela feeding pump or the alleged syringe nonconformity indicating the diameter of the two syringes labeled Monoject were different. The complaint was closed without opening a CAPA.\n\nA Class I recall to remove the Monoject Luer lock and Enteral sterile syringes manufactured by your firm under K113091 and K190502 was initiated by Cardinal Health on December 28, 2023 following an earlier Class 1 recall for the Monoject Luer lock syringes Cardinal Health initiated on September 20, 2023, due to recognition and compatibility issues with syringe pumps. As part of this recall activity, FDA also issued a Letter to Healthcare Providers to advise that Cardinal Health Monoject syringes, when used with syringe pumps or patient-controlled analgesia (PCA) pumps, may result in recognition, compatibility, and pump performance issues such as overdose, underdose, delay in therapy, and delays in occlusion alarms. Based on FDA’s inspectional findings, it appears that your firm’s failure to thoroughly analyze and investigate complaint data for these syringes may have contributed to a delay in recognition that the risk of incompatibility applied to additional sizes of Cardinal Health Monoject syringes.\n\nWe reviewed your firm’s responses and concluded that they are not adequate. Your response included revised CAPA and complaint handling procedures, but you have not provided evidence to support that the new procedures have been implemented, or that they are effective. Your response states that a retrospective review of complaints from 2019-2024 was performed which resulted in opening 12 new CAPAs, but documentation of the complaint analysis and investigations that resulted in opening these CAPAs was not provided.\n\n2. Failure to establish and maintain procedures for validating the device design, including risk analysis, as required by 21 CFR 820.30(g).\n\nSpecifically, your Risk Management Report for Disposable Syringes without Needles, RMR-ZSQ02, Ver. B0, dated December 30, 2022, and effective when your firm began manufacturing these devices for Cardinal Health under the brand name “Monoject”, did not include the hazard of use in an infusion pump. Your firm updated this report (Ver C0) on November 10, 2023, to include the hazard of “The syringe is connected to pump”, with an assigned risk level of 4 (which your firm considers acceptable), a severity level of S2 “serious” and a probability level of P2 “Very few happened”, even though your firm had received dozens of syringe pump incompatibility complaints of which at least 11 were MDR reportable events related to over-delivery of medication in critical care patients. Your firm was also aware that the use of these syringes in infusion pumps\n\nresulted in the initiation of a Class I recall by Cardinal Health because these Cardinal Health Monoject syringes, when used with syringe pumps, may result in pump performance issues such as overdose, underdose, delay in therapy, and delays in occlusion alarms. Your updated risk analysis determinations in Version C0 do not seem appropriate given your firm’s awareness of complaints, MDRs and the Class 1 recall associated with the hazard of use in an infusion pump for these syringes.\n\nYour firm also failed to verify that the risk control measures identified in Version C0 for this hazard were implemented or effective. Your firm lists “Identify professional use or Rx only on the labels and IFU” as the risk control measure for the hazard of the use in pumps. However, no instructions for use, or IFU, were provided with these devices.\n\nFurther, though the device labels do contain an Rx symbol, FDA is not aware of any information provided to date from your firm that explains whether the inclusion of an Rx symbol without an IFU for these devices is an effective risk control measure with respect to the hazard of use in an infusion pump for these devices.\n\nSyringe infusion pumps are used to deliver precise doses of high-risk medications to vulnerable patient populations including infusions in neonates and delivery of anesthesia drugs during surgery. Your risk analysis process should be able to continually identify, evaluate, control, and monitor the risks associated with the use of your device.\n\nWe reviewed your firm’s responses and concluded that they are not adequate. Your response provided an Updated Risk Assessment Report for sterile single use syringes that now includes as the risk control action for pump use “IFU states that the syringes should be used manually.” Your response also states that you have reviewed your US syringe SKUs (CAINA US SKU LIST-labeling IFU Check) and evaluated if the labeling of these products complies with the applicable risk analysis. Products without compliant labeling have been identified and shipment has been stopped until updated instructions can be included. The products identified as needing updated instructions all refer to K113091 and are sold under the brands Vesco, McKesson, Monoject, One-Care, Wellmed, Ceros, Avanos, Caina, Resilient, and Henry Schein. The Revised Package Label for Cardinal Health Monoject syringes has been provided which includes additional warnings not to use in pumps on the outer labeling. However, the risk severity level and probability level of the pump use hazard in your risk analysis has not changed. For the other 45 SKUs identified in the response as needing updated labels or IFUs, no updated labeling has been provided.\n\nIn addition, we offer the following comment regarding Observation 1 on the FDA 483, along with our review of your responses as they pertain to this citation:\n\n• Failure to submit a report to the FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that your firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\n\nFor example, the information included for Complaint Nos. 20230909, 20230910, 20231001, 20231003, 20231012, 20231102, 20231202, 20231204, 20240101 and 20240102 reasonably suggests that your firm’s syringes malfunctioned (i.e., compatibility issues, leaks, contamination, and ruptures) while in use. Your firm initiated recall Z-0112-2024 and recalls Z-1937-2024, Z-0146-2024 to Z-0150-2024 for the same referenced malfunctions. Per the Preamble, in the Medical Devices; Medical User Facility and Manufacturer Reporting, Certification and Registration; Final Rule, 60 Fed. Reg. 63585 (Dec. 11, 1995), Comment 12, a malfunction is reportable if the manufacturer takes or would be required to take an action under sections 518 or 519(g) of the act as a result of the malfunction of the device or other similar devices. There is no information included for the complaints that rules out that the referenced malfunctions would not be likely to cause or contribute to a death or serious injury if they were to recur. As such, each of the referenced complaints represents a reportable malfunction, as defined in 21 CFR 803.3. However, your firm failed to submit MDRs for each of the referenced complaints.\n\nThe adequacy of your firm’s responses dated April 16, 2024, and May 15, 2024, cannot be determined at this time. In the response dated April 16, 2024, your firm states that you are conducting a retrospective review of complaints received from 2019 to the present, including both US and non-US products, using your updated MDR procedure. However, your firm has not provided documentation or evidence indicating the completeness of the planned corrective actions, as they are still ongoing. The response dated May 15, 2024, did not include any information.\n\n• In addition, FDA discovered during its inspection that once the outer packaging of these devices is removed the only remaining labeling on the syringe barrel is “Monoject.” FDA is aware of at least one example from complaint 20230705, received by your firm on July 27, 2023, which stated that “Once the package is open the staff cannot tell them apart because Covidien and Cardinal Health is not written on the syringe to identify it.” and “BD and Monoject syringes are the only ones approved for the OR due to compatibility with Anesthesia syringe pumps.” FDA does not have any information to date from your firm regarding whether the sole use of term “Monoject” printed directly on these devices reduces the probability that these devices will be used in infusion pumps, given that healthcare professionals who are trained to use syringe infusion pumps may recognize that “Monoject” syringes are listed in the compatible syringe libraries of most infusion pumps and may not be able to distinguish between what “Monoject” syringes are appropriate for use with a particular type of infusion pump when no other differentiating information is provided.\n\nGiven the serious nature of the violations of the Act, sterile and non-sterile syringes manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA has taken steps to refuse entry of these devices into the United States, known as “detention without physical examination,” until these violations are addressed. In order to remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and address the violation(s) described in this letter. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #687033 when replying. If you have any questions about the contents of this letter, please contact: Shruti Mistry at Shruti.Mistry@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nKellie B. Kelm, Ph.D.\n\nActing Director\n\nOHT 3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\nOfficial correspondent:\n\nJun Lu at jun.lu@cainamed.com\n\nUS AGENT:\n\nMarco Mu\n\nMid-Link International Co., Ltd,\n\n2219 Rimlang Drive\n\nSuite 301\n\nBellingham, WA US 98226\n\nEmail: us.agent@mid-link.net\n\nPhone: (702) 209-5185","Jiangsu Caina Medical Co., Ltd","jiangsu-caina-medical-co-ltd-687033-07182024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjiangsu-caina-medical-co-ltd-687033-07182024","2026-10-26T08:09:03.947003+00:00","2024-07-18","687033","Jun Lu Board","2026-08-19T23:57:20.177+00:00",{"id":75,"raw":76,"subject":80,"body_html":81,"body_text":82,"firm_name":83,"letter_id":84,"created_at":85,"fei_number":20,"letter_url":86,"updated_at":47,"action_type":23,"case_status":48,"posted_date":87,"marcs_cms_no":88,"product_type":89,"closeout_date":20,"issuing_office":39,"recipient_name":90,"body_fetched_at":91,"delivery_method":54,"recipient_title":20,"reference_number":92,"action_taken_date":93,"medical_device_id":20,"response_letter_date":20},22102,[77,78,79,39,80,13,13,13],"\u003Ctime datetime=\"2026-11-03T05:00:00Z\">11\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-26T04:00:00Z\">10\u002F26\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fguangdong-bangze-medicine-co-ltd-734509-10262026\">Guangdong Bangze Medicine Co., Ltd.\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-27-10\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Yongliang Fang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Guangdong Bangze Medicine Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 300 Shangfang Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Simapu Town\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chaonan Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Shantou Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Guangdong Sheng\u003C\u002Fspan>, \u003Cspan>515149\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)\"> (b)(4)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 26, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference number: 320-27-10\u003C\u002Fp>\u003Cp>To Mr. Yongliang Fang:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your products and records submitted from your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during review of your drug manufacturing facility, Guangdong Bangze Medicine Co., Ltd., FDA Establishment Identifier (FEI) 3035364398. This review was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\u003C\u002Fp>\u003Cp>Your facility is registered with the FDA as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our January 20, 2026, request and subsequent correspondence, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request, do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures OTC drug products including \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Based on the records and information you provided, you did not demonstrate that you adequately tested the identity, purity, or strength of components used in the manufacture of your drug products. You also relied on your suppliers' certificates of analysis (COA) for \u003Cstrong>(b)(4)\u003C\u002Fstrong> without demonstrating the reliability of your suppliers' test analyses at appropriate intervals.\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your incoming inspection records for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> active ingredient failed to include appropriate compendial identity testing, assay, or impurity testing.\u003C\u002Fp>\u003Cp>You manufacture drugs that contain \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> contaminated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cstrong>(b)(4).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your incoming inspection records for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> component similarly failed to include compendial identity testing and lacked appropriate \u003Cstrong>(b)(4)\u003C\u002Fstrong> limit testing. Identity testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong> and certain other high-risk drug components includes a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records you provided, you did not perform appropriate \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing, on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used to manufacture your drug products. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> specifications reference the Chinese Pharmacopeia rather than USP for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Without adequate \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing, you do not have scientific evidence that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used as a component in your drug product manufacturing conforms to appropriate specifications.\u003C\u002Fp>\u003Cp>Component testing is fundamental to quality. Without adequate testing, you do not have scientific evidence that your components conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release. Your firm also failed to conduct appropriate laboratory testing, as necessary, for each batch of drug product required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records and information you provided, you did not demonstrate that you adequately test your OTC finished drug products prior to release for distribution to the United States. Specifically, the certificate of analyses (COA) that you provided did not include identity, assay, or impurity test results. In addition, the COAs provided also reveal that you lacked appropriate testing for objectionable microorganisms for each batch.\u003C\u002Fp>\u003Cp>Testing is an essential part of CGMP to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Drug products must be tested for identity and strength of the active ingredient prior to release and distribution. Without adequate testing, you do not have scientific evidence to assure that your drug products conform to appropriate specifications before release.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Your firm’s quality unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. For example, your QU failed to ensure:\u003C\u002Fp>\u003Cul>\u003Cli>The establishment of an adequate, ongoing stability program (21 CFR 211.166(a)).\u003C\u002Fli>\u003Cli>Adequate procedures ensuring appropriate production and process controls, including appropriate qualification of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system (21 CFR 211.100(a)).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm’s quality systems are inadequate. For help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, see FDA’s guidance documents \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified in your response, you should engage a consultant qualified as set forth in 21 CFR 211.34, to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventive measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on August 7, 2026.\u003C\u002Fp>\u003Cp>FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Guangdong Bangze Medicine Co., Ltd., No. 300 Shangfang Avenue, Simapu Town, Chaonan District, Shantou, Guangdong, 515149 China, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3035364398 and ATTN: Christopher Jenner in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>FDA posts warning letters to www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003Cbr>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>Cc: Registered U.S. Agent\u003Cbr>Frosa Technology, LLC\u003Cbr>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nReference #:\n\n320-27-10\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Yongliang Fang\n\nRecipient Title\n\nGeneral Manager\n\nGuangdong Bangze Medicine Co., Ltd.\n\nNo. 300 Shangfang Avenue\n\nSimapu Town\n\nChaonan Qu\n\nShantou Shi\n\nGuangdong Sheng, 515149\n\nChina\n\n(b)(4)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nOctober 26, 2026\nWARNING LETTER\nReference number: 320-27-10\nTo Mr. Yongliang Fang:\nThis warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your products and records submitted from your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice.\nFDA Review\nViolations were identified and documented during review of your drug manufacturing facility, Guangdong Bangze Medicine Co., Ltd., FDA Establishment Identifier (FEI) 3035364398. This review was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\nYour facility is registered with the FDA as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our January 20, 2026, request and subsequent correspondence, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request, do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)).\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations at your facility.\n1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYour firm manufactures OTC drug products including (b)(4). Based on the records and information you provided, you did not demonstrate that you adequately tested the identity, purity, or strength of components used in the manufacture of your drug products. You also relied on your suppliers' certificates of analysis (COA) for (b)(4) without demonstrating the reliability of your suppliers' test analyses at appropriate intervals.\n(b)(4)\nYour incoming inspection records for your (b)(4) active ingredient failed to include appropriate compendial identity testing, assay, or impurity testing.\nYou manufacture drugs that contain (b)(4). The use of (b)(4) contaminated with (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document (b)(4).\n(b)(4)\nYour incoming inspection records for your (b)(4) component similarly failed to include compendial identity testing and lacked appropriate (b)(4) limit testing. Identity testing for (b)(4) and certain other high-risk drug components includes a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of (b)(4).\nThe use of ingredients contaminated with (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document (b)(4)\n(b)(4)\nBased on the records you provided, you did not perform appropriate (b)(4) testing, including (b)(4) testing, on the (b)(4) used to manufacture your drug products. Your (b)(4) specifications reference the Chinese Pharmacopeia rather than USP for (b)(4). Without adequate (b)(4) testing, you do not have scientific evidence that the (b)(4) used as a component in your drug product manufacturing conforms to appropriate specifications.\nComponent testing is fundamental to quality. Without adequate testing, you do not have scientific evidence that your components conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\n2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release. Your firm also failed to conduct appropriate laboratory testing, as necessary, for each batch of drug product required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\nBased on the records and information you provided, you did not demonstrate that you adequately test your OTC finished drug products prior to release for distribution to the United States. Specifically, the certificate of analyses (COA) that you provided did not include identity, assay, or impurity test results. In addition, the COAs provided also reveal that you lacked appropriate testing for objectionable microorganisms for each batch.\nTesting is an essential part of CGMP to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Drug products must be tested for identity and strength of the active ingredient prior to release and distribution. Without adequate testing, you do not have scientific evidence to assure that your drug products conform to appropriate specifications before release.\n3. Your firm’s quality unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nThe records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. For example, your QU failed to ensure:\nThe establishment of an adequate, ongoing stability program (21 CFR 211.166(a)).\nAdequate procedures ensuring appropriate production and process controls, including appropriate qualification of the (b)(4) system (21 CFR 211.100(a)).\nYour firm’s quality systems are inadequate. For help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, see FDA’s guidance documents Quality Systems Approach to Pharmaceutical CGMP Regulations at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified in your response, you should engage a consultant qualified as set forth in 21 CFR 211.34, to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventive measures to ensure future and sustained compliance so that these violations and any others do not occur.\nFDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on August 7, 2026.\nFDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Guangdong Bangze Medicine Co., Ltd., No. 300 Shangfang Avenue, Simapu Town, Chaonan District, Shantou, Guangdong, 515149 China, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3035364398 and ATTN: Christopher Jenner in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nFDA posts warning letters to www.FDA.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\nCc: Registered U.S. Agent\nFrosa Technology, LLC\n(b)(4)","Guangdong Bangze Medicine Co., Ltd.","guangdong-bangze-medicine-co-ltd-734509-10262026","2026-11-10T01:02:16.121874+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fguangdong-bangze-medicine-co-ltd-734509-10262026","2026-11-03","734509","Drugs Over-the-Counter Drugs","Mr. Yongliang Fang","2026-11-10T01:02:34.865+00:00","320-27-10","2026-10-26",{"id":95,"raw":96,"subject":99,"body_html":100,"body_text":101,"firm_name":102,"letter_id":103,"created_at":45,"fei_number":20,"letter_url":104,"updated_at":47,"action_type":23,"case_status":48,"posted_date":49,"marcs_cms_no":105,"product_type":51,"closeout_date":20,"issuing_office":39,"recipient_name":106,"body_fetched_at":107,"delivery_method":108,"recipient_title":20,"reference_number":109,"action_taken_date":110,"medical_device_id":20,"response_letter_date":20},22011,[36,97,98,39,99,13,13,13],"\u003Ctime datetime=\"2026-10-22T04:00:00Z\">10\u002F22\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorthland-nuclear-medicine-llc-736893-10222026\">Northland Nuclear Medicine, LLC\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE WITH RETURN RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                      \u003Cbr>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                          \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-27-08\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Nathan J. Fleck, Pharm.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Northland Nuclear Medicine, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1815 Michigan Ave.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bismarck\u003C\u002Fspan>, \u003Cspan>ND\u003C\u002Fspan> \u003Cspan>58504-6121\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)\"> (b)(4)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 22, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference number: 320-27-08\u003C\u002Fp>\u003Cp>To Dr. Nathan J. Fleck:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Inspection\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were observed and documented during an inspection of your drug manufacturing facility, Northland Nuclear Medicine, LLC, FDA Establishment Identifier (FEI) 3005334016, located at 1815 Michigan Ave., Bismarck, from May 26 to 29, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for positron emission tomography (PET) drugs. See Title 21 Code of Federal Regulations (CFR), part 212 (21 CFR part 212).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packaging, or holding do not conform to CGMP, your PET drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your June 11, 2026, response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supporting documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations observed during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to conduct adequate investigations and take appropriate corrective action when a failure of a production batch or any component of the batch failed to meet any of its specifications (21 CFR 212.20(d)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Investigation of Out-of-Limit Environmental Monitoring Results\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm failed to adequately investigate out-of-limit (OOL) environmental monitoring (EM) results, identify the root cause of recurring microbial recoveries, and implement appropriate corrective actions. EM data from March 2024 through April 2026 revealed an adverse trend with over 100 microbial recoveries from ISO 5 areas (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> and laminar airflow workstation (LAFW)), including counts of \u003Cstrong>(b)(4)\u003C\u002Fstrong> colony forming units (CFUs). These recoveries were not formally identified, preventing your firm from conducting adequate investigations. More than 90 ISO 5 isolates were documented as “resembles previously identified \u003Cem>Bacillus\u003C\u002Fem> colonies” or “resembles previously identified colonies” in lieu of formal microbial identification, with no record of which previously identified organism the colony purportedly resembled. Since December 2024, of approximately 75 ISO 5 microbial recoveries, only two were sent for formal identification. No genus or species recovered in ISO 5 areas has been recorded in your EM log since September 2025. Operator training for interpreting \u003Cstrong>(b)(4)\u003C\u002Fstrong> plate results consisted of a single presentation slide instructing personnel to “count CFUs and record results,” with no instruction regarding microbial identification.\u003C\u002Fp>\u003Cp>Additionally, \u003Cstrong>(b)(4)\u003C\u002Fstrong> ISO 7 cleanroom certification results for areas surrounding your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and LAFW revealed microbial recoveries that exceeded your action limits and were not adequately investigated. For example, a \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU active air recovery described as bacterial and yeast was not adequately identified because the sample plates were received with \u003Cstrong>(b)(4)\u003C\u002Fstrong> on the lid. For a \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU recovery sent for identification, \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU were identified as \u003Cem>Pseudopithomyces palmicola\u003C\u002Fem> and the remaining \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU were identified as \u003Cem>Micrococcus\u003C\u002Fem> spp. and coryneform bacillus. Investigations were not initiated. Further, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product review acknowledges “excess CFUs as an ongoing issue in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanroom.”\u003C\u002Fp>\u003Cp>Your firm systematically failed to adequately investigate out-of-limit environmental monitoring results, to identify root causes of recurring microbial contamination in critical ISO 5 areas, and to implement effective corrective action and preventive action (CAPA).\u003C\u002Fp>\u003Cp>In your response, you commit to ensuring that future microbial colony recoveries from ISO 5 areas will be properly identified and documented. Your response is inadequate because it does not include a retrospective assessment of the unidentified recoveries or an evaluation of adverse trends, does not assess the adequacy of past batch release decisions made in the absence of organism identification, and does not address the documented presence of spore-forming bacteria and fungi in your ISO-classified environments.\u003C\u002Fp>\u003Cp>Environmental isolate identification data provides essential information for an investigation into routes of contamination, such as when investigating an adverse environmental control trend, media fill contamination, or a product sterility testing failure. EM should include routine identification of microorganisms to the species (or, where appropriate, genus) level, including isolates recovered from an ISO 5 environment, its surrounding cleanroom, and personnel.\u003C\u002Fp>\u003Cp>It is essential that cleaning and disinfection procedures are described in sufficient detail, including the preparation, disinfectant selection, and contact time to enable reproducibility and ensure that potential contaminants are adequately removed from surfaces. The effectiveness of disinfection procedures should be evaluated through a routine EM program, and adverse trends should prompt reassessment of disinfectant selection, concentration, contact time, and application frequency.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Investigation and CAPA for Recurring Manufacturing Deficiencies\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to conduct adequate effectiveness checks for CAPAs to prevent recurrence.\u003C\u002Fp>\u003Cp>Multiple CAPAs for recurring low \u003Cstrong>(b)(4)\u003C\u002Fstrong> yields were closed without your required effectiveness checks. Yields continued to fall below your established \u003Cstrong>(b)(4)\u003C\u002Fstrong>% limit. No investigations were initiated for approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches manufactured between August 2024 and April 2025 that failed the \u003Cstrong>(b)(4)\u003C\u002Fstrong>% limit, with yields as low as \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. Rather than identifying and correcting the root cause, you lowered the yield limit from \u003Cstrong>(b)(4)\u003C\u002Fstrong>% to \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. Yields subsequently fell below your revised \u003Cstrong>(b)(4)\u003C\u002Fstrong>% limit. Notably, Incident Report NNM 2025 08 states, “This has been an ongoing issue now for more than a year. We are continuing to evaluate the situation in an attempt to increase yields.” The effectiveness check for that incident was marked “No” with no additional corrective action identified. You continue to manufacture your PET drug without resolving the root cause of the low yields.\u003C\u002Fp>\u003Cp>PET drug producers must establish appropriate action limits for radiochemical yield and investigate and correct the root cause when those limits are exceeded. Low yields or a downward trend in yield are recognized indicators that the production process may be losing control. Lowering a yield limit to accommodate a failing process does not satisfy this requirement. Producers must maintain adequate production and process controls to ensure consistent production and must implement appropriate CAPA to prevent recurrence of nonconforming results.\u003C\u002Fp>\u003Cp>In your response, you commit to retrain manufacturing personnel on effectiveness check requirements and to formally complete the incident report form. Your response is inadequate because you have not conducted a retrospective evaluation of the batches manufactured and it fails to address the root cause of the persistent low-yield problem. Additionally, your response does not address the adequacy of lowering your yield limit from \u003Cstrong>(b)(4)\u003C\u002Fstrong>% to \u003Cstrong>(b)(4)\u003C\u002Fstrong>% as a corrective measure in lieu of identifying and resolving the root cause of persistent yield failures.\u003C\u002Fp>\u003Cp>To ensure proper root cause analysis and appropriate CAPA implementation, investigations must be thorough, well-documented, scientifically sound, and timely. Training alone does not address the systemic failures that allowed deficient investigations to persist undetected by quality unit (QU) oversight.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>An independent, comprehensive review of your EM program to ensure vigilant, timely detection and response to potential product contamination hazards in your manufacturing environment. This assessment should include, but not be limited to:\u003Cbr>o establishing appropriate limits,\u003Cbr>o sampling methods,\u003Cbr>o sampling locations and frequencies,\u003Cbr>o trend analysis,\u003Cbr>o appropriate investigation of deviations and adverse trends,\u003Cbr>o and a comprehensive CAPA plan based on the findings of the assessment.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, OOL results, and failures. Provide a detailed action plan to remediate this system, encompassing the following:\u003Cbr>o staff competencies (including use of appropriate subject matter experts)\u003Cbr>o written procedures\u003Cbr>o scientific rigor and foundation\u003Cbr>o scope determination\u003Cbr>o root cause evaluations\u003Cbr>o CAPA effectiveness\u003Cbr>o quality unit lead functional roles, and oversight to ensure all phases of investigations are appropriately conducted.\u003Cbr>o and, based on above, detailed systemic improvements to the investigation system\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o a determination of whether procedures used by your firm are robust and\u003Cbr>o appropriate\u003Cbr>o provisions for QU oversight throughout your operations to evaluate\u003Cbr>o adherence to appropriate practices\u003Cbr>o a complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>o oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Procedures to ensure that all equipment is clean, suitable for its intended purposes, properly installed, maintained, and capable of repeatedly producing valid results, are not adequately followed. (21 CFR 212.30(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Control of Environmental Monitoring Plates\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to adequately control your EM contact plates used to monitor your production operations.\u003C\u002Fp>\u003Cp>EM plates were stored inside a \u003Cstrong>(b)(4)\u003C\u002Fstrong> containing a significant amount of \u003Cstrong>(b)(4)\u003C\u002Fstrong> solution before and after sampling. You failed to assess the impact of this practice on microbial recovery.\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> is a \u003Cstrong>(b)(4)\u003C\u002Fstrong> with well-documented sporicidal activity. Exposure of EM plates to \u003Cstrong>(b)(4)\u003C\u002Fstrong> can kill or suppress the microorganisms these tests are designed to recover, rendering results unreliable and potentially generating false negatives.\u003C\u002Fp>\u003Cp>In your response, you state that personnel have stopped spraying EM plates and that procedures have been updated accordingly. Your response is inadequate because it does not address the reliability of historical EM data collected using the compromised methodology, does not include a retrospective assessment of past EM results that were affected by \u003Cstrong>(b)(4)\u003C\u002Fstrong> exposure, and does not evaluate the adequacy of prior batch release decisions made in the absence of reliable environmental monitoring data.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Airflow Visualization Studies (Smoke Studies)\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm failed to ensure adequate control of airflow in the ISO 5 critical aseptic processing area. Smoke studies conducted at your facility did not include a dynamic evaluation of LAFW or \u003Cstrong>(b)(4)\u003C\u002Fstrong> operations and therefore do not adequately demonstrate that unidirectional airflow effectively controls air quality during aseptic manufacturing.\u003C\u002Fp>\u003Cp>Adequate contamination control in an aseptic PET drug manufacturing environment requires that monitoring tools, disinfection practices, and airflow qualification studies be designed and executed in a manner that meaningfully protects the sterility of the product. Compromised environmental monitoring media, inadequate airflow qualification, and failure to disinfect product-contact surfaces prior to aseptic operations collectively undermine the sterility assurance of your PET drugs.\u003C\u002Fp>\u003Cp>In your response, you commit to include transfer of starting components and materials prior to mock operations going forward. Your response is inadequate because you do not address the absence of a validated, dynamic evaluation of actual LAFW and \u003Cstrong>(b)(4)\u003C\u002Fstrong> operations under representative conditions.\u003C\u002Fp>\u003Cp>\u003Cem>Failure to Adequately Disinfect \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to adequately disinfect the exterior surfaces of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> prior to aseptic manufacturing operations and failed to establish written procedures for the cleaning and disinfection of \u003Cstrong>(b)(4)\u003C\u002Fstrong> surfaces.\u003C\u002Fp>\u003Cp>In your response, you indicate that personnel were informed and retrained on the procedures for proper disinfection. Your response is inadequate because it does not establish a written disinfection procedure for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> as a required step in your aseptic manufacturing process.\u003C\u002Fp>\u003Cp>PET drug products have short expiry periods. Consequently, PET drug products are released and administered before the results of batch specific sterility testing and EM are known. Your ongoing EM program is essential to detect and respond to potential product contamination hazards in your manufacturing environment in a timely manner. Loss of environmental control in an aseptic manufacturing facility can ultimately pose a serious hazard to patients. Cleaning and disinfection should be performed frequently to ensure consistent control of environmental quality.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive CAPA, overseen by a qualified consultant, for handling microbiological sampling media to ensure robust and reliable data. Establish a system that ensures uninterrupted custody and full reconciliation of all microbiological samples, including but not limited to:\u003Cbr>o unique labeling of each sample\u003Cbr>o signatures of all staff who handle the sample\u003Cbr>o complete tracking of sample integrity and custody\u003Cbr>o date and time of each activity (e.g., sample collection, delivery, incubation, removal from incubator)\u003Cbr>o digital time-stamped photos of all plates\u003Cbr>o signatures of personnel performing reading of microbial counts\u003Cbr>o provisions for verifications and routine quality assurance oversight.\u003C\u002Fli>\u003Cli>Comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including but not limited to:\u003Cbr>o all human interactions within the ISO 5 area (e.g., risk reduction or elimination of manual interventions wherever possible)\u003Cbr>o equipment suitability (e.g., reliability, capability, ergonomics, placement) and sufficient cleanroom space\u003Cbr>o air quality in the ISO 5 area and surrounding room including, but not limited to, air volume and flow\u003Cbr>o facility layout\u003Cbr>o personnel Flow and Material Flow (movement throughout all rooms used to conduct and support sterile operations, and all material transfers)\u003Cbr>o disinfection practices and procedures\u003Cbr>o specific CAPA recommendations that will comprehensively address the design and control hazards identified in the risk assessment\u003C\u002Fli>\u003Cli>A thorough, independent evaluation of airflow unidirectionality in your aseptic process. Ensure smoke studies are conducted under dynamic conditions, with comprehensive evaluations of aseptic processing airflow unidirectionality, including the impact of aseptic interventions and surrounding cleanroom hazards. Conduct the smoke studies after you remediate your aseptic operation, using proper practices (e.g., neutrally buoyant media) to appropriately visualize airflow.\u003C\u002Fli>\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility and explain how this CAPA plan will robustly remediate your deficient sterile manufacturing operations. Include comprehensive changes to the design of both your aseptic processing lines and cleanrooms. Also, describe your plans for qualification and validation of your extensively remediated operations.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Repeat Violations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In a regulatory meeting held on December 13, 2023, FDA discussed similar CGMP violations. You proposed specific remediation for these violations. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\u003Cp>\u003Cstrong>Guidance on PET Drugs\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>See FDA’s guidance document, \u003Cem>PET Drugs—Current Good Manufacturing Practice\u003C\u002Fem>, to help you meet the CGMP requirements when manufacturing PET drugs, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71013\u002Fdownload. This guidance document also references FDA’s guidance document, \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem> for additional concepts and expectations that may apply to PET drug manufacturing, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Unresolved violations may prevent other Federal agencies from awarding contracts. Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356c(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3005334016 and ATTN: Compliance officer Michael Klapal in the letter or in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>FDA posts warning letters to www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE WITH RETURN RECEIPT REQUESTED\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nReference #:\n\n320-27-08\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nNathan J. Fleck, Pharm.D.\n\nRecipient Title\n\nPresident & Owner\n\nNorthland Nuclear Medicine, LLC\n\n1815 Michigan Ave.\n\nBismarck, ND 58504-6121\n\nUnited States\n\n(b)(4)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nOctober 22, 2026\nWARNING LETTER\nReference number: 320-27-08\nTo Dr. Nathan J. Fleck:\nThis warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\nFDA Inspection\nViolations were observed and documented during an inspection of your drug manufacturing facility, Northland Nuclear Medicine, LLC, FDA Establishment Identifier (FEI) 3005334016, located at 1815 Michigan Ave., Bismarck, from May 26 to 29, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for positron emission tomography (PET) drugs. See Title 21 Code of Federal Regulations (CFR), part 212 (21 CFR part 212).\nBecause your methods, facilities, or controls for manufacturing, processing, packaging, or holding do not conform to CGMP, your PET drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your June 11, 2026, response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supporting documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations observed during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility.\n1. Your firm failed to conduct adequate investigations and take appropriate corrective action when a failure of a production batch or any component of the batch failed to meet any of its specifications (21 CFR 212.20(d)).\nInadequate Investigation of Out-of-Limit Environmental Monitoring Results\nYour firm failed to adequately investigate out-of-limit (OOL) environmental monitoring (EM) results, identify the root cause of recurring microbial recoveries, and implement appropriate corrective actions. EM data from March 2024 through April 2026 revealed an adverse trend with over 100 microbial recoveries from ISO 5 areas (e.g., (b)(4) and laminar airflow workstation (LAFW)), including counts of (b)(4) colony forming units (CFUs). These recoveries were not formally identified, preventing your firm from conducting adequate investigations. More than 90 ISO 5 isolates were documented as “resembles previously identified Bacillus colonies” or “resembles previously identified colonies” in lieu of formal microbial identification, with no record of which previously identified organism the colony purportedly resembled. Since December 2024, of approximately 75 ISO 5 microbial recoveries, only two were sent for formal identification. No genus or species recovered in ISO 5 areas has been recorded in your EM log since September 2025. Operator training for interpreting (b)(4) plate results consisted of a single presentation slide instructing personnel to “count CFUs and record results,” with no instruction regarding microbial identification.\nAdditionally, (b)(4) ISO 7 cleanroom certification results for areas surrounding your (b)(4) and LAFW revealed microbial recoveries that exceeded your action limits and were not adequately investigated. For example, a (b)(4) CFU active air recovery described as bacterial and yeast was not adequately identified because the sample plates were received with (b)(4) on the lid. For a (b)(4) CFU recovery sent for identification, (b)(4) CFU were identified as Pseudopithomyces palmicola and the remaining (b)(4) CFU were identified as Micrococcus spp. and coryneform bacillus. Investigations were not initiated. Further, your (b)(4) product review acknowledges “excess CFUs as an ongoing issue in the (b)(4) cleanroom.”\nYour firm systematically failed to adequately investigate out-of-limit environmental monitoring results, to identify root causes of recurring microbial contamination in critical ISO 5 areas, and to implement effective corrective action and preventive action (CAPA).\nIn your response, you commit to ensuring that future microbial colony recoveries from ISO 5 areas will be properly identified and documented. Your response is inadequate because it does not include a retrospective assessment of the unidentified recoveries or an evaluation of adverse trends, does not assess the adequacy of past batch release decisions made in the absence of organism identification, and does not address the documented presence of spore-forming bacteria and fungi in your ISO-classified environments.\nEnvironmental isolate identification data provides essential information for an investigation into routes of contamination, such as when investigating an adverse environmental control trend, media fill contamination, or a product sterility testing failure. EM should include routine identification of microorganisms to the species (or, where appropriate, genus) level, including isolates recovered from an ISO 5 environment, its surrounding cleanroom, and personnel.\nIt is essential that cleaning and disinfection procedures are described in sufficient detail, including the preparation, disinfectant selection, and contact time to enable reproducibility and ensure that potential contaminants are adequately removed from surfaces. The effectiveness of disinfection procedures should be evaluated through a routine EM program, and adverse trends should prompt reassessment of disinfectant selection, concentration, contact time, and application frequency.\nInadequate Investigation and CAPA for Recurring Manufacturing Deficiencies\nYou failed to conduct adequate effectiveness checks for CAPAs to prevent recurrence.\nMultiple CAPAs for recurring low (b)(4) yields were closed without your required effectiveness checks. Yields continued to fall below your established (b)(4)% limit. No investigations were initiated for approximately (b)(4) batches manufactured between August 2024 and April 2025 that failed the (b)(4)% limit, with yields as low as (b)(4)%. Rather than identifying and correcting the root cause, you lowered the yield limit from (b)(4)% to (b)(4)%. Yields subsequently fell below your revised (b)(4)% limit. Notably, Incident Report NNM 2025 08 states, “This has been an ongoing issue now for more than a year. We are continuing to evaluate the situation in an attempt to increase yields.” The effectiveness check for that incident was marked “No” with no additional corrective action identified. You continue to manufacture your PET drug without resolving the root cause of the low yields.\nPET drug producers must establish appropriate action limits for radiochemical yield and investigate and correct the root cause when those limits are exceeded. Low yields or a downward trend in yield are recognized indicators that the production process may be losing control. Lowering a yield limit to accommodate a failing process does not satisfy this requirement. Producers must maintain adequate production and process controls to ensure consistent production and must implement appropriate CAPA to prevent recurrence of nonconforming results.\nIn your response, you commit to retrain manufacturing personnel on effectiveness check requirements and to formally complete the incident report form. Your response is inadequate because you have not conducted a retrospective evaluation of the batches manufactured and it fails to address the root cause of the persistent low-yield problem. Additionally, your response does not address the adequacy of lowering your yield limit from (b)(4)% to (b)(4)% as a corrective measure in lieu of identifying and resolving the root cause of persistent yield failures.\nTo ensure proper root cause analysis and appropriate CAPA implementation, investigations must be thorough, well-documented, scientifically sound, and timely. Training alone does not address the systemic failures that allowed deficient investigations to persist undetected by quality unit (QU) oversight.\nIn response to this letter, provide:\nAn independent, comprehensive review of your EM program to ensure vigilant, timely detection and response to potential product contamination hazards in your manufacturing environment. This assessment should include, but not be limited to:\no establishing appropriate limits,\no sampling methods,\no sampling locations and frequencies,\no trend analysis,\no appropriate investigation of deviations and adverse trends,\no and a comprehensive CAPA plan based on the findings of the assessment.\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, OOL results, and failures. Provide a detailed action plan to remediate this system, encompassing the following:\no staff competencies (including use of appropriate subject matter experts)\no written procedures\no scientific rigor and foundation\no scope determination\no root cause evaluations\no CAPA effectiveness\no quality unit lead functional roles, and oversight to ensure all phases of investigations are appropriately conducted.\no and, based on above, detailed systemic improvements to the investigation system\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no a determination of whether procedures used by your firm are robust and\no appropriate\no provisions for QU oversight throughout your operations to evaluate\no adherence to appropriate practices\no a complete and final review of each batch and its related information before the QU disposition decision\no oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n2. Procedures to ensure that all equipment is clean, suitable for its intended purposes, properly installed, maintained, and capable of repeatedly producing valid results, are not adequately followed. (21 CFR 212.30(b)).\nInadequate Control of Environmental Monitoring Plates\nYou failed to adequately control your EM contact plates used to monitor your production operations.\nEM plates were stored inside a (b)(4) containing a significant amount of (b)(4) solution before and after sampling. You failed to assess the impact of this practice on microbial recovery.\n(b)(4) is a (b)(4) with well-documented sporicidal activity. Exposure of EM plates to (b)(4) can kill or suppress the microorganisms these tests are designed to recover, rendering results unreliable and potentially generating false negatives.\nIn your response, you state that personnel have stopped spraying EM plates and that procedures have been updated accordingly. Your response is inadequate because it does not address the reliability of historical EM data collected using the compromised methodology, does not include a retrospective assessment of past EM results that were affected by (b)(4) exposure, and does not evaluate the adequacy of prior batch release decisions made in the absence of reliable environmental monitoring data.\nInadequate Airflow Visualization Studies (Smoke Studies)\nYour firm failed to ensure adequate control of airflow in the ISO 5 critical aseptic processing area. Smoke studies conducted at your facility did not include a dynamic evaluation of LAFW or (b)(4) operations and therefore do not adequately demonstrate that unidirectional airflow effectively controls air quality during aseptic manufacturing.\nAdequate contamination control in an aseptic PET drug manufacturing environment requires that monitoring tools, disinfection practices, and airflow qualification studies be designed and executed in a manner that meaningfully protects the sterility of the product. Compromised environmental monitoring media, inadequate airflow qualification, and failure to disinfect product-contact surfaces prior to aseptic operations collectively undermine the sterility assurance of your PET drugs.\nIn your response, you commit to include transfer of starting components and materials prior to mock operations going forward. Your response is inadequate because you do not address the absence of a validated, dynamic evaluation of actual LAFW and (b)(4) operations under representative conditions.\nFailure to Adequately Disinfect (b)(4)\nYou failed to adequately disinfect the exterior surfaces of the (b)(4) prior to aseptic manufacturing operations and failed to establish written procedures for the cleaning and disinfection of (b)(4) surfaces.\nIn your response, you indicate that personnel were informed and retrained on the procedures for proper disinfection. Your response is inadequate because it does not establish a written disinfection procedure for the (b)(4) as a required step in your aseptic manufacturing process.\nPET drug products have short expiry periods. Consequently, PET drug products are released and administered before the results of batch specific sterility testing and EM are known. Your ongoing EM program is essential to detect and respond to potential product contamination hazards in your manufacturing environment in a timely manner. Loss of environmental control in an aseptic manufacturing facility can ultimately pose a serious hazard to patients. Cleaning and disinfection should be performed frequently to ensure consistent control of environmental quality.\nIn response to this letter, provide:\nA comprehensive CAPA, overseen by a qualified consultant, for handling microbiological sampling media to ensure robust and reliable data. Establish a system that ensures uninterrupted custody and full reconciliation of all microbiological samples, including but not limited to:\no unique labeling of each sample\no signatures of all staff who handle the sample\no complete tracking of sample integrity and custody\no date and time of each activity (e.g., sample collection, delivery, incubation, removal from incubator)\no digital time-stamped photos of all plates\no signatures of personnel performing reading of microbial counts\no provisions for verifications and routine quality assurance oversight.\nComprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including but not limited to:\no all human interactions within the ISO 5 area (e.g., risk reduction or elimination of manual interventions wherever possible)\no equipment suitability (e.g., reliability, capability, ergonomics, placement) and sufficient cleanroom space\no air quality in the ISO 5 area and surrounding room including, but not limited to, air volume and flow\no facility layout\no personnel Flow and Material Flow (movement throughout all rooms used to conduct and support sterile operations, and all material transfers)\no disinfection practices and procedures\no specific CAPA recommendations that will comprehensively address the design and control hazards identified in the risk assessment\nA thorough, independent evaluation of airflow unidirectionality in your aseptic process. Ensure smoke studies are conducted under dynamic conditions, with comprehensive evaluations of aseptic processing airflow unidirectionality, including the impact of aseptic interventions and surrounding cleanroom hazards. Conduct the smoke studies after you remediate your aseptic operation, using proper practices (e.g., neutrally buoyant media) to appropriately visualize airflow.\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility and explain how this CAPA plan will robustly remediate your deficient sterile manufacturing operations. Include comprehensive changes to the design of both your aseptic processing lines and cleanrooms. Also, describe your plans for qualification and validation of your extensively remediated operations.\nRepeat Violations at Facility\nIn a regulatory meeting held on December 13, 2023, FDA discussed similar CGMP violations. You proposed specific remediation for these violations. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\nGuidance on PET Drugs\nSee FDA’s guidance document, PET Drugs—Current Good Manufacturing Practice, to help you meet the CGMP requirements when manufacturing PET drugs, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71013\u002Fdownload. This guidance document also references FDA’s guidance document, Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice for additional concepts and expectations that may apply to PET drug manufacturing, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nYou are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nUnresolved violations may prevent other Federal agencies from awarding contracts. Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356c(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3005334016 and ATTN: Compliance officer Michael Klapal in the letter or in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nFDA posts warning letters to www.FDA.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration","Northland Nuclear Medicine, LLC","northland-nuclear-medicine-llc-736893-10222026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorthland-nuclear-medicine-llc-736893-10222026","736893","Nathan J. Fleck, Pharm.D.","2026-11-03T01:02:46.643+00:00","VIA UNITED PARCEL SERVICE WITH RETURN RECEIPT REQUESTED VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","320-27-08","2026-10-22",{"id":112,"raw":113,"subject":117,"body_html":118,"body_text":119,"firm_name":120,"letter_id":121,"created_at":122,"fei_number":20,"letter_url":123,"updated_at":47,"action_type":23,"case_status":48,"posted_date":124,"marcs_cms_no":125,"product_type":51,"closeout_date":20,"issuing_office":39,"recipient_name":20,"body_fetched_at":126,"delivery_method":54,"recipient_title":20,"reference_number":20,"action_taken_date":127,"medical_device_id":20,"response_letter_date":20},21697,[114,115,116,39,117,13,13,13],"\u003Ctime datetime=\"2026-10-06T04:00:00Z\">10\u002F06\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-09-24T04:00:00Z\">09\u002F24\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcheap-medicine-shopwwwcheapmedicineshopcom-737810-09242026\">Cheap Medicine Shop\u002Fwww.cheapmedicineshop.com\u003C\u002Fa>","Unapproved New Drugs\u002FMisbranded (Internet Pharmacy)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Cheap Medicine Shop\u002Fwww.cheapmedicineshop.com\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ana@cheapmedicineshop.com\"> ana@cheapmedicineshop.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 24, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference Number: MARCS-CMS 737810\u003C\u002Fp>\u003Cp>To Cheap Medicine shop:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website www.cheapmedicineshop.com. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that you comply with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>As discussed below, FDA has observed that www.cheapmedicineshop.com introduces into interstate commerce unapproved and misbranded injectable semaglutide drug products. There are inherent risks to consumers who purchase unapproved and misbranded drug products. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body's natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis.\u003C\u002Fp>\u003Cp>Accordingly, FDA requests that www.cheapmedicineshop.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of your website www.cheapmedicineshop.com, FDA Establishment Identifier (FEI) 3041109073, on August 26, 2026, and September 2, 2026.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On your website at internet address www.cheapmedicineshop.com, you introduce into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), 301(d), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 331(a), 331(d), 352(f)(1), 353(b)(1), and 355(a)).\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>\u003Cem>Unapproved New Drug Violations\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Certain products offered for sale by www.cheapmedicineshop.com are drugs within the meaning of section 201(g) of the FD&amp;C Act (21 U.S.C. 321(g)) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For because they are intended to affect the structure or function of the body. These drugs are also new drugs as defined by section 201(p) of the FD&amp;C Act (21 U.S.C. 321(p)), because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>You failed to obtain approved applications pursuant to section 505 of the FD&amp;C Act (21 U.S.C. 355) for these products that you have introduced into interstate commerce. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>An example of an unapproved semaglutide drug product you offer for sale on www.cheapmedicineshop.com is semaglutide marketed as \"Semanext Injection.\" Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 Code of Federal Regulations (CFR) 201.128) includes the claim \"Semanext Injection is a weekly injectable medicine used for controlling blood sugar in adults. It also supports weight loss and obesity management in individuals with weight-related health conditions.\"\u003C\u002Fp>\u003Cp>While there are FDA-approved versions of semaglutide drug products on the market in the United States, there are no approved drug applications pursuant to section 505 of the FD&amp;C Act in effect for \"Semanext Injection” offered by www.cheapmedicineshop.com. Currently there are several semaglutide products FDA-approved for the U.S. market, and these products are only available pursuant to a prescription from a licensed practitioner.\u003C\u002Fp>\u003Cp>FDA-approved semaglutide injection marketed under the brand name OZEMPIC is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; to reduce the risk of major adverse cardiovascular (CV) events in adults with type 2 diabetes mellitus and established CV disease; and to reduce the risk of sustained eGFR decline, end-stage kidney disease, and CV death in adults with type 2 diabetes mellitus and chronic kidney disease.\u003C\u002Fp>\u003Cp>FDA-approved semaglutide injection marketed under the brand name WEGOVY is indicated as an adjunct to a reduced calorie diet and increased physical activity to reduce the risk of major adverse CV events in adults with established CV disease and either obesity or overweight, to reduce excess body weight and maintain weight reduction long term in certain adult and pediatric patients, and for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis in adults.\u003C\u002Fp>\u003Cp>Furthermore, FDA-approved semaglutide products bear a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses the risk of thyroid C-cell tumors.\u003C\u002Fp>\u003Cp>\u003Cem>Misbranded Drug Violations\u003C\u002Fem>\u003C\u002Fp>\u003Cp>A drug is misbranded under section 502(f)(1) of the FD&amp;C Act if its labeling fails to bear adequate directions for use. \"Adequate directions for use\" means directions under which a layperson can use a drug safely and for the purposes for which it is intended (see 21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1) of the FD&amp;C Act include those that, because of their toxicity or other potentiality for harmful effect, or the method of their use, or the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&amp;C Act (21 U.S.C. 353(b)(1)(A)), can be used safely only at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\u003Cp>You failed to bear adequate directions for use on the labeling for this drug product that you have introduced into interstate commerce. Because the aforementioned drug is a prescription drug intended for conditions that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use the product safely for their intended use. Consequently, the labeling for this drug product fails to bear adequate directions for use, causing it to be misbranded under section 502(f)(1) of the FD&amp;C Act. Because this drug is not approved in the United States, it is also not exempt under 21 CFR 201.115(a) from the requirements of section 502(f)(1) of the FD&amp;C Act. By offering this drug for sale to U.S. consumers, www.cheapmedicineshop.com is causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov within 15 business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your written response with reference number “MARCS-CMS 737810” in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.fda.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>Sangeeta Vaswani Chatterjee, PharmD\u003Cbr>Director\u003Cbr>Office of Drug Security, Integrity, and Response\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nCheap Medicine Shop\u002Fwww.cheapmedicineshop.com\n\nIndia\n\nana@cheapmedicineshop.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSeptember 24, 2026\nWARNING LETTER\nReference Number: MARCS-CMS 737810\nTo Cheap Medicine shop:\nThis warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website www.cheapmedicineshop.com. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that you comply with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\nAs discussed below, FDA has observed that www.cheapmedicineshop.com introduces into interstate commerce unapproved and misbranded injectable semaglutide drug products. There are inherent risks to consumers who purchase unapproved and misbranded drug products. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body's natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis.\nAccordingly, FDA requests that www.cheapmedicineshop.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm.\nFDA Review\nViolations were identified and documented during a review of your website www.cheapmedicineshop.com, FDA Establishment Identifier (FEI) 3041109073, on August 26, 2026, and September 2, 2026.\nViolations of the Federal Food, Drug, and Cosmetic Act\nOn your website at internet address www.cheapmedicineshop.com, you introduce into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), 301(d), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 331(a), 331(d), 352(f)(1), 353(b)(1), and 355(a)).\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nUnapproved New Drug Violations\nCertain products offered for sale by www.cheapmedicineshop.com are drugs within the meaning of section 201(g) of the FD&C Act (21 U.S.C. 321(g)) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For because they are intended to affect the structure or function of the body. These drugs are also new drugs as defined by section 201(p) of the FD&C Act (21 U.S.C. 321(p)), because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act.\nYou failed to obtain approved applications pursuant to section 505 of the FD&C Act (21 U.S.C. 355) for these products that you have introduced into interstate commerce. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act.\nAn example of an unapproved semaglutide drug product you offer for sale on www.cheapmedicineshop.com is semaglutide marketed as \"Semanext Injection.\" Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 Code of Federal Regulations (CFR) 201.128) includes the claim \"Semanext Injection is a weekly injectable medicine used for controlling blood sugar in adults. It also supports weight loss and obesity management in individuals with weight-related health conditions.\"\nWhile there are FDA-approved versions of semaglutide drug products on the market in the United States, there are no approved drug applications pursuant to section 505 of the FD&C Act in effect for \"Semanext Injection” offered by www.cheapmedicineshop.com. Currently there are several semaglutide products FDA-approved for the U.S. market, and these products are only available pursuant to a prescription from a licensed practitioner.\nFDA-approved semaglutide injection marketed under the brand name OZEMPIC is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; to reduce the risk of major adverse cardiovascular (CV) events in adults with type 2 diabetes mellitus and established CV disease; and to reduce the risk of sustained eGFR decline, end-stage kidney disease, and CV death in adults with type 2 diabetes mellitus and chronic kidney disease.\nFDA-approved semaglutide injection marketed under the brand name WEGOVY is indicated as an adjunct to a reduced calorie diet and increased physical activity to reduce the risk of major adverse CV events in adults with established CV disease and either obesity or overweight, to reduce excess body weight and maintain weight reduction long term in certain adult and pediatric patients, and for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis in adults.\nFurthermore, FDA-approved semaglutide products bear a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses the risk of thyroid C-cell tumors.\nMisbranded Drug Violations\nA drug is misbranded under section 502(f)(1) of the FD&C Act if its labeling fails to bear adequate directions for use. \"Adequate directions for use\" means directions under which a layperson can use a drug safely and for the purposes for which it is intended (see 21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1) of the FD&C Act include those that, because of their toxicity or other potentiality for harmful effect, or the method of their use, or the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act (21 U.S.C. 353(b)(1)(A)), can be used safely only at the direction, and under the supervision, of a licensed practitioner.\nYou failed to bear adequate directions for use on the labeling for this drug product that you have introduced into interstate commerce. Because the aforementioned drug is a prescription drug intended for conditions that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use the product safely for their intended use. Consequently, the labeling for this drug product fails to bear adequate directions for use, causing it to be misbranded under section 502(f)(1) of the FD&C Act. Because this drug is not approved in the United States, it is also not exempt under 21 CFR 201.115(a) from the requirements of section 502(f)(1) of the FD&C Act. By offering this drug for sale to U.S. consumers, www.cheapmedicineshop.com is causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&C Act.\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nSend your written response to FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov within 15 business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your written response with reference number “MARCS-CMS 737810” in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nIf you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\nPlease note FDA posts warning letters on www.fda.gov.\nSincerely,\n\u002FS\u002F\nSangeeta Vaswani Chatterjee, PharmD\nDirector\nOffice of Drug Security, Integrity, and Response\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration","Cheap Medicine Shop\u002Fwww.cheapmedicineshop.com","cheap-medicine-shopwwwcheapmedicineshopcom-737810-09242026","2026-10-14T12:31:16.41489+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcheap-medicine-shopwwwcheapmedicineshopcom-737810-09242026","2026-10-06","737810","2026-10-14T12:32:55.392+00:00","2026-09-24",{"id":129,"raw":130,"subject":133,"body_html":134,"body_text":135,"firm_name":136,"letter_id":137,"created_at":122,"fei_number":20,"letter_url":138,"updated_at":47,"action_type":23,"case_status":48,"posted_date":124,"marcs_cms_no":139,"product_type":51,"closeout_date":20,"issuing_office":39,"recipient_name":20,"body_fetched_at":140,"delivery_method":54,"recipient_title":20,"reference_number":20,"action_taken_date":141,"medical_device_id":20,"response_letter_date":20},21696,[114,131,132,39,133,13,13,13],"\u003Ctime datetime=\"2026-09-23T04:00:00Z\">09\u002F23\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fonline-generic-medicinewwwonlinegenericmedicinecom-737806-09232026\">Online Generic Medicine\u002Fwww.onlinegenericmedicine.com\u003C\u002Fa>","Unapproved New Drug\u002FMisbranded (Internet Pharmacy)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Online Generic Medicine\u002Fwww.onlinegenericmedicine.com\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 23, 2026\u003Cbr>\u003Cbr>info@onlinegenericmedicine.com\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference Number: MARCS-CMS 737806\u003C\u002Fp>\u003Cp>To Online Generic Medicine:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website www.onlinegenericmedicine.com. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that you comply with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>As discussed below, FDA has observed that www.onlinegenericmedicine.com introduces into interstate commerce unapproved and misbranded injectable semaglutide drug products. There are inherent risks to consumers who purchase unapproved and misbranded drug products. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body's natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis.\u003C\u002Fp>\u003Cp>Accordingly, FDA requests that www.onlinegenericmedicine.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of your website www.onlinegenericmedicine.com, FDA Establishment Identifier (FEI) 3048678145, on August 26, 2026, and September 2, 2026.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On your website at internet address www.onlinegenericmedicine.com, you introduce into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), 301(d), 301(k), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 331(a), 331(d), 331(k), 352(f)(1), 353(b)(1), and 355(a)).\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>\u003Cem>Unapproved New Drug Violations\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Certain products offered for sale by www.onlinegenericmedicine.com are drugs within the meaning of section 201(g) of the FD&amp;C Act (21 U.S.C. 321(g)) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For because they are intended to affect the structure or function of the body. These drugs are also new drugs as defined by section 201(p) of the FD&amp;C Act (21 U.S.C. 321(p)), because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>You failed to obtain approved applications pursuant to section 505 of the FD&amp;C Act (21 U.S.C. 355) for these products that you have introduced into interstate commerce. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>An example of an unapproved semaglutide drug product you offer for sale on www.onlinegenericmedicine.com is semaglutide marketed as \"Semanat Injection (Semaglutide).\" Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 Code of Federal Regulations (CFR) 201.128) includes the claim \"Semanat Injection, [sic] is a potent glucagon-like peptide-1 (GLP-1) receptor agonist wich [sic] is designed to help manage blood sugar levels in type 2 diabetes and support weight management.\"\u003C\u002Fp>\u003Cp>While there are FDA-approved versions of semaglutide drug products on the market in the United States, there are no approved drug applications pursuant to section 505 of the FD&amp;C Act in effect for \"Semanat Injection (Semaglutide)” offered by www.onlinegenericmedicine.com. Currently there are several semaglutide products FDA-approved for the U.S. market, and these products are only available pursuant to a prescription from a licensed practitioner.\u003C\u002Fp>\u003Cp>FDA-approved semaglutide injection marketed under the brand name OZEMPIC is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; to reduce the risk of major adverse cardiovascular (CV) events in adults with type 2 diabetes mellitus and established CV disease; and to reduce the risk of sustained eGFR decline, end-stage kidney disease, and CV death in adults with type 2 diabetes mellitus and chronic kidney disease.\u003C\u002Fp>\u003Cp>FDA-approved semaglutide injection marketed under the brand name WEGOVY is indicated as an adjunct to a reduced calorie diet and increased physical activity to reduce the risk of major adverse CV events in adults with established CV disease and either obesity or overweight, to reduce excess body weight and maintain weight reduction long term in certain adult and pediatric patients, and for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis in adults.\u003C\u002Fp>\u003Cp>Furthermore, FDA-approved semaglutide products bear a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses the risk of thyroid C-cell tumors.\u003C\u002Fp>\u003Cp>\u003Cem>Misbranded Drug Violations\u003C\u002Fem>\u003C\u002Fp>\u003Cp>A drug is misbranded under section 502(f)(1) of the FD&amp;C Act if its labeling fails to bear adequate directions for use. \"Adequate directions for use\" means directions under which a layperson can use a drug safely and for the purposes for which it is intended (see 21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1) of the FD&amp;C Act include those that, because of their toxicity or other potentiality for harmful effect, or the method of their use, or the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&amp;C Act (21 U.S.C. 353(b)(1)(A)), can be used safely only at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\u003Cp>You failed to bear adequate directions for use on the labeling for this drug product that you have introduced into interstate commerce. Because the aforementioned drug is a prescription drug intended for conditions that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use the product safely for their intended use. Consequently, the labeling for this drug product fails to bear adequate directions for use, causing it to be misbranded under section 502(f)(1) of the FD&amp;C Act. Because this drug is not approved in the United States, it is also not exempt under 21 CFR 201.115(a) from the requirements of section 502(f)(1) of the FD&amp;C Act. By offering this drug for sale to U.S. consumers, www.onlinegenericmedicine.com is causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Furthermore, under U.S. law, prescription drugs can be dispensed only pursuant to a prescription from a health care practitioner licensed by law to administer prescription drugs. By offering the aforementioned drug product without requiring a prescription, www.onlinegenericmedicine.com jeopardizes patient safety and misbrands the drug product under section 503(b)(1) of the FD&amp;C Act. Dispensing a prescription drug without a prescription is an act which results in the drug being misbranded while held for sale, in violation of section 301(k) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov within 15 business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your written response with reference number “MARCS-CMS 737806” in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.fda.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>Sangeeta Vaswani Chatterjee, PharmD\u003Cbr>Director\u003Cbr>Office of Drug Security, Integrity, and Response\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nOnline Generic Medicine\u002Fwww.onlinegenericmedicine.com\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSeptember 23, 2026\n\ninfo@onlinegenericmedicine.com\nWARNING LETTER\nReference Number: MARCS-CMS 737806\nTo Online Generic Medicine:\nThis warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website www.onlinegenericmedicine.com. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that you comply with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\nAs discussed below, FDA has observed that www.onlinegenericmedicine.com introduces into interstate commerce unapproved and misbranded injectable semaglutide drug products. There are inherent risks to consumers who purchase unapproved and misbranded drug products. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body's natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis.\nAccordingly, FDA requests that www.onlinegenericmedicine.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm.\nFDA Review\nViolations were identified and documented during a review of your website www.onlinegenericmedicine.com, FDA Establishment Identifier (FEI) 3048678145, on August 26, 2026, and September 2, 2026.\nViolations of the Federal Food, Drug, and Cosmetic Act\nOn your website at internet address www.onlinegenericmedicine.com, you introduce into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), 301(d), 301(k), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 331(a), 331(d), 331(k), 352(f)(1), 353(b)(1), and 355(a)).\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nUnapproved New Drug Violations\nCertain products offered for sale by www.onlinegenericmedicine.com are drugs within the meaning of section 201(g) of the FD&C Act (21 U.S.C. 321(g)) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For because they are intended to affect the structure or function of the body. These drugs are also new drugs as defined by section 201(p) of the FD&C Act (21 U.S.C. 321(p)), because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act.\nYou failed to obtain approved applications pursuant to section 505 of the FD&C Act (21 U.S.C. 355) for these products that you have introduced into interstate commerce. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act.\nAn example of an unapproved semaglutide drug product you offer for sale on www.onlinegenericmedicine.com is semaglutide marketed as \"Semanat Injection (Semaglutide).\" Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 Code of Federal Regulations (CFR) 201.128) includes the claim \"Semanat Injection, [sic] is a potent glucagon-like peptide-1 (GLP-1) receptor agonist wich [sic] is designed to help manage blood sugar levels in type 2 diabetes and support weight management.\"\nWhile there are FDA-approved versions of semaglutide drug products on the market in the United States, there are no approved drug applications pursuant to section 505 of the FD&C Act in effect for \"Semanat Injection (Semaglutide)” offered by www.onlinegenericmedicine.com. Currently there are several semaglutide products FDA-approved for the U.S. market, and these products are only available pursuant to a prescription from a licensed practitioner.\nFDA-approved semaglutide injection marketed under the brand name OZEMPIC is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; to reduce the risk of major adverse cardiovascular (CV) events in adults with type 2 diabetes mellitus and established CV disease; and to reduce the risk of sustained eGFR decline, end-stage kidney disease, and CV death in adults with type 2 diabetes mellitus and chronic kidney disease.\nFDA-approved semaglutide injection marketed under the brand name WEGOVY is indicated as an adjunct to a reduced calorie diet and increased physical activity to reduce the risk of major adverse CV events in adults with established CV disease and either obesity or overweight, to reduce excess body weight and maintain weight reduction long term in certain adult and pediatric patients, and for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis in adults.\nFurthermore, FDA-approved semaglutide products bear a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses the risk of thyroid C-cell tumors.\nMisbranded Drug Violations\nA drug is misbranded under section 502(f)(1) of the FD&C Act if its labeling fails to bear adequate directions for use. \"Adequate directions for use\" means directions under which a layperson can use a drug safely and for the purposes for which it is intended (see 21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1) of the FD&C Act include those that, because of their toxicity or other potentiality for harmful effect, or the method of their use, or the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act (21 U.S.C. 353(b)(1)(A)), can be used safely only at the direction, and under the supervision, of a licensed practitioner.\nYou failed to bear adequate directions for use on the labeling for this drug product that you have introduced into interstate commerce. Because the aforementioned drug is a prescription drug intended for conditions that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use the product safely for their intended use. Consequently, the labeling for this drug product fails to bear adequate directions for use, causing it to be misbranded under section 502(f)(1) of the FD&C Act. Because this drug is not approved in the United States, it is also not exempt under 21 CFR 201.115(a) from the requirements of section 502(f)(1) of the FD&C Act. By offering this drug for sale to U.S. consumers, www.onlinegenericmedicine.com is causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&C Act.\nFurthermore, under U.S. law, prescription drugs can be dispensed only pursuant to a prescription from a health care practitioner licensed by law to administer prescription drugs. By offering the aforementioned drug product without requiring a prescription, www.onlinegenericmedicine.com jeopardizes patient safety and misbrands the drug product under section 503(b)(1) of the FD&C Act. Dispensing a prescription drug without a prescription is an act which results in the drug being misbranded while held for sale, in violation of section 301(k) of the FD&C Act.\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nSend your written response to FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov within 15 business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your written response with reference number “MARCS-CMS 737806” in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nIf you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\nPlease note FDA posts warning letters on www.fda.gov.\nSincerely,\n\u002FS\u002F\nSangeeta Vaswani Chatterjee, PharmD\nDirector\nOffice of Drug Security, Integrity, and Response\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration","Online Generic Medicine\u002Fwww.onlinegenericmedicine.com","online-generic-medicinewwwonlinegenericmedicinecom-737806-09232026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fonline-generic-medicinewwwonlinegenericmedicinecom-737806-09232026","737806","2026-10-14T12:33:20.472+00:00","2026-09-23",{"id":143,"raw":144,"subject":99,"body_html":148,"body_text":149,"firm_name":150,"letter_id":151,"created_at":152,"fei_number":20,"letter_url":153,"updated_at":154,"action_type":23,"case_status":48,"posted_date":155,"marcs_cms_no":156,"product_type":51,"closeout_date":20,"issuing_office":39,"recipient_name":157,"body_fetched_at":158,"delivery_method":159,"recipient_title":20,"reference_number":160,"action_taken_date":161,"medical_device_id":20,"response_letter_date":20},854,[145,146,147,39,99,13,13,13],"\u003Ctime datetime=\"2025-06-03T04:00:00Z\">06\u002F03\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-03-24T04:00:00Z\">03\u002F24\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhuangshi-hygienic-material-medicine-co-ltd-700658-03242025\">Huangshi Hygienic Material Medicine Co., Ltd.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-56\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Ye Lin Chairman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager, and Owner \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Huangshi Hygienic Material Medicine Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>386 Shenxia Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Huangshi Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hubei Sheng\u003C\u002Fspan>, \u003Cspan>435003\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-56\u003C\u002Fp>\u003Cp>March 24, 2025\u003Cbr>\u003Cbr>Dear Mr. Lin,\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Huangshi Hygienic Material Medicine Co., Ltd., FEI 3005543486, at 386 Shenxia Road, Huangshi, Hubei, 435003, from August 26 to 30, 2024.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your September 20, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to perform appropriate testing on your drug products prior to release for distribution. Your facility management stated to our investigator that testing for identity and strength of each active ingredient prior to release had not been performed for approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches manufactured for the U.S. market.\u003C\u002Fp>\u003Cp>Full release testing, including for identity, strength, and purity, must be performed prior to batch release and distribution. Without adequate finished product release testing, you do not have scientific evidence that each batch of drug product conforms to appropriate specifications before release.\u003C\u002Fp>\u003Cp>In your response, you state that exported products are manufactured using the same process and formulation as domestic products. As a result, the internal quality standards for export products are based on those for domestic sales products, which does not require testing for identity or quantity of active ingredients.\u003C\u002Fp>\u003Cp>Your response is inadequate. You state that your internal quality standards and operating procedures for export products will be revised to include the identity or quantity of active ingredients. Both identity and quantity of active ingredients testing are required to be performed prior to release. You fail to assess the risk of drugs products that were released to the U.S. market without adequate testing. In addition, you do not discuss your plan to perform validation (or verification, as appropriate) of your test methods.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a batch disposition decision.\u003Cbr>o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to assure that the drug product bore an expiration date that was supported by appropriate stability testing (21 CFR 211.137(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to establish an adequate stability program and lacked chemical and microbial testing data to demonstrate that your over-the-counter (OTC) drug products will remain acceptable throughout their assigned expiry period.\u003C\u002Fp>\u003Cp>You assigned U.S. marketed product expiration dates based on your domestic (China) product stability testing. However, the formulations and components for products intended for the U.S. market differed from your domestic product formulations.\u003C\u002Fp>\u003Cp>In your response, you state you communicated with distributors of products marketed in the United States to request samples of each product for stability testing.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide sufficient information regarding the batches, formulation, analytical method, and testing interval for the remaining expiry period. We acknowledge that you have not shipped product to the U.S. market since \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your drug products in the U.S. market will expire by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. For products without appropriate stability studies, you lack sufficient scientific evidence to support that the drug products will meet established specifications and retain their quality attributes throughout their labeled expiry. Please refer to 21 CFR 211.166, “Stability testing,” for the requirements of stability testing.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability indicating methods.\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\u003Cbr>o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid. Include your plan to ensure appropriate procedures are in place regarding maintaining reserve samples as required under 21 CFR 211.170.\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint).\u003C\u002Fli>\u003Cli>All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\u003Cli>Provide interim measures to ensure that products currently in the U.S. market meet the required quality attributes.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your chemical and microbiological drug test methods to determine the suitability of the method. If verification or validation is needed, provide a plan and timeline for completion of the appropriate activity.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Huangshi Hygienic Material Medicine Co. Ltd., 386 Shenxia Road, Huangshi, Hubei, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3005543486 and ATTN: Marva Taylor.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>Cc: Mr. Sen Lin, Vice President of Operations\u003Cbr>linsen@hswcpharma.com\u003C\u002Fp>\u003Cp>_______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> i.e. Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-25-56\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Ye Lin Chairman\n\nRecipient Title\n\nGeneral Manager, and Owner\n\nHuangshi Hygienic Material Medicine Co., Ltd.\n\n386 Shenxia Road\n\nHuangshi Shi\n\nHubei Sheng, 435003\n\nChina\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-56\nMarch 24, 2025\n\nDear Mr. Lin,\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Huangshi Hygienic Material Medicine Co., Ltd., FEI 3005543486, at 386 Shenxia Road, Huangshi, Hubei, 435003, from August 26 to 30, 2024.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your September 20, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\nYour firm failed to perform appropriate testing on your drug products prior to release for distribution. Your facility management stated to our investigator that testing for identity and strength of each active ingredient prior to release had not been performed for approximately (b)(4) batches manufactured for the U.S. market.\nFull release testing, including for identity, strength, and purity, must be performed prior to batch release and distribution. Without adequate finished product release testing, you do not have scientific evidence that each batch of drug product conforms to appropriate specifications before release.\nIn your response, you state that exported products are manufactured using the same process and formulation as domestic products. As a result, the internal quality standards for export products are based on those for domestic sales products, which does not require testing for identity or quantity of active ingredients.\nYour response is inadequate. You state that your internal quality standards and operating procedures for export products will be revised to include the identity or quantity of active ingredients. Both identity and quantity of active ingredients testing are required to be performed prior to release. You fail to assess the risk of drugs products that were released to the U.S. market without adequate testing. In addition, you do not discuss your plan to perform validation (or verification, as appropriate) of your test methods.\nIn response to this letter, provide:\nA list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a batch disposition decision.\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n2. Your firm failed to assure that the drug product bore an expiration date that was supported by appropriate stability testing (21 CFR 211.137(a)).\nYour firm failed to establish an adequate stability program and lacked chemical and microbial testing data to demonstrate that your over-the-counter (OTC) drug products will remain acceptable throughout their assigned expiry period.\nYou assigned U.S. marketed product expiration dates based on your domestic (China) product stability testing. However, the formulations and components for products intended for the U.S. market differed from your domestic product formulations.\nIn your response, you state you communicated with distributors of products marketed in the United States to request samples of each product for stability testing.\nYour response is inadequate. You do not provide sufficient information regarding the batches, formulation, analytical method, and testing interval for the remaining expiry period. We acknowledge that you have not shipped product to the U.S. market since (b)(4). However, your drug products in the U.S. market will expire by (b)(4). For products without appropriate stability studies, you lack sufficient scientific evidence to support that the drug products will meet established specifications and retain their quality attributes throughout their labeled expiry. Please refer to 21 CFR 211.166, “Stability testing,” for the requirements of stability testing.\nIn response to this letter, provide:\nA comprehensive assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods.\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid. Include your plan to ensure appropriate procedures are in place regarding maintaining reserve samples as required under 21 CFR 211.170.\no Detailed definition of the specific attributes to be tested at each station (timepoint).\nAll procedures that describe these and other elements of your remediated stability program.\nProvide interim measures to ensure that products currently in the U.S. market meet the required quality attributes.\nA comprehensive, independent assessment of your chemical and microbiological drug test methods to determine the suitability of the method. If verification or validation is needed, provide a plan and timeline for completion of the appropriate activity.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit1 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Huangshi Hygienic Material Medicine Co. Ltd., 386 Shenxia Road, Huangshi, Hubei, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3005543486 and ATTN: Marva Taylor.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nCc: Mr. Sen Lin, Vice President of Operations\nlinsen@hswcpharma.com\n_______________________\n1 i.e. Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Huangshi Hygienic Material Medicine Co., Ltd.","huangshi-hygienic-material-medicine-co-ltd-700658-03242025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhuangshi-hygienic-material-medicine-co-ltd-700658-03242025","2026-10-26T08:08:56.469554+00:00","2025-06-03","700658","Mr. Ye Lin Chairman","2026-08-19T16:42:37.345+00:00","VIA UPS","320-25-56","2025-03-24",{"id":163,"raw":164,"subject":171,"body_html":172,"body_text":173,"firm_name":174,"letter_id":175,"created_at":176,"fei_number":20,"letter_url":177,"updated_at":178,"action_type":23,"case_status":24,"posted_date":179,"marcs_cms_no":180,"product_type":51,"closeout_date":181,"issuing_office":168,"recipient_name":182,"body_fetched_at":183,"delivery_method":31,"recipient_title":20,"reference_number":20,"action_taken_date":184,"medical_device_id":20,"response_letter_date":20},3124,[165,166,167,168,169,13,170,13],"\u003Ctime datetime=\"2021-10-05T13:20:00Z\">10\u002F05\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-09-17T04:00:00Z\">09\u002F17\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwalfer-corporation-dba-medicine-shoppe-pharmacy-611017-09172021\">Walfer Corporation dba The Medicine Shoppe Pharmacy\u003C\u002Fa>","Office of Pharmaceutical Quality Operations, Division II","Compounding Pharmacy\u002FAdulterated Drug Products ","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwalfer-corporation-dba-wallace-pharmacy-611017-09202022\">\u003Ctime datetime=\"2022-09-26T04:00:00Z\">09\u002F26\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","Compounding Pharmacy\u002FAdulterated Drug Products","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Wayne Wallace\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Walfer Corporation dba The Medicine Shoppe Pharmacy\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3524 B Tamiami Trl\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Port Charlotte\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33952-8100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:0703@medicineshoppe.com\"> 0703@medicineshoppe.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Pharmaceutical Quality Operations, Division II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 17, 2021\u003C\u002Fp>\n\n\u003Cp>Case # 611017\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Mr. Wallace:\u003C\u002Fp>\n\n\u003Cp>From March 9, 2020, to March 16, 2020, U.S. Food and Drug Administration (FDA) investigators inspected your facility, Walfer Corporation dba The Medicine Shoppe Pharmacy, located at 3524 B Tamiami Trl, Port Charlotte, Florida 33952. During the inspection, the investigators noted that drug products you produced failed to meet the conditions of section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353a] for exemption from certain provisions of the FDCA. In addition, the investigators noted serious deficiencies in your practices for producing drug products, which put patients at risk.\u003C\u002Fp>\n\n\u003Cp>FDA issued a Form FDA 483 to your firm on March 16, 2020. FDA acknowledges receipt of your facility’s response, dated April 6, 2020 and emails from your counsel on April 1 and 2, 2020. FDA also acknowledges your firm’s statement that “[t]he Pharmacy no longer produces sterile products.” FDA further acknowledges that on March 16, 2020, March 23, 2020, and April 6, 2020, your firm initiated recalls that together constituted all drug products produced by your firm within expiry. Based on this inspection, it appears that you produced drug products that violate the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A. Compounded Drug Products Under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Section 503A of the FDCA describes the conditions under which human drug products compounded by a licensed pharmacist in a State licensed pharmacy or a Federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Receipt of valid prescriptions for individually-identified patients is one of the conditions for the exemptions under section 503A.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>B. Failure to Meet the Conditions of Section 503A\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During the inspection, the FDA investigators noted that drug products produced by your firm failed to meet the conditions of section 503A. For example, the investigators noted that your firm did not receive valid prescriptions for individually-identified patients for a portion of the drug products you produced.\u003C\u002Fp>\n\n\u003Cp>Therefore, you compounded drug products that do not meet the conditions of section 503A and are not eligible for the exemptions in that section, including the FDA approval requirement of section 505 of the FDCA, the requirement under section 502(f)(1) of the FDCA that labeling bear adequate directions for use, and the requirement of compliance with CGMP under section 501(a)(2)(B) of the FDCA. In the remainder of this letter, we refer to your drug products that do not qualify for exemptions under section 503A as the “ineligible drug products.”\u003C\u002Fp>\n\n\u003Cp>Specific violations are described below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>C. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The FDA investigators noted that drug products were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA [21 U.S.C. § 351(a)(2)(A)]. For example, the investigators observed that:\u003C\u002Fp>\n\n\u003Cp>1. Vermin were present in your production area. Specifically, dead ants were observed on the floor of the unclassified general production area, and dead cockroaches were observed within a drawer adjacent to the \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>hood where drug products were produced.\u003C\u002Fp>\n\n\u003Cp>2. Non-microbial contamination was present in your production area. Specifically, your firm’s \u003Cstrong>(b)(4)\u003C\u002Fstrong> hoods contained stained balances and one of the hoods contained stains within close proximity to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> air filters.\u003C\u002Fp>\n\n\u003Cp>3. Your production area contained unsealed, loose ceiling tiles, including one cracked, and one stained ceiling tile.\u003C\u002Fp>\n\n\u003Cp>4. Your firm handled hazardous drug products without providing adequate containment, segregation, or cleaning of work surfaces and utensils to prevent cross-contamination.\u003C\u002Fp>\n\n\u003Cp>Furthermore, the manufacture of the ineligible drug products is subject to FDA’s CGMP regulations, Title 21, Code of Federal Regulations (CFR), parts 210 and 211. The FDA investigators observed significant CGMP violations at your facility, causing the ineligible drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA.\u003Cbr>\nThe violations included, for example:\u003C\u002Fp>\n\n\u003Cp>1. Your firm failed to maintain the buildings used in the manufacture, processing, packing, or holding of a drug product in a clean and sanitary condition and to keep them free of infestation by rodents, birds, insects, and other vermin (21 CFR 211.56(a)).\u003C\u002Fp>\n\n\u003Cp>2. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\u003C\u002Fp>\n\n\u003Cp>It is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The ineligible drug products you compounded are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Accordingly, these ineligible drug products are misbranded under section 502(f)(1) of the FDCA. It is a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>D. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s responses to the Form FDA 483. We acknowledge your recall of all drugs within expiry on March 16, 2020, March 23, 2020, and April 6, 2020. Regarding your responses related to the insanitary conditions, some of your corrective actions appear adequate; however, we cannot fully evaluate the adequacy of the following corrective actions described in your April 6, 2020 response because you did not provide sufficient information or supporting documentation:\u003C\u002Fp>\n\n\u003Cp>1. In your April 6, 2020 response to Observation 2 of the Form FDA 483, you stated that the “Pharmacy conducted a deep clean of all areas where vermin were observed …[and] brought in pest control services on 3\u002F10\u002F20, the day after the initial inspection.” Further, you stated that the “pest control company will continue to service the pharmacy \u003Cstrong>(b)(4)\u003C\u002Fstrong> for an indefinite period...” You provided two photos. However, you did not provide adequate information and documentation such as the cleaning schedule or the pest remediation actions for us to be able to fully evaluate your response.\u003C\u002Fp>\n\n\u003Cp>2. In your April 6, 2020 response to Observation 5 of the Form FDA 483, you state that you have removed the clutter from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> hoods, will keep the area within and around the \u003Cstrong>(b)(4)\u003C\u002Fstrong> hoods clutter free, and will clean the area within and surrounding the \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>hoods after every use. You also provided two photos. However, you did not provide adequate information and documentation, such as completed cleaning logs and revised cleaning procedures, for us to fully evaluate your proposed corrections.\u003C\u002Fp>\n\n\u003Cp>3. In your April 6, 2020 response to Observation 13 of the Form FDA 483, you state that you have replaced unsealed, cracked and stained ceiling tiles and will maintain all ceiling tiles in clean condition. However, you have not provided adequate information and documentation for us to fully evaluate your response. Additionally, one of the pictures provided in response to Observation 6 of the Form FDA 483 appears to show visible brown stain indicative of water damage on one of the ceiling tiles, still. We remain concerned about the potential impact of the visibly brown stained tiles and any water damage that could potentially cause mold growth and contamination in production areas.\u003C\u002Fp>\n\n\u003Cp>4. In your April 6, 2020 response to Observation 14 of the Form FDA 483, you stated that you have segregated all hazardous drug products and are working with a third-party vendor to develop procedures and to obtain a deactivation agent. However, you have not provided adequate information and documentation for us to fully evaluate your response, such as revised cleaning procedures.\u003C\u002Fp>\n\n\u003Cp>Please be aware that section 501(a)(2)(A) of the FDCA concerning insanitary conditions applies regardless of whether drug products you compound meet the conditions of section 503A, including the condition on receipt of a prescription for an identified individual patient prior to compounding and distributing drug.\u003C\u002Fp>\n\n\u003Cp>In addition, regarding observations related to the conditions of section 503A of the FDCA, you verbally stated that you will discontinue distributing drugs without patient-specific prescriptions, but we are unable to fully evaluate this corrective action due to lack of adequate supporting documentation.\u003C\u002Fp>\n\n\u003Cp>Should you continue to compound and distribute drug products that do not meet the conditions of section 503A, the compounding and distribution of such drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the drug CGMP regulations. Before doing so, you must comply with the requirements of section 505 and 502(f)(1) and fully implement corrections that meet the minimum requirements of the CGMP regulations.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>In addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither&nbsp;adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b)]. FDA strongly recommends that if you decide to resume production of sterile drugs, your management first undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\u003C\u002Fp>\n\n\u003Cp>We also note that, during the inspection, the FDA investigators collected evidence indicating that, at least on some occasions, your firm compounded drug products that appear to be essentially copies of commercially available drug products (e.g., Oxycodone Hydrochloride 30mg capsules). For your awareness, we note that under section 503A of the FDCA, a drug product is not eligible for certain exemptions if it is prepared by a pharmacist or physician who compounds “regularly or inordinate amounts (as defined by the Secretary)” any drug products that are essentially copies of a commercially available drug product (section 503A(b)(1)(D) of the FDCA). The term “essentially a copy of a commercially available drug product” does not include a drug product in which there is a change, made for an identified individual patient, which produces for that patient a significant difference, as determined by the prescribing practitioner, between the compounded drug and the comparable commercially available drug product (section 503A(b)(2) of the FDCA).\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>E. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to correct the violations cited in this letter. Failure to adequately address this matter may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing if you have taken any specific steps to correct the violations cited in this letter. If you intend to resume production of sterile drugs in the future, please include an explanation of each step being taken to provide sterility assurance, considering, in particular, the conditions that contributed to your recall of sterile drugs, as well as copies of related documentation. If you do not believe that the products discussed above violated the FDCA, include your reasoning and any supporting information for our consideration. In addition to taking appropriate corrective actions, you should notify this office fifteen (15) working days prior to resuming production of any sterile drugs in the future.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to the Warning Letter Number above (Case # 611017). Please electronically submit your signed reply on your firm’s letterhead to CDR John W. Diehl, M.S., Director, Compliance Branch, at john.diehl@fda.hhs.gov and orapharm2_responses@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, you may contact Mr. Thao Ta, Compliance Officer, via phone at 214-253-5217 or e-mail at thao.ta@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Tamala Bogan\u003Cbr>\nActing Program Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations,\u003Cbr>\nDivision II\u003C\u002Fp>\n\n\u003Cp>cc: Via Electronic Mail\u003C\u002Fp>\n\n\u003Cp>Jonathan Meltz, Esq.\u003Cbr>\nCHAPMAN LAW GROUP\u003Cbr>\n1001 Brickell Bay Dr., Suite 1714\u003Cbr>\nMiami, Florida 33131\u003Cbr>\nJMeltz@ChapmanLawGroup.com\u003C\u002Fp>\n\n\u003Cp>Michael C. Kaufmann, CEO\u003Cbr>\nCardinal Health Company\u003Cbr>\n7000 Cardinal Place\u003Cbr>\nDublin, Ohio 43017\u003Cbr>\nmike.kaufmann@cardinalhealth.com\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Your ineligible drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> In this letter we do not address whether your proposed corrective actions would resolve the CGMP violations noted above.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>See FDA’s guidance, Compounded Drug Products That Are Essentially Copies of a Commercially&nbsp;Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act (“503A copies guidance”), available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM510154.pdf\">https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM510154.pdf\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nWayne Wallace\n\nRecipient Title\n\nOwner\n\nWalfer Corporation dba The Medicine Shoppe Pharmacy\n\n3524 B Tamiami Trl\n\nPort Charlotte, FL 33952-8100\n\nUnited States\n\n0703@medicineshoppe.com\n\nIssuing Office:\n\nOffice of Pharmaceutical Quality Operations, Division II\n\nUnited States\n\nSeptember 17, 2021\n\nCase # 611017\n\nWARNING LETTER\n\nMr. Wallace:\n\nFrom March 9, 2020, to March 16, 2020, U.S. Food and Drug Administration (FDA) investigators inspected your facility, Walfer Corporation dba The Medicine Shoppe Pharmacy, located at 3524 B Tamiami Trl, Port Charlotte, Florida 33952. During the inspection, the investigators noted that drug products you produced failed to meet the conditions of section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353a] for exemption from certain provisions of the FDCA. In addition, the investigators noted serious deficiencies in your practices for producing drug products, which put patients at risk.\n\nFDA issued a Form FDA 483 to your firm on March 16, 2020. FDA acknowledges receipt of your facility’s response, dated April 6, 2020 and emails from your counsel on April 1 and 2, 2020. FDA also acknowledges your firm’s statement that “[t]he Pharmacy no longer produces sterile products.” FDA further acknowledges that on March 16, 2020, March 23, 2020, and April 6, 2020, your firm initiated recalls that together constituted all drug products produced by your firm within expiry. Based on this inspection, it appears that you produced drug products that violate the FDCA.\n\nA. Compounded Drug Products Under the FDCA\n\nSection 503A of the FDCA describes the conditions under which human drug products compounded by a licensed pharmacist in a State licensed pharmacy or a Federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].1 Receipt of valid prescriptions for individually-identified patients is one of the conditions for the exemptions under section 503A.\n\nB. Failure to Meet the Conditions of Section 503A\n\nDuring the inspection, the FDA investigators noted that drug products produced by your firm failed to meet the conditions of section 503A. For example, the investigators noted that your firm did not receive valid prescriptions for individually-identified patients for a portion of the drug products you produced.\n\nTherefore, you compounded drug products that do not meet the conditions of section 503A and are not eligible for the exemptions in that section, including the FDA approval requirement of section 505 of the FDCA, the requirement under section 502(f)(1) of the FDCA that labeling bear adequate directions for use, and the requirement of compliance with CGMP under section 501(a)(2)(B) of the FDCA. In the remainder of this letter, we refer to your drug products that do not qualify for exemptions under section 503A as the “ineligible drug products.”\n\nSpecific violations are described below.\n\nC. Violations of the FDCA\n\nAdulterated Drug Products\n\nThe FDA investigators noted that drug products were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA [21 U.S.C. § 351(a)(2)(A)]. For example, the investigators observed that:\n\n1. Vermin were present in your production area. Specifically, dead ants were observed on the floor of the unclassified general production area, and dead cockroaches were observed within a drawer adjacent to the (b)(4) hood where drug products were produced.\n\n2. Non-microbial contamination was present in your production area. Specifically, your firm’s (b)(4) hoods contained stained balances and one of the hoods contained stains within close proximity to the (b)(4) air filters.\n\n3. Your production area contained unsealed, loose ceiling tiles, including one cracked, and one stained ceiling tile.\n\n4. Your firm handled hazardous drug products without providing adequate containment, segregation, or cleaning of work surfaces and utensils to prevent cross-contamination.\n\nFurthermore, the manufacture of the ineligible drug products is subject to FDA’s CGMP regulations, Title 21, Code of Federal Regulations (CFR), parts 210 and 211. The FDA investigators observed significant CGMP violations at your facility, causing the ineligible drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA.\n\nThe violations included, for example:\n\n1. Your firm failed to maintain the buildings used in the manufacture, processing, packing, or holding of a drug product in a clean and sanitary condition and to keep them free of infestation by rodents, birds, insects, and other vermin (21 CFR 211.56(a)).\n\n2. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\n\nIt is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\n\nMisbranded Drug Products\n\nThe ineligible drug products you compounded are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses.2 Accordingly, these ineligible drug products are misbranded under section 502(f)(1) of the FDCA. It is a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\n\nD. Corrective Actions\n\nWe have reviewed your firm’s responses to the Form FDA 483. We acknowledge your recall of all drugs within expiry on March 16, 2020, March 23, 2020, and April 6, 2020. Regarding your responses related to the insanitary conditions, some of your corrective actions appear adequate; however, we cannot fully evaluate the adequacy of the following corrective actions described in your April 6, 2020 response because you did not provide sufficient information or supporting documentation:\n\n1. In your April 6, 2020 response to Observation 2 of the Form FDA 483, you stated that the “Pharmacy conducted a deep clean of all areas where vermin were observed …[and] brought in pest control services on 3\u002F10\u002F20, the day after the initial inspection.” Further, you stated that the “pest control company will continue to service the pharmacy (b)(4) for an indefinite period...” You provided two photos. However, you did not provide adequate information and documentation such as the cleaning schedule or the pest remediation actions for us to be able to fully evaluate your response.\n\n2. In your April 6, 2020 response to Observation 5 of the Form FDA 483, you state that you have removed the clutter from the (b)(4) hoods, will keep the area within and around the (b)(4) hoods clutter free, and will clean the area within and surrounding the (b)(4) hoods after every use. You also provided two photos. However, you did not provide adequate information and documentation, such as completed cleaning logs and revised cleaning procedures, for us to fully evaluate your proposed corrections.\n\n3. In your April 6, 2020 response to Observation 13 of the Form FDA 483, you state that you have replaced unsealed, cracked and stained ceiling tiles and will maintain all ceiling tiles in clean condition. However, you have not provided adequate information and documentation for us to fully evaluate your response. Additionally, one of the pictures provided in response to Observation 6 of the Form FDA 483 appears to show visible brown stain indicative of water damage on one of the ceiling tiles, still. We remain concerned about the potential impact of the visibly brown stained tiles and any water damage that could potentially cause mold growth and contamination in production areas.\n\n4. In your April 6, 2020 response to Observation 14 of the Form FDA 483, you stated that you have segregated all hazardous drug products and are working with a third-party vendor to develop procedures and to obtain a deactivation agent. However, you have not provided adequate information and documentation for us to fully evaluate your response, such as revised cleaning procedures.\n\nPlease be aware that section 501(a)(2)(A) of the FDCA concerning insanitary conditions applies regardless of whether drug products you compound meet the conditions of section 503A, including the condition on receipt of a prescription for an identified individual patient prior to compounding and distributing drug.\n\nIn addition, regarding observations related to the conditions of section 503A of the FDCA, you verbally stated that you will discontinue distributing drugs without patient-specific prescriptions, but we are unable to fully evaluate this corrective action due to lack of adequate supporting documentation.\n\nShould you continue to compound and distribute drug products that do not meet the conditions of section 503A, the compounding and distribution of such drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the drug CGMP regulations. Before doing so, you must comply with the requirements of section 505 and 502(f)(1) and fully implement corrections that meet the minimum requirements of the CGMP regulations.3\n\nIn addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b)]. FDA strongly recommends that if you decide to resume production of sterile drugs, your management first undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\n\nWe also note that, during the inspection, the FDA investigators collected evidence indicating that, at least on some occasions, your firm compounded drug products that appear to be essentially copies of commercially available drug products (e.g., Oxycodone Hydrochloride 30mg capsules). For your awareness, we note that under section 503A of the FDCA, a drug product is not eligible for certain exemptions if it is prepared by a pharmacist or physician who compounds “regularly or inordinate amounts (as defined by the Secretary)” any drug products that are essentially copies of a commercially available drug product (section 503A(b)(1)(D) of the FDCA). The term “essentially a copy of a commercially available drug product” does not include a drug product in which there is a change, made for an identified individual patient, which produces for that patient a significant difference, as determined by the prescribing practitioner, between the compounded drug and the comparable commercially available drug product (section 503A(b)(2) of the FDCA).4\n\nE. Conclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to correct the violations cited in this letter. Failure to adequately address this matter may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing if you have taken any specific steps to correct the violations cited in this letter. If you intend to resume production of sterile drugs in the future, please include an explanation of each step being taken to provide sterility assurance, considering, in particular, the conditions that contributed to your recall of sterile drugs, as well as copies of related documentation. If you do not believe that the products discussed above violated the FDCA, include your reasoning and any supporting information for our consideration. In addition to taking appropriate corrective actions, you should notify this office fifteen (15) working days prior to resuming production of any sterile drugs in the future.\n\nYour written notification should refer to the Warning Letter Number above (Case # 611017). Please electronically submit your signed reply on your firm’s letterhead to CDR John W. Diehl, M.S., Director, Compliance Branch, at john.diehl@fda.hhs.gov and orapharm2_responses@fda.hhs.gov.\n\nIf you have questions regarding the contents of this letter, you may contact Mr. Thao Ta, Compliance Officer, via phone at 214-253-5217 or e-mail at thao.ta@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nTamala Bogan\n\nActing Program Division Director\n\nOffice of Pharmaceutical Quality Operations,\n\nDivision II\n\ncc: Via Electronic Mail\n\nJonathan Meltz, Esq.\n\nCHAPMAN LAW GROUP\n\n1001 Brickell Bay Dr., Suite 1714\n\nMiami, Florida 33131\n\nJMeltz@ChapmanLawGroup.com\n\nMichael C. Kaufmann, CEO\n\nCardinal Health Company\n\n7000 Cardinal Place\n\nDublin, Ohio 43017\n\nmike.kaufmann@cardinalhealth.com\n\n_____________________\n\n1 We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FDCA.\n\n2 Your ineligible drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).\n\n3 In this letter we do not address whether your proposed corrective actions would resolve the CGMP violations noted above.\n\n4 See FDA’s guidance, Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act (“503A copies guidance”), available at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM510154.pdf.","Walfer Corporation dba The Medicine Shoppe Pharmacy","walfer-corporation-dba-medicine-shoppe-pharmacy-611017-09172021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwalfer-corporation-dba-medicine-shoppe-pharmacy-611017-09172021","2026-10-26T08:10:29.74962+00:00","2021-10-05","611017","2022-09-26","Wayne Wallace","2026-08-20T02:35:15.373+00:00","2021-09-17",{"id":186,"raw":187,"subject":193,"body_html":194,"body_text":195,"firm_name":196,"letter_id":197,"created_at":19,"fei_number":20,"letter_url":198,"updated_at":199,"action_type":23,"case_status":48,"posted_date":200,"marcs_cms_no":201,"product_type":202,"closeout_date":20,"issuing_office":203,"recipient_name":204,"body_fetched_at":205,"delivery_method":206,"recipient_title":20,"reference_number":207,"action_taken_date":208,"medical_device_id":20,"response_letter_date":20},2006,[188,189,190,191,192,13,13,13],"\u003Ctime datetime=\"2023-07-11T13:20:00Z\">07\u002F11\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-06-27T04:00:00Z\">06\u002F27\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnew-hope-center-reproductive-medicine-658251-06272023\">The New Hope Center for Reproductive Medicine\u003C\u002Fa>"," Division of Biological Products Operations I ","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>23-658251\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Robin L. Poe-Zeigler, MD\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Medical Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>The New Hope Center for Reproductive Medicine\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>448 Viking Drive, Suite 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Virginia Beach\u003C\u002Fspan>, \u003Cspan>VA\u003C\u002Fspan> \u003Cspan>23452\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Biological Products Operations I \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>06\u002F27\u002F2023\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Poe-Zeigler:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm, The New Hope Center for Reproductive Medicine located at 448 Viking Drive, Suite #100, Virginia Beach, VA, between December 8, 2022 and January 23, 2023. During the inspection, an FDA Investigator documented significant deviations from the regulations for human cells, tissues, and cellular and tissue-based products (HCT\u002FPs) set forth in Title 21, Code of Federal Regulations (CFR) Part 1271 (21 CFR 1271) and issued under the authority of Section 361 of the Public Health Service Act [42 U.S.C. 264].\u003C\u002Fp>\n\n\u003Cp>The deviations documented on the Form FDA-483, List of Inspectional Observations (FDA 483), were presented to and discussed with you at the conclusion of the inspection. The items of concern include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1) Failure to screen a donor of reproductive cells or tissue by reviewing the donor’s relevant medical records for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases [21 CFR 1271.75(a)]. FDA’s regulations at 21 CFR 1271.3(s) define the term “relevant medical records” to include a current donor medical history interview and a current report of the physical examination of a living donor. For example:\u003C\u002Fp>\n\n\u003Cp>a. During the inspection, your firm stated that donors complete a questionnaire online via your firm’s website which was the only medical screening questionnaire presented to the donors. However, our review of your anonymous and directed donor records since May2021, found that the donor records were missing this questionnaire, to include documentation of most, if not all, required questions that screen for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases (RCDADs). For example:\u003C\u002Fp>\n\n\u003Cp>i. Directed oocyte donor \u003Cstrong>(b)(6),\u003C\u002Fstrong>&nbsp;\u003Cstrong>(b)(7)(C)\u003C\u002Fstrong>&nbsp;was determined eligible on 3\u002F5\u002F2022 and oocytes were recovered from the donor on \u003Cstrong>(b)(6),\u003C\u002Fstrong>&nbsp;\u003Cstrong>(b)(7)(C)\u003C\u002Fstrong>;\u003Cbr>\n\u003Cbr>\nii. Directed oocyte donor \u003Cstrong>(b)(6),\u003C\u002Fstrong>&nbsp;\u003Cstrong>(b)(7)(C)\u003C\u002Fstrong> was determined eligible on 2\u002F8\u002F2022 and oocytes were recovered from the donor on \u003Cstrong>(b)(6),\u003C\u002Fstrong>&nbsp;\u003Cstrong>(b)(7)(C)\u003C\u002Fstrong>;\u003C\u002Fp>\n\n\u003Cp>iii. Anonymous oocyte donor \u003Cstrong>(b)(6),\u003C\u002Fstrong>&nbsp;\u003Cstrong>(b)(7)(C)\u003C\u002Fstrong> was determined eligible on 11\u002F14\u002F2021 and oocytes were recovered from the donor on \u003Cstrong>(b)(6),\u003C\u002Fstrong>&nbsp;\u003Cstrong>(b)(7)(C)\u003C\u002Fstrong>;\u003C\u002Fp>\n\n\u003Cp>iv. Directed semen donor \u003Cstrong>(b)(6),\u003C\u002Fstrong>&nbsp;\u003Cstrong>(b)(7)(C)\u003C\u002Fstrong> was determined eligible on 10\u002F1\u002F2021 and semen was recovered from the donor on \u003Cstrong>(b)(6),\u003C\u002Fstrong>&nbsp;\u003Cstrong>(b)(7)(C)\u003C\u002Fstrong>; and\u003C\u002Fp>\n\n\u003Cp>v. Anonymous oocyte donor \u003Cstrong>(b)(6),\u003C\u002Fstrong>&nbsp;\u003Cstrong>(b)(7)(C)\u003C\u002Fstrong> was determined eligible on 7\u002F20\u002F2021 and oocytes were recovered from the donor on \u003Cstrong>(b)(6),\u003C\u002Fstrong>&nbsp;\u003Cstrong>(b)(7)(C)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>b. Our review of donor records for anonymous oocyte donor \u003Cstrong>(b)(6),\u003C\u002Fstrong>&nbsp;\u003Cstrong>(b)(7)(C)\u003C\u002Fstrong> found that oocytes were recovered from the donor on \u003Cstrong>(b)(6),\u003C\u002Fstrong>&nbsp;\u003Cstrong>(b)(7)(C)\u003C\u002Fstrong>; however, a physical examination was documented on \u003Cstrong>(b)(6),\u003C\u002Fstrong>&nbsp;\u003Cstrong>(b)(7)(C)\u003C\u002Fstrong>, more than \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;prior to the donation.\u003C\u002Fp>\n\n\u003Cp>2) Failure to collect a donor specimen for testing for relevant communicable diseases at the time of recovery of cells or tissue from the donor; or for oocyte donors, up to 30 days before recovery or up to seven days after recovery [21 CFR 1271.80(b)]. For example, a specimen for communicable disease testing was collected from anonymous oocyte donor \u003Cstrong>(b)(6),\u003C\u002Fstrong>&nbsp;\u003Cstrong>(b)(7)(C)\u003C\u002Fstrong> on \u003Cstrong>(b)(6),\u003C\u002Fstrong>&nbsp;\u003Cstrong>(b)(7)(C)\u003C\u002Fstrong>. However, oocytes were recovered from the donor on \u003Cstrong>(b)(6),\u003C\u002Fstrong>&nbsp;\u003Cstrong>(b)(7)(C)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>3) Failure to establish and maintain procedures for all steps performed in testing, screening, and determining donor eligibility, and complying with all other requirements of Subpart C “Donor Eligibility” in 21 CFR Part 1271.45-1271.90. “Establish and maintain” means define, document (in writing or electronically), and implement; then follow, review, and as needed, revise on an ongoing basis [21 CFR 1271.47 (a)]. For example, your firm’s procedures do not include all steps and risk factors for donor screening, all required tests and timeframes for donor testing, the steps and requirements for determining donor eligibility, criteria that would make a donor ineligible, and all additional relevant requirements in Subpart C of 21 CFR Part 1271.\u003C\u002Fp>\n\n\u003Cp>The deviations identified above are not intended to be an all-inclusive list of deficiencies at your facility. It is your responsibility to ensure that your establishment is in compliance with all applicable requirements of the federal regulations. You are responsible for reviewing your firm’s operations as a whole to ensure that you are in compliance with all applicable FDA regulatory requirements.\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your letter dated 2\u002F3\u002F2023, in response to FDA’s inspectional observations. We have reviewed the corrective actions outlined in the response, and we have determined that the response is inadequate to address our concerns. We have the following comments regarding your FDA 483 response.\u003C\u002Fp>\n\n\u003Cp>In response to Observation 1, you submitted a new \u003Cem>Donor Medical History Interview Form\u003C\u002Fem> that includes screening questions to evaluate donors for risk factors for relevant communicable disease agents and diseases. However, we note that the form is missing questions that evaluate donors for certain risk factors or the questions as written do not adequately screen donors for that specific risk factor. Your form should be updated to include this information, as follows:\u003C\u002Fp>\n\n\u003Cp>1. The form does not include a question regarding persons who have had a past diagnosis of clinical, symptomatic viral hepatitis after their 11th birthday, unless evidence from the time of illness documents that the hepatitis was identified as being caused by hepatitis A virus, Epstein-Barr virus (EBV), or cytomegalovirus (CMV).\u003C\u002Fp>\n\n\u003Cp>2. Question 12 asks about a medical diagnosis of West Nile virus (WNV) infection but does not ask about a suspicion of WNV.\u003C\u002Fp>\n\n\u003Cp>3. The form does not include a question that screens donors for testing positive or reactive for WNV infection using an FDA-licensed or investigational WNV NAT donor screening test in the preceding 120 days.\u003C\u002Fp>\n\n\u003Cp>4. Question 28 asks about travel to an area with active Zika virus (ZIKV) transmission in the past 6 months, but should ask about residence in, or travel to, an area with an increased risk for ZIKV transmission.\u003C\u002Fp>\n\n\u003Cp>5. Question 29 asks about sex with a male who has been diagnosed with ZIKV but should ask whether the donor has had sex with a person who has been diagnosed with ZIKV in the past 6 months.\u003C\u002Fp>\n\n\u003Cp>In response to Observations 1 through 5, you stated that you have re-screened donors who were not evaluated for all required RCDAD risk factors, updated Summary of Records forms, and marked as “ineligible” donors who were not tested in accordance with regulatory requirements. Please note that all your donors were missing screening for multiple risk factors for RCDADs at the time of donation. Additionally, certain donors were not tested in accordance with 21 CFR 1271 or were missing documentation of a current physical examination.\u003C\u002Fp>\n\n\u003Cp>As required under 21 CFR 1271.50(a), you must determine whether a donor is eligible based upon the results of donor screening in accordance with 21 CFR 1271.75 and donor testing in accordance with 21 CFR 1271.80 and 1271.85. Donors whose screening and\u002For testing were not performed in compliance with the aforementioned regulatory citations cannot be determined “eligible” or “ineligible.” FDA considers the donor eligibility determination to be incomplete, and all HCT\u002FPs remaining in storage from these donors must be stored under quarantine. As this affects all your donors, we have provided at the end of the letter information regarding exemption requests and labeling should you need to remove any of these HCT\u002FPs from storage.\u003C\u002Fp>\n\n\u003Cp>In response to Observation 6, we acknowledge that you have revised specific sections of \u003Cem>The New Hope Center Donor Oocyte Program\u003C\u002Fem> procedure, but your procedures remain deficient for the reasons set forth below. Please note that this list is not all-inclusive. It continues to be your responsibility to ensure that your establishment is in full compliance with 21 CFR 1271 at all times.\u003Cbr>\n\u003Cbr>\nWe recommend that you review your firm’s procedures and make the necessary changes to ensure they include all steps that you perform in testing, screening, determining donor eligibility, and complying with all other requirements in accordance with 21 CFR 1271 of Subpart C - Donor Eligibility.\u003C\u002Fp>\n\n\u003Cp>1. Your response to Observation 6 states, “We have added specific testing into our SOP’s (\u003Cem>sic\u003C\u002Fem>) that instructs the tests needed to be performed are HIV, Hep B, Hep C, HTPE, Creutzfeldt Jacob (sic) Disease, and communicable disease risks associated with Xenotransplantation.” We note that screening donors for communicable disease risks of Creutzfeldt-Jakob Disease (CJD) and xenotransplantation is done through donor history questions that are part of the screening process. There are currently no tests that can evaluate a donor’s risk for CJD or xenotransplantation.\u003C\u002Fp>\n\n\u003Cp>2. Your procedure includes testing for ZIKV under the “Final Serology Testing” section. Please note that there are currently no available tests for ZIKV that are considered appropriate for preventing transmission of ZIKV through HCT\u002FPs.\u003C\u002Fp>\n\n\u003Cp>3. The procedure is still missing many of the requirements in Subpart C of 21 CFR 1271.Under 21 CFR 1271.47(a), you must establish and maintain procedures for all steps that you perform in testing, screening, determining donor eligibility, and complying with all other requirements of the subpart.\u003C\u002Fp>\n\n\u003Cp>Please note that if you still have \u003Cstrong>oocytes and\u002For semen\u003C\u002Fstrong> in storage from donors whose screening and\u002For testing was not completed in accordance with 21 CFR Part 1271, FDA considers the donor eligibility determinations to be incomplete for these donors. For example, this includes donors who were screened using a donor history questionnaire that was missing required screening questions, donors who were missing a physical examination, and donors who were not tested for relevant communicable disease agents in accordance with regulatory requirements. Therefore, as required by 21 CFR 1271.60(a), you must keep these HCT\u002FPs in quarantine.\u003C\u002Fp>\n\n\u003Cp>Should the need arise in the future to remove any of these HCT\u002FPs from quarantine, either for use in your own establishment or for transport to another establishment, you may request an exemption or alternative from a requirement in subpart C, 21 CFR Part 1271, as specified in 21 CFR 1271.155. Additional information can be found at: http:\u002F\u002Fwww.fda.gov\u002FBiologicsBloodVaccines\u002FTissueTissueProducts\u002FRegulationofTissues\u002FExempt ionsandAlternativeProcedures\u002Fdefault.htm). The email address for submissions is HCTPExemptions@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Please note that 21 CFR 1271.155 requires that you provide justification for use of HCT\u002FPs from these donors, as well as information on how you have mitigated the risk consistent with the goals of protecting the public health and\u002For preventing the introduction, transmission, or spread of communicable diseases. Before any of these HCT\u002FPs can be removed from quarantine, the request must be granted by FDA.\u003C\u002Fp>\n\n\u003Cp>If you still have \u003Cstrong>embryos\u003C\u002Fstrong> in storage for which the donor eligibility requirements under 21 CFR Part 1271, Subpart C are not met, please note that FDA considers the donor eligibility determinations to be incomplete for these donors. Therefore, as required by 21 CFR 1271.60(a), you must keep these HCT\u002FPs in quarantine. Should the need arise in the future to remove any of these HCT\u002FPs from quarantine, either for use in your own establishment or for transport to another establishment, you may release these HCT\u002FPs from quarantine (21 CFR 1271.90(b)) provided they are labeled in accordance with the applicable regulations at 21 CFR 1271.90(c).\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to correct the violations addressed in this letter and prevent their recurrence. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct the noted violations, including an explanation of how you plan to prevent these violations, or similar violations, from occurring again. If you believe that your products are not in violation of the law, include your reasoning and any supporting information for our consideration. Additionally, include any documentation necessary to show that correction of any of the above-noted violations has been achieved. If you cannot complete all corrections within fifteen (15) working days, please explain the reason for your delay and the time frame within which the remaining corrections will be completed.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to LT Yvesna Blaise, Compliance Officer at the following email address: Yvesna.blaise@fda.hhs.gov. If you have any questions, please contact LT Blaise at 973-331-4970 or via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Michael W. Roosevelt\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations – Division 1\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nReference #:\n\n23-658251\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nRobin L. Poe-Zeigler, MD\n\nRecipient Title\n\nMedical Director\n\nThe New Hope Center for Reproductive Medicine\n\n448 Viking Drive, Suite 100\n\nVirginia Beach, VA 23452\n\nUnited States\n\nIssuing Office:\n\nDivision of Biological Products Operations I\n\nUnited States\n\nWARNING LETTER\n\n06\u002F27\u002F2023\n\nDear Dr. Poe-Zeigler:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm, The New Hope Center for Reproductive Medicine located at 448 Viking Drive, Suite #100, Virginia Beach, VA, between December 8, 2022 and January 23, 2023. During the inspection, an FDA Investigator documented significant deviations from the regulations for human cells, tissues, and cellular and tissue-based products (HCT\u002FPs) set forth in Title 21, Code of Federal Regulations (CFR) Part 1271 (21 CFR 1271) and issued under the authority of Section 361 of the Public Health Service Act [42 U.S.C. 264].\n\nThe deviations documented on the Form FDA-483, List of Inspectional Observations (FDA 483), were presented to and discussed with you at the conclusion of the inspection. The items of concern include, but are not limited to, the following:\n\n1) Failure to screen a donor of reproductive cells or tissue by reviewing the donor’s relevant medical records for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases [21 CFR 1271.75(a)]. FDA’s regulations at 21 CFR 1271.3(s) define the term “relevant medical records” to include a current donor medical history interview and a current report of the physical examination of a living donor. For example:\n\na. During the inspection, your firm stated that donors complete a questionnaire online via your firm’s website which was the only medical screening questionnaire presented to the donors. However, our review of your anonymous and directed donor records since May2021, found that the donor records were missing this questionnaire, to include documentation of most, if not all, required questions that screen for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases (RCDADs). For example:\n\ni. Directed oocyte donor (b)(6), (b)(7)(C) was determined eligible on 3\u002F5\u002F2022 and oocytes were recovered from the donor on (b)(6), (b)(7)(C);\n\nii. Directed oocyte donor (b)(6), (b)(7)(C) was determined eligible on 2\u002F8\u002F2022 and oocytes were recovered from the donor on (b)(6), (b)(7)(C);\n\niii. Anonymous oocyte donor (b)(6), (b)(7)(C) was determined eligible on 11\u002F14\u002F2021 and oocytes were recovered from the donor on (b)(6), (b)(7)(C);\n\niv. Directed semen donor (b)(6), (b)(7)(C) was determined eligible on 10\u002F1\u002F2021 and semen was recovered from the donor on (b)(6), (b)(7)(C); and\n\nv. Anonymous oocyte donor (b)(6), (b)(7)(C) was determined eligible on 7\u002F20\u002F2021 and oocytes were recovered from the donor on (b)(6), (b)(7)(C).\n\nb. Our review of donor records for anonymous oocyte donor (b)(6), (b)(7)(C) found that oocytes were recovered from the donor on (b)(6), (b)(7)(C); however, a physical examination was documented on (b)(6), (b)(7)(C), more than (b)(4) prior to the donation.\n\n2) Failure to collect a donor specimen for testing for relevant communicable diseases at the time of recovery of cells or tissue from the donor; or for oocyte donors, up to 30 days before recovery or up to seven days after recovery [21 CFR 1271.80(b)]. For example, a specimen for communicable disease testing was collected from anonymous oocyte donor (b)(6), (b)(7)(C) on (b)(6), (b)(7)(C). However, oocytes were recovered from the donor on (b)(6), (b)(7)(C).\n\n3) Failure to establish and maintain procedures for all steps performed in testing, screening, and determining donor eligibility, and complying with all other requirements of Subpart C “Donor Eligibility” in 21 CFR Part 1271.45-1271.90. “Establish and maintain” means define, document (in writing or electronically), and implement; then follow, review, and as needed, revise on an ongoing basis [21 CFR 1271.47 (a)]. For example, your firm’s procedures do not include all steps and risk factors for donor screening, all required tests and timeframes for donor testing, the steps and requirements for determining donor eligibility, criteria that would make a donor ineligible, and all additional relevant requirements in Subpart C of 21 CFR Part 1271.\n\nThe deviations identified above are not intended to be an all-inclusive list of deficiencies at your facility. It is your responsibility to ensure that your establishment is in compliance with all applicable requirements of the federal regulations. You are responsible for reviewing your firm’s operations as a whole to ensure that you are in compliance with all applicable FDA regulatory requirements.\n\nWe acknowledge receipt of your letter dated 2\u002F3\u002F2023, in response to FDA’s inspectional observations. We have reviewed the corrective actions outlined in the response, and we have determined that the response is inadequate to address our concerns. We have the following comments regarding your FDA 483 response.\n\nIn response to Observation 1, you submitted a new Donor Medical History Interview Form that includes screening questions to evaluate donors for risk factors for relevant communicable disease agents and diseases. However, we note that the form is missing questions that evaluate donors for certain risk factors or the questions as written do not adequately screen donors for that specific risk factor. Your form should be updated to include this information, as follows:\n\n1. The form does not include a question regarding persons who have had a past diagnosis of clinical, symptomatic viral hepatitis after their 11th birthday, unless evidence from the time of illness documents that the hepatitis was identified as being caused by hepatitis A virus, Epstein-Barr virus (EBV), or cytomegalovirus (CMV).\n\n2. Question 12 asks about a medical diagnosis of West Nile virus (WNV) infection but does not ask about a suspicion of WNV.\n\n3. The form does not include a question that screens donors for testing positive or reactive for WNV infection using an FDA-licensed or investigational WNV NAT donor screening test in the preceding 120 days.\n\n4. Question 28 asks about travel to an area with active Zika virus (ZIKV) transmission in the past 6 months, but should ask about residence in, or travel to, an area with an increased risk for ZIKV transmission.\n\n5. Question 29 asks about sex with a male who has been diagnosed with ZIKV but should ask whether the donor has had sex with a person who has been diagnosed with ZIKV in the past 6 months.\n\nIn response to Observations 1 through 5, you stated that you have re-screened donors who were not evaluated for all required RCDAD risk factors, updated Summary of Records forms, and marked as “ineligible” donors who were not tested in accordance with regulatory requirements. Please note that all your donors were missing screening for multiple risk factors for RCDADs at the time of donation. Additionally, certain donors were not tested in accordance with 21 CFR 1271 or were missing documentation of a current physical examination.\n\nAs required under 21 CFR 1271.50(a), you must determine whether a donor is eligible based upon the results of donor screening in accordance with 21 CFR 1271.75 and donor testing in accordance with 21 CFR 1271.80 and 1271.85. Donors whose screening and\u002For testing were not performed in compliance with the aforementioned regulatory citations cannot be determined “eligible” or “ineligible.” FDA considers the donor eligibility determination to be incomplete, and all HCT\u002FPs remaining in storage from these donors must be stored under quarantine. As this affects all your donors, we have provided at the end of the letter information regarding exemption requests and labeling should you need to remove any of these HCT\u002FPs from storage.\n\nIn response to Observation 6, we acknowledge that you have revised specific sections of The New Hope Center Donor Oocyte Program procedure, but your procedures remain deficient for the reasons set forth below. Please note that this list is not all-inclusive. It continues to be your responsibility to ensure that your establishment is in full compliance with 21 CFR 1271 at all times.\n\nWe recommend that you review your firm’s procedures and make the necessary changes to ensure they include all steps that you perform in testing, screening, determining donor eligibility, and complying with all other requirements in accordance with 21 CFR 1271 of Subpart C - Donor Eligibility.\n\n1. Your response to Observation 6 states, “We have added specific testing into our SOP’s (sic) that instructs the tests needed to be performed are HIV, Hep B, Hep C, HTPE, Creutzfeldt Jacob (sic) Disease, and communicable disease risks associated with Xenotransplantation.” We note that screening donors for communicable disease risks of Creutzfeldt-Jakob Disease (CJD) and xenotransplantation is done through donor history questions that are part of the screening process. There are currently no tests that can evaluate a donor’s risk for CJD or xenotransplantation.\n\n2. Your procedure includes testing for ZIKV under the “Final Serology Testing” section. Please note that there are currently no available tests for ZIKV that are considered appropriate for preventing transmission of ZIKV through HCT\u002FPs.\n\n3. The procedure is still missing many of the requirements in Subpart C of 21 CFR 1271.Under 21 CFR 1271.47(a), you must establish and maintain procedures for all steps that you perform in testing, screening, determining donor eligibility, and complying with all other requirements of the subpart.\n\nPlease note that if you still have oocytes and\u002For semen in storage from donors whose screening and\u002For testing was not completed in accordance with 21 CFR Part 1271, FDA considers the donor eligibility determinations to be incomplete for these donors. For example, this includes donors who were screened using a donor history questionnaire that was missing required screening questions, donors who were missing a physical examination, and donors who were not tested for relevant communicable disease agents in accordance with regulatory requirements. Therefore, as required by 21 CFR 1271.60(a), you must keep these HCT\u002FPs in quarantine.\n\nShould the need arise in the future to remove any of these HCT\u002FPs from quarantine, either for use in your own establishment or for transport to another establishment, you may request an exemption or alternative from a requirement in subpart C, 21 CFR Part 1271, as specified in 21 CFR 1271.155. Additional information can be found at: http:\u002F\u002Fwww.fda.gov\u002FBiologicsBloodVaccines\u002FTissueTissueProducts\u002FRegulationofTissues\u002FExempt ionsandAlternativeProcedures\u002Fdefault.htm). The email address for submissions is HCTPExemptions@fda.hhs.gov.\n\nPlease note that 21 CFR 1271.155 requires that you provide justification for use of HCT\u002FPs from these donors, as well as information on how you have mitigated the risk consistent with the goals of protecting the public health and\u002For preventing the introduction, transmission, or spread of communicable diseases. Before any of these HCT\u002FPs can be removed from quarantine, the request must be granted by FDA.\n\nIf you still have embryos in storage for which the donor eligibility requirements under 21 CFR Part 1271, Subpart C are not met, please note that FDA considers the donor eligibility determinations to be incomplete for these donors. Therefore, as required by 21 CFR 1271.60(a), you must keep these HCT\u002FPs in quarantine. Should the need arise in the future to remove any of these HCT\u002FPs from quarantine, either for use in your own establishment or for transport to another establishment, you may release these HCT\u002FPs from quarantine (21 CFR 1271.90(b)) provided they are labeled in accordance with the applicable regulations at 21 CFR 1271.90(c).\n\nYou should take prompt action to correct the violations addressed in this letter and prevent their recurrence. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct the noted violations, including an explanation of how you plan to prevent these violations, or similar violations, from occurring again. If you believe that your products are not in violation of the law, include your reasoning and any supporting information for our consideration. Additionally, include any documentation necessary to show that correction of any of the above-noted violations has been achieved. If you cannot complete all corrections within fifteen (15) working days, please explain the reason for your delay and the time frame within which the remaining corrections will be completed.\n\nYour response should be sent to LT Yvesna Blaise, Compliance Officer at the following email address: Yvesna.blaise@fda.hhs.gov. If you have any questions, please contact LT Blaise at 973-331-4970 or via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nMichael W. Roosevelt\n\nProgram Division Director\n\nOffice of Biological Products Operations – Division 1","The New Hope Center for Reproductive Medicine","new-hope-center-reproductive-medicine-658251-06272023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnew-hope-center-reproductive-medicine-658251-06272023","2026-10-26T08:09:32.33494+00:00","2023-07-11","658251","Biologics","Division of Biological Products Operations I","Robin L. Poe-Zeigler, MD","2026-08-20T00:55:25.083+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","23-658251","2023-06-27",{"id":210,"raw":211,"subject":215,"body_html":216,"body_text":217,"firm_name":218,"letter_id":219,"created_at":152,"fei_number":20,"letter_url":220,"updated_at":221,"action_type":23,"case_status":48,"posted_date":222,"marcs_cms_no":223,"product_type":51,"closeout_date":20,"issuing_office":39,"recipient_name":224,"body_fetched_at":225,"delivery_method":226,"recipient_title":20,"reference_number":20,"action_taken_date":227,"medical_device_id":20,"response_letter_date":20},678,[212,213,214,39,215,13,13,13],"\u003Ctime datetime=\"2025-09-02T04:00:00Z\">09\u002F02\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-08-25T04:00:00Z\">08\u002F25\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhomeopathic-educational-services-dba-homeopathic-family-medicine-708635-08252025\">Homeopathic Educational Services dba Homeopathic Family Medicine \u003C\u002Fa>","Unapproved New Drugs\u002FOphthalmic Drug Products","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dana Ullman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Homeopathic Educational Services dba Homeopathic Family Medicine \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>812Camelia Street, Suite C\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Berkeley\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>94710-1418\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:email@homeopathic.com\"> email@homeopathic.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>August 25, 2025\u003C\u002Fp>\u003Cp>RE: 708635\u003C\u002Fp>\u003Cp>Dear Dana Ullman:\u003C\u002Fp>\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fhomeopathic.com\u002F in May 2025. The FDA has observed that your website offers “Cineraria Maritima Eye Drops” for sale in the United States. Based on our review, this product is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>Your “Cineraria Maritima Eye Drops” product is especially concerning from a public health perspective. Ophthalmic drug products, which are intended for administration into the eyes, in general pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.\u003C\u002Fp>\u003Cp>Based on a review of your website, your “Cineraria Maritima Eye Drops” product is a drug under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples of claims from your website that provide evidence of the intended use of this product as a drug include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>Cineraria Maritima Eye Drops\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fhomeopathic.com\u002Fproduct\u002Fcineraria-maritima-eye-drops-without-alcohol-10ml-qcin\u002F:\u003C\u002Fp>\u003Cul>\u003Cli>“The most common indicaton [sic] for Cineraria Maritima is cataracts.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your “Cineraria Maritima Eye Drops” is not generally recognized as safe and effective (GRASE) for its above referenced use and, therefore, this product is a “new drug” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). There is no FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, in effect for this product. Accordingly, the introduction or delivery for introduction into interstate commerce of this product violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>We recognize that your “Cineraria Maritima Eye Drops” is labeled as a homeopathic drug with active ingredient(s) measured in homeopathic strengths (i.e., Cineraria Maritima D2). Under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&amp;C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction. In addition, please note that unapproved new drugs are subject to refusal of admission into the United States, and such products may be subject to detention without physical examination. For more information about detention without physical examination, see Import Alert 66-41.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Please include your firm name and the unique identifier “708635” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDana Ullman\n\nRecipient Title\n\nOwner\n\nHomeopathic Educational Services dba Homeopathic Family Medicine\n\n812Camelia Street, Suite C\n\nBerkeley, CA 94710-1418\n\nUnited States\n\nemail@homeopathic.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nAugust 25, 2025\nRE: 708635\nDear Dana Ullman:\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fhomeopathic.com\u002F in May 2025. The FDA has observed that your website offers “Cineraria Maritima Eye Drops” for sale in the United States. Based on our review, this product is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nYour “Cineraria Maritima Eye Drops” product is especially concerning from a public health perspective. Ophthalmic drug products, which are intended for administration into the eyes, in general pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.\nBased on a review of your website, your “Cineraria Maritima Eye Drops” product is a drug under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples of claims from your website that provide evidence of the intended use of this product as a drug include, but may not be limited to, the following:\nCineraria Maritima Eye Drops\nOn the webpage https:\u002F\u002Fhomeopathic.com\u002Fproduct\u002Fcineraria-maritima-eye-drops-without-alcohol-10ml-qcin\u002F:\n“The most common indicaton [sic] for Cineraria Maritima is cataracts.”\nYour “Cineraria Maritima Eye Drops” is not generally recognized as safe and effective (GRASE) for its above referenced use and, therefore, this product is a “new drug” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). There is no FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, in effect for this product. Accordingly, the introduction or delivery for introduction into interstate commerce of this product violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nWe recognize that your “Cineraria Maritima Eye Drops” is labeled as a homeopathic drug with active ingredient(s) measured in homeopathic strengths (i.e., Cineraria Maritima D2). Under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction. In addition, please note that unapproved new drugs are subject to refusal of admission into the United States, and such products may be subject to detention without physical examination. For more information about detention without physical examination, see Import Alert 66-41.\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\nPlease include your firm name and the unique identifier “708635” in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration","Homeopathic Educational Services dba Homeopathic Family Medicine","homeopathic-educational-services-dba-homeopathic-family-medicine-708635-08252025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhomeopathic-educational-services-dba-homeopathic-family-medicine-708635-08252025","2026-10-26T08:08:55.416262+00:00","2025-09-02","708635","Dana Ullman","2026-08-19T16:26:57.049+00:00","Via Email","2025-08-25",{"id":229,"raw":230,"subject":236,"body_html":237,"body_text":238,"firm_name":239,"letter_id":240,"created_at":19,"fei_number":20,"letter_url":241,"updated_at":242,"action_type":23,"case_status":48,"posted_date":243,"marcs_cms_no":244,"product_type":51,"closeout_date":20,"issuing_office":234,"recipient_name":245,"body_fetched_at":246,"delivery_method":247,"recipient_title":20,"reference_number":20,"action_taken_date":248,"medical_device_id":20,"response_letter_date":20},2143,[231,232,233,234,235,13,13,13],"\u003Ctime datetime=\"2023-03-28T13:20:00Z\">03\u002F28\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-03-14T04:00:00Z\">03\u002F14\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frobert-j-hayashi-mdwashington-university-school-medicine-department-pediatrics-654873-03142023\">Robert J. Hayashi, M.D.\u002FWashington University School of Medicine, Department of Pediatrics\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Bioresearch Monitoring Program\u002FIRB ","Bioresearch Monitoring Program\u002FIRB","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE AND VIA E-MAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Robert J. Hayashi, M.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Robert J. Hayashi, M.D.\u002FWashington University School of Medicine, Department of Pediatrics\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>660 South Euclid Avenue, Box 8116\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Saint Louis\u003C\u002Fspan>, \u003Cspan>MO\u003C\u002Fspan> \u003Cspan>63110-1010\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Ref.: 23-HFD-45-03-02\u003Cbr>\n\u003Cbr>\nDear Dr. Hayashi:\u003C\u002Fp>\n\n\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at your clinical site between June 23, 2022, and July 8, 2022. Investigator Carmen Y. Fisher, representing FDA, reviewed your conduct of the following clinical investigations:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” of the investigational drug \u003Cstrong>(b)(4)\u003C\u002Fstrong>, performed for the \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>, of investigational drug \u003Cstrong>(b)(4)\u003C\u002Fstrong> performed for the \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>This inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, Investigator Fisher presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your July 28, 2022, written response to the Form FDA 483.\u003C\u002Fp>\n\n\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your July 28, 2022, written response, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, part 312 [21 CFR 312] governing the conduct of clinical investigations and the protection of human subjects. We wish to emphasize the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>You failed to ensure that the investigation was conducted according to the investigational plan [21 CFR 312.60].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>As a clinical investigator, you are required to ensure that your clinical studies are conducted in accordance with the investigational plan. The investigational plan for Protocol \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>requires that you omit certain \u003Cstrong>(b)(4)\u003C\u002Fstrong> treatments for subjects randomized into the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, the investigational plan for Protocol&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> requires you to ensure that subjects meet certain treatment eligibility criteria before each treatment cycle. You failed to adhere to these requirements. Specifically:\u003C\u002Fp>\n\n\u003Cp>1. The investigational plan for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> requires that you omit administration of Day 1 \u003Cstrong>(b)(4)\u003C\u002Fstrong> during the final 2 cycles of maintenance therapy for subjects randomized into the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Subject \u003Cstrong>(b)(6)\u003C\u002Fstrong> was a pediatric subject (5 years old) randomized to the \u003Cstrong>(b)(4)\u003C\u002Fstrong>; however, this subject was administered 12 mg of \u003Cstrong>(b)(4)\u003C\u002Fstrong> on Day 1 of the subject’s final two cycles of maintenance therapy (Cycles 5 and 6), on \u003Cstrong>(b)(6)\u003C\u002Fstrong>, respectively. As a result, this subject underwent invasive procedures associated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> administration, including lumbar punctures for the collection of cerebrospinal fluid and the use of general and local anesthesia. Subjects administered \u003Cstrong>(b)(4)\u003C\u002Fstrong> are exposed to an increased risk of neurotoxicity (for example, seizures and encephalopathies) associated with \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and an increased risk of infection associated with lumbar punctures.\u003C\u002Fp>\n\n\u003Cp>In your July 28, 2022, written response to the Form FDA 483, you acknowledged the observation, stating that you take full responsibility for this deviation. You stated that once the error was brought to your attention on February 8, 2022, you notified the subject’s mother, the study chair, and the National Cancer Institute, Pediatric Central IRB (Pediatric CIRB). You stated that the subject experienced no adverse events resulting from the additional doses of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and lumbar punctures. You also created and began implementing a Corrective and Preventive Action Plan (CAPA).\u003C\u002Fp>\n\n\u003Cp>You also stated that you assembled a team, the Clinical Trials Command Center (CTCC), which includes members of the clinical trials task force, the Quality and Safety Committee, and divisional leadership, to field prompt notifications of challenges to your clinical operations as they relate to clinical trial conduct on a weekly basis, and to formulate strategies and actions to eliminate difficulties to prevent errors and optimize patient safety. You described protocol-specific actions that the CTCC has implemented and will monitor. For example, updates to the electronic medical record (EMR) ordering system were made to remove \u003Cstrong>(b)(4)\u003C\u002Fstrong> from Day 1 of Cycles 5 and 6 for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, in anticipation that the end of therapy will be in proximity to these cycles, and therefore subjects will not receive \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Furthermore, you stated that you contacted the Children’s Oncology Group (COG) Quality Assurance Office and the study chairs, and that you shared suggestions for a protocol amendment that could raise awareness of this issue, to minimize any recurrence of this event at your center and other centers. You also stated that education was provided to the study staff caring for patients on Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, reinforcing the need to calculate the end of therapy and when the last administration of \u003Cstrong>(b)(4)\u003C\u002Fstrong> is planned. Additionally, you stated that procedural standard operating procedures (SOPs) were created for \u003Cstrong>(b)(6)&nbsp;\u003C\u002Fstrong>ordering, to minimize errors in \u003Cstrong>(b)(6)\u003C\u002Fstrong> administration, and that training on these SOPs was provided.\u003C\u002Fp>\n\n\u003Cp>2. The investigational plan for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> requires an \u003Cstrong>(b)(4)\u003C\u002Fstrong> before the initiation of any cycle of 3-day interval of \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>(\u003Cstrong>(b)(4)\u003C\u002Fstrong>) administration. If this treatment eligibility criterion is not met, the 3-day course of \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) is not initiated. Subject \u003Cstrong>(b)(6)\u003C\u002Fstrong> had a calculated \u003Cstrong>(b)(4)\u003C\u002Fstrong> on \u003Cstrong>(b)(6)\u003C\u002Fstrong>; however, this subject received a 3-day course of&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) on Days 1 to 3 of Cycle 3 (\u003Cstrong>(b)(6)\u003C\u002Fstrong>). Thus, you failed to ensure that the only enrolled subject in Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Subject \u003Cstrong>(b)(6)\u003C\u002Fstrong>, met the required treatment eligibility criterion before the administration of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>In your July 28, 2022, written response to the Form FDA 483, you acknowledge the observation, stating that you take full responsibility for this deviation. You explained that a provider examining the subject had mistakenly understood the protocol to require an&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> for the initiation of a cycle, and this provider had authorized the study drug to be dispensed.\u003C\u002Fp>\n\n\u003Cp>As described above, you stated that you created and began implementing a CAPA. Corrective actions included notifying the subject’s family and the study chair. You also stated that the subject was monitored for toxicity, and that there were no identifiable significant adverse events associated with this error.\u003C\u002Fp>\n\n\u003Cp>Additionally, you stated that preventative actions include: (1) the initiation of a “double check” system, in which a nurse and a provider check the drug and dose before dispensing an oral investigational \u003Cstrong>(b)(6)\u003C\u002Fstrong> agent; (2) the creation of procedural SOPs for \u003Cstrong>(b)(6)\u003C\u002Fstrong> ordering, to minimize errors in \u003Cstrong>(b)(6)\u003C\u002Fstrong>, with training on these SOPs; (3) education for providers and nurse coordinators on the calculation of \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and (4) good clinical practice training.\u003C\u002Fp>\n\n\u003Cp>We acknowledge the corrective and preventive actions that your site has taken and plans to take. However, given the significance of the protocol deviations involving pediatric subjects, we request documentation following up on some of the trainings you listed in your CAPA. For example, you stated in your CAPA that you were going to provide mandatory training by August 15, 2022, to all study personnel who participate in the management of clinical trials subject to an IND. We request that you submit documentation that this training occurred, and that you explain how this training will ensure that ongoing and future clinical investigations will be conducted in compliance with applicable FDA regulations. We cannot undertake an informed evaluation of your written response until you submit this information.\u003C\u002Fp>\n\n\u003Cp>We emphasize that as the clinical investigator, it is your responsibility to ensure that studies are conducted in accordance with the investigational plan, to protect the rights, safety, and welfare of subjects and to ensure the integrity of study data. Your failure to conduct the clinical study in accordance with the protocol resulted in the unnecessary administration of intrathecal methotrexate and the performance of invasive procedures, such as lumbar punctures and the sedation of a pediatric subject; and the initiation of study treatment cycles for a subject, despite that subject’s not meeting the treatment eligibility criterion. This conduct raises significant concerns about your protection of the study subjects enrolled at your site, and also raises concerns about the validity and integrity of the data collected at your site.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies with your clinical study of an investigational drug. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future.\u003C\u002Fp>\n\n\u003Cp>Failure to adequately address this matter may lead to regulatory action. If you believe you have complied with the FD&amp;C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you have any questions, please call Miah Jung, Pharm.D., M.S., at 240-402-3728. Alternatively, you may e-mail FDA at CDER-OSI-Communications@fda.hhs.gov. Your written response and any pertinent documentation should be addressed to:\u003C\u002Fp>\n\n\u003Cp>Miah Jung, Pharm.D., M.S.\u003Cbr>\nBranch Chief\u003Cbr>\nCompliance Enforcement Branch\u003Cbr>\nDivision of Enforcement and Postmarketing Safety\u003Cbr>\nOffice of Scientific Investigations\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nBuilding 51, Room 5352\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n{See appended electronic signature page}\u003Cbr>\nDavid C. Burrow, Pharm.D., J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Scientific Investigations\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\n\u003Cbr>\n--------------------------------------------------------------------------------------------\u003Cbr>\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\u003Cbr>\n--------------------------------------------------------------------------------------------\u003Cbr>\n\u002Fs\u002F\u003Cbr>\n------------------------------------------------------------\u003Cbr>\nDAVID C BURROW\u003Cbr>\n03\u002F14\u002F2023 07:42:17 AM\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE AND VIA E-MAIL\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nRobert J. Hayashi, M.D.\n\nRobert J. Hayashi, M.D.\u002FWashington University School of Medicine, Department of Pediatrics\n\n660 South Euclid Avenue, Box 8116\n\nSaint Louis, MO 63110-1010\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nRef.: 23-HFD-45-03-02\n\nDear Dr. Hayashi:\n\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at your clinical site between June 23, 2022, and July 8, 2022. Investigator Carmen Y. Fisher, representing FDA, reviewed your conduct of the following clinical investigations:\n\nProtocol (b)(4), “(b)(4),” of the investigational drug (b)(4), performed for the (b)(4)\n\nProtocol (b)(4), “(b)(4), of investigational drug (b)(4) performed for the (b)(4)\n\nThis inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\n\nAt the conclusion of the inspection, Investigator Fisher presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your July 28, 2022, written response to the Form FDA 483.\n\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your July 28, 2022, written response, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, part 312 [21 CFR 312] governing the conduct of clinical investigations and the protection of human subjects. We wish to emphasize the following:\n\nYou failed to ensure that the investigation was conducted according to the investigational plan [21 CFR 312.60].\n\nAs a clinical investigator, you are required to ensure that your clinical studies are conducted in accordance with the investigational plan. The investigational plan for Protocol (b)(4) requires that you omit certain (b)(4) treatments for subjects randomized into the (b)(4). In addition, the investigational plan for Protocol (b)(4) requires you to ensure that subjects meet certain treatment eligibility criteria before each treatment cycle. You failed to adhere to these requirements. Specifically:\n\n1. The investigational plan for Protocol (b)(4) requires that you omit administration of Day 1 (b)(4) during the final 2 cycles of maintenance therapy for subjects randomized into the (b)(4). Subject (b)(6) was a pediatric subject (5 years old) randomized to the (b)(4); however, this subject was administered 12 mg of (b)(4) on Day 1 of the subject’s final two cycles of maintenance therapy (Cycles 5 and 6), on (b)(6), respectively. As a result, this subject underwent invasive procedures associated with (b)(4) administration, including lumbar punctures for the collection of cerebrospinal fluid and the use of general and local anesthesia. Subjects administered (b)(4) are exposed to an increased risk of neurotoxicity (for example, seizures and encephalopathies) associated with (b)(4), and an increased risk of infection associated with lumbar punctures.\n\nIn your July 28, 2022, written response to the Form FDA 483, you acknowledged the observation, stating that you take full responsibility for this deviation. You stated that once the error was brought to your attention on February 8, 2022, you notified the subject’s mother, the study chair, and the National Cancer Institute, Pediatric Central IRB (Pediatric CIRB). You stated that the subject experienced no adverse events resulting from the additional doses of (b)(4) and lumbar punctures. You also created and began implementing a Corrective and Preventive Action Plan (CAPA).\n\nYou also stated that you assembled a team, the Clinical Trials Command Center (CTCC), which includes members of the clinical trials task force, the Quality and Safety Committee, and divisional leadership, to field prompt notifications of challenges to your clinical operations as they relate to clinical trial conduct on a weekly basis, and to formulate strategies and actions to eliminate difficulties to prevent errors and optimize patient safety. You described protocol-specific actions that the CTCC has implemented and will monitor. For example, updates to the electronic medical record (EMR) ordering system were made to remove (b)(4) from Day 1 of Cycles 5 and 6 for (b)(4), in anticipation that the end of therapy will be in proximity to these cycles, and therefore subjects will not receive (b)(4).\n\nFurthermore, you stated that you contacted the Children’s Oncology Group (COG) Quality Assurance Office and the study chairs, and that you shared suggestions for a protocol amendment that could raise awareness of this issue, to minimize any recurrence of this event at your center and other centers. You also stated that education was provided to the study staff caring for patients on Protocol (b)(4), reinforcing the need to calculate the end of therapy and when the last administration of (b)(4) is planned. Additionally, you stated that procedural standard operating procedures (SOPs) were created for (b)(6) ordering, to minimize errors in (b)(6) administration, and that training on these SOPs was provided.\n\n2. The investigational plan for Protocol (b)(4) requires an (b)(4) before the initiation of any cycle of 3-day interval of (b)(4) ((b)(4)) administration. If this treatment eligibility criterion is not met, the 3-day course of (b)(4) ((b)(4)) is not initiated. Subject (b)(6) had a calculated (b)(4) on (b)(6); however, this subject received a 3-day course of (b)(4) ((b)(4)) on Days 1 to 3 of Cycle 3 ((b)(6)). Thus, you failed to ensure that the only enrolled subject in Protocol (b)(4), Subject (b)(6), met the required treatment eligibility criterion before the administration of (b)(4).\n\nIn your July 28, 2022, written response to the Form FDA 483, you acknowledge the observation, stating that you take full responsibility for this deviation. You explained that a provider examining the subject had mistakenly understood the protocol to require an (b)(4) for the initiation of a cycle, and this provider had authorized the study drug to be dispensed.\n\nAs described above, you stated that you created and began implementing a CAPA. Corrective actions included notifying the subject’s family and the study chair. You also stated that the subject was monitored for toxicity, and that there were no identifiable significant adverse events associated with this error.\n\nAdditionally, you stated that preventative actions include: (1) the initiation of a “double check” system, in which a nurse and a provider check the drug and dose before dispensing an oral investigational (b)(6) agent; (2) the creation of procedural SOPs for (b)(6) ordering, to minimize errors in (b)(6), with training on these SOPs; (3) education for providers and nurse coordinators on the calculation of (b)(4); and (4) good clinical practice training.\n\nWe acknowledge the corrective and preventive actions that your site has taken and plans to take. However, given the significance of the protocol deviations involving pediatric subjects, we request documentation following up on some of the trainings you listed in your CAPA. For example, you stated in your CAPA that you were going to provide mandatory training by August 15, 2022, to all study personnel who participate in the management of clinical trials subject to an IND. We request that you submit documentation that this training occurred, and that you explain how this training will ensure that ongoing and future clinical investigations will be conducted in compliance with applicable FDA regulations. We cannot undertake an informed evaluation of your written response until you submit this information.\n\nWe emphasize that as the clinical investigator, it is your responsibility to ensure that studies are conducted in accordance with the investigational plan, to protect the rights, safety, and welfare of subjects and to ensure the integrity of study data. Your failure to conduct the clinical study in accordance with the protocol resulted in the unnecessary administration of intrathecal methotrexate and the performance of invasive procedures, such as lumbar punctures and the sedation of a pediatric subject; and the initiation of study treatment cycles for a subject, despite that subject’s not meeting the treatment eligibility criterion. This conduct raises significant concerns about your protection of the study subjects enrolled at your site, and also raises concerns about the validity and integrity of the data collected at your site.\n\nThis letter is not intended to be an all-inclusive list of deficiencies with your clinical study of an investigational drug. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\n\nThis letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future.\n\nFailure to adequately address this matter may lead to regulatory action. If you believe you have complied with the FD&C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\n\nIf you have any questions, please call Miah Jung, Pharm.D., M.S., at 240-402-3728. Alternatively, you may e-mail FDA at CDER-OSI-Communications@fda.hhs.gov. Your written response and any pertinent documentation should be addressed to:\n\nMiah Jung, Pharm.D., M.S.\n\nBranch Chief\n\nCompliance Enforcement Branch\n\nDivision of Enforcement and Postmarketing Safety\n\nOffice of Scientific Investigations\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\nBuilding 51, Room 5352\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993\n\nSincerely yours,\n\n{See appended electronic signature page}\n\nDavid C. Burrow, Pharm.D., J.D.\n\nDirector\n\nOffice of Scientific Investigations\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\n--------------------------------------------------------------------------------------------\n\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\n\n--------------------------------------------------------------------------------------------\n\n\u002Fs\u002F\n\n------------------------------------------------------------\n\nDAVID C BURROW\n\n03\u002F14\u002F2023 07:42:17 AM","Robert J. Hayashi, M.D.\u002FWashington University School of Medicine, Department of Pediatrics","robert-j-hayashi-mdwashington-university-school-medicine-department-pediatrics-654873-03142023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frobert-j-hayashi-mdwashington-university-school-medicine-department-pediatrics-654873-03142023","2026-10-26T08:09:50.433203+00:00","2023-03-28","654873","Robert J. Hayashi, M.D.","2026-08-20T01:10:40.684+00:00","VIA UNITED PARCEL SERVICE AND VIA E-MAIL","2023-03-14",{"id":250,"raw":251,"subject":171,"body_html":257,"body_text":258,"firm_name":259,"letter_id":260,"created_at":176,"fei_number":20,"letter_url":261,"updated_at":262,"action_type":23,"case_status":24,"posted_date":263,"marcs_cms_no":264,"product_type":51,"closeout_date":265,"issuing_office":255,"recipient_name":266,"body_fetched_at":267,"delivery_method":268,"recipient_title":20,"reference_number":20,"action_taken_date":269,"medical_device_id":20,"response_letter_date":20},3024,[252,253,254,255,171,13,256,13],"\u003Ctime datetime=\"2021-11-16T14:20:00Z\">11\u002F16\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-11-10T05:00:00Z\">11\u002F10\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadvanced-nutriceuticals-llc-dba-guyer-institute-molecular-medicine-615908-11102021\">Advanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine\u003C\u002Fa>","Division of Pharmaceutical Quality Operations Division III","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadvanced-nutriceuticals-llc-dba-guyer-institute-molecular-medicine-615908-02242026\">\u003Ctime datetime=\"2026-03-17T04:00:00Z\">03\u002F17\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS Next Day\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Leonard D. Guyer, MD\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder and Medical Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Advanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>836 E. 86th Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Indianapolis\u003C\u002Fspan>, \u003Cspan>IN\u003C\u002Fspan> \u003Cspan>46240-1806\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations Division III\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WL # 615908\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 10, 2021\u003Cbr>\n\u003Cbr>\nDear Dr. Guyer:\u003C\u002Fp>\n\n\u003Cp>From October 13, 2020, to October 29, 2020, U.S. Food and Drug Administration (FDA) investigators inspected your facility, Advanced Nutriceuticals LLC dba The Guyer Institute of Molecular Medicine located at 836 E. 86th Street, Indianapolis, Indiana 46240. During the inspection, the investigators collected evidence indicating that drug products you produced failed to meet the conditions of section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353a] for exemption from certain provisions of the FDCA. In addition, the investigators noted serious deficiencies in your practices for producing sterile drug products, which put patients at risk.\u003C\u002Fp>\n\n\u003Cp>FDA issued a Form FDA 483 to your firm on October 29, 2020. FDA acknowledges receipt of your facility’s response, dated November 18, 2020. Additionally, FDA acknowledges that your firm voluntarily ceased sterile production while corrective actions are implemented and, on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, initiated a voluntary recall of all compounded sterile products within expiry due to a lack of sterility assurance. Based on this inspection, it appears that you produced drug products that violate the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A. Compounded Drug Products Under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Section 503A of the FDCA describes the conditions under which human drug products compounded by a licensed pharmacist in a state licensed pharmacy or a federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Receipt of valid prescriptions for individually-identified patients is one of the conditions for the exemptions under section 503A.\u003C\u002Fp>\n\n\u003Cp>In addition, for a compounded drug product to qualify for the exemptions under section 503A, bulk drug substances used to compound it must: (I) comply with the standards of an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph, if a monograph exists, and the USP chapter on pharmacy compounding; (II) if such a monograph does not exist, be components of drugs approved by the Secretary; or (III) if such a monograph does not exist and the drug substance is not a component of a drug approved by the Secretary, appear on a list developed by the Secretary through regulation (“503A bulks list”) (section 503A(b)(1)(A)(i) of the FDCA).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>B. Failure to Meet the Conditions of Section 503A\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During the inspection, the FDA investigators collected evidence indicating that drug products produced by your firm failed to meet the conditions of section 503A. For example, the investigators collected evidence indicating:\u003C\u002Fp>\n\n\u003Cp>1. Your firm did not receive valid prescriptions for individually-identified patients for a portion of the drug products you produced, such as your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” products, including Energy Boost.\u003C\u002Fp>\n\n\u003Cp>2. Your firm compounded drug products using \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Drug products compounded using \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> are not eligible for the exemptions provided by section 503A(a), because \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> are not the subject of an applicable USP or NF monograph, are not components of FDA-approved human drugs, and do not appear on the 503A bulks list.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Therefore, you compounded drug products that do not meet the conditions of section 503A and are not eligible for the exemptions in that section, including the FDA approval requirement of section 505 of the FDCA, the requirement under section 502(f)(1) of the FDCA that labeling bear adequate directions for use, and the requirement of compliance with CGMP under section 501(a)(2)(B) of the FDCA. In the remainder of this letter, we refer to your drug products that do not qualify for exemptions under section 503A as the “ineligible drug products.”\u003C\u002Fp>\n\n\u003Cp>Specific violations are described below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>C. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The FDA investigators noted that drug products were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigators observed that:\u003C\u002Fp>\n\n\u003Cp>1. Your operator was observed conducting aseptic operations outside of a certified ISO 5 area. The filling of sterile drug products into syringes, which were not for immediate administration to patients, but for shipment to patients across the country, was conducted in the unclassified dispensary area by personnel in street clothes with no gloves donned.\u003C\u002Fp>\n\n\u003Cp>2. Your “IV Hood” used to produce drug products purporting to be sterile is located in an unclassified room. In addition, this hood has not been certified in over two years.\u003C\u002Fp>\n\n\u003Cp>3. Your personnel performing sterile operations have never conducted media fills. Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility.\u003C\u002Fp>\n\n\u003Cp>4. Your operator engaged in aseptic processing while wearing non-sterile gloves, street clothes, and with exposed skin within the ISO 5 aseptic processing area.\u003C\u002Fp>\n\n\u003Cp>5. Your personnel engaged in poor aseptic technique on multiple occasions during the processing of sterile drug products. For example:\u003Cbr>\n&nbsp; a. An operator placed their gloved hands outside the ISO 5 work area repeatedly to retrieve supplies without sanitizing their gloved hands before re-entry into the ISO 5 hood.\u003Cbr>\n&nbsp; b. An operator failed to sanitize or change gloves after contact with non-sterile materials (e.g., face mask, trash can) during sterile processing.\u003Cbr>\n&nbsp; c. An operator blocked first air by placing gloved hands directly in line with the sterile filter and open sterile containers.\u003C\u002Fp>\n\n\u003Cp>6. An operator was observed manually stoppering sterile drug vials and touching product contact surfaces during the process.\u003C\u002Fp>\n\n\u003Cp>7. Your firm exposed a stock solution intended to be sterile to worse than ISO 5 air after the stopper had been punctured multiple times. Specifically, the stock solution was stored in an unclassified area for further use after the container closure system had been punctured multiple times, and therefore compromised, throughout the assigned expiry period.\u003C\u002Fp>\n\n\u003Cp>8. Your firm stores unused product vials in non-sterile plastic bags, which are allowed to be reused in sterile production. The vials stored in these bags are not \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Moreover, your firm’s temperature and time conditions used for \u003Cstrong>(b)(4)\u003C\u002Fstrong> of product vials are not known to be \u003Cstrong>(b)(4)\u003C\u002Fstrong> microorganisms.\u003C\u002Fp>\n\n\u003Cp>9. Your firm has not conducted environmental monitoring since 2018.\u003C\u002Fp>\n\n\u003Cp>10. Your aseptic processing and surrounding areas had difficult to clean and visibly dirty equipment or surfaces. For example:\u003Cbr>\n&nbsp; a. HEPA filters were discolored and\u002For damaged in the ISO 5 cleanroom hood.\u003Cbr>\n&nbsp; b. Your ISO 5 cleanroom workbench was constructed of laminated wood.\u003Cbr>\n&nbsp; c. A heating vent located below the ISO 5 cleanroom hood was visibly dirty and had no filtering device.\u003C\u002Fp>\n\n\u003Cp>11. Your firm handled hazardous drugs without providing adequate containment, segregation, or cleaning of work surfaces and utensils to prevent cross-contamination.\u003C\u002Fp>\n\n\u003Cp>Furthermore, the manufacture of the ineligible drug products is subject to FDA’s CGMP regulations, Title 21, Code of Federal Regulations (CFR), parts 210 and 211. The FDA investigators observed significant CGMP violations at your facility, causing the ineligible drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations included, for example:\u003C\u002Fp>\n\n\u003Cp>1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fp>\n\n\u003Cp>2. Your firm failed to ensure that manufacturing personnel wear clothing appropriate to protect drug product from contamination (21 CFR 211.28(a)).\u003C\u002Fp>\n\n\u003Cp>3. Your firm failed to clean and sterilize and process, where indicated by the nature of the drug, container closures to remove pyrogenic properties to assure they are suitable for their intended use (21 CFR 211.94(c)).\u003C\u002Fp>\n\n\u003Cp>4. Your firm failed to establish a system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\u003C\u002Fp>\n\n\u003Cp>5. Your firm failed to have buildings used in the manufacture, processing, packing, or holding of drug products of a suitable size, construction and location to facilitate cleaning, maintenance, and proper operations (21 CFR 211.42(a)).\u003C\u002Fp>\n\n\u003Cp>6. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fp>\n\n\u003Cp>7. Your firm failed to prepare batch production and control records for each batch of drug product that include documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch (21 CFR 211.188(b)).\u003C\u002Fp>\n\n\u003Cp>8. Your firm failed to retest or reexamine components, as appropriate, for identity, strength, quality, and purity and your quality control unit failed to approve or reject components (21 CFR 211.87).\u003C\u002Fp>\n\n\u003Cp>Under section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You do not have any FDA-approved applications on file for the ineligible drug products that you compounded.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. § 331(d)], a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The ineligible drug products you compounded are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Accordingly, these ineligible drug products are misbranded under section 502(f)(1) of the FDCA. The introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA. It is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>D. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response to the Form FDA 483. We acknowledge that your firm voluntarily ceased sterile production while corrective actions are implemented and, on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, initiated a voluntary recall of all compounded sterile products within expiry due to a lack of sterility assurance.\u003C\u002Fp>\n\n\u003Cp>Regarding your responses related to the insanitary conditions, some of your corrective actions appear adequate. Furthermore, we acknowledge your intention to install new modular cleanrooms in a separate building on your property to be used for sterile operations in the future. However, we cannot fully evaluate the adequacy of the following corrective actions described in your response because you did not include sufficient information or supporting documentation. For example:\u003C\u002Fp>\n\n\u003Cp>1. Your response to multiple observations includes the creation or revision of procedures and\u002For personnel training. None of the pertinent documentation was provided.\u003C\u002Fp>\n\n\u003Cp>2. You committed to the cessation of pre-filling syringes for shipment to patients. Your response states that staff have been counseled and refresher training on proper aseptic technique would be completed, but no documentation related to this was provided.\u003C\u002Fp>\n\n\u003Cp>3. Your response states that \u003Cstrong>(b)(4)\u003C\u002Fstrong>, but no further details about the kits were provided. It cannot be determined from the available information if the kits \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>4. Your response states you intend \u003Cstrong>(b)(4)\u003C\u002Fstrong> building which will include \u003Cstrong>(b)(4)\u003C\u002Fstrong>. No additional information or supporting documentation was provided regarding this renovation; no response updates have been received.\u003C\u002Fp>\n\n\u003Cp>5. Your response states your firm has implemented several corrections such as the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. No supporting documentation was provided for those corrective actions. No additional information was provided related to the ISO 5 hood with the laminated work surface, which you stated you are \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>6. Your response states that you plan to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, but intend to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, no information was provided about the type of equipment and proposed timeline for this corrective action.\u003C\u002Fp>\n\n\u003Cp>7. Your response states that you would \u003Cstrong>(b)(4)\u003C\u002Fstrong> which would be more conducive to maneuvering in the cleanroom. It is unclear whether this is referring to \u003Cstrong>(b)(4)\u003C\u002Fstrong> to go inside the hood or beside the hood. If inside, dynamic smoke studies have not been provided to evaluate the effect of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> on laminar airflow.\u003C\u002Fp>\n\n\u003Cp>If outside the hood, employees may continue to have issues reaching in and out of the hood to retrieve needed supplies during sterile operations.\u003C\u002Fp>\n\n\u003Cp>8. Your response did not provide sufficient detail for an evaluation of your corrections related to the handling of hazardous drugs to prevent cross contamination.\u003C\u002Fp>\n\n\u003Cp>9. Your response refers to staff members responsible for administering IVs being allowed to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. It is unclear which staff members this refers to, where this operation is to occur, and whether those employees will also be conducting \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>You did not address certain observations related to insanitary conditions, for example:\u003C\u002Fp>\n\n\u003Cp>1. Your response states that \u003Cstrong>(b)(4)\u003C\u002Fstrong> building on the property. The response does not address how or if the current ISO 7\u002F8 suite of rooms will be used in the future.\u003C\u002Fp>\n\n\u003Cp>2. Your response states that \u003Cstrong>(b)(4)\u003C\u002Fstrong> units to be installed but does not address the \u003Cstrong>(b)(4)\u003C\u002Fstrong> monitoring in your current classified areas.\u003C\u002Fp>\n\n\u003Cp>3. Your response did not address the lack of \u003Cstrong>(b)(4)\u003C\u002Fstrong> by your operators during aseptic production.\u003C\u002Fp>\n\n\u003Cp>4. Your response failed to address your lack of routine environmental monitoring.\u003C\u002Fp>\n\n\u003Cp>5. Your response did not address what actions, if any, were taken to ensure the IV hood located in the unclassified room is no longer used.\u003C\u002Fp>\n\n\u003Cp>6. Your response did not address the cleaning and mitigation of the visible drug residues on your current shared equipment that was observed during the inspection.\u003C\u002Fp>\n\n\u003Cp>Regarding your responses related to the insanitary conditions, the following corrective actions appear deficient:\u003C\u002Fp>\n\n\u003Cp>1. Your response states that opened vials will \u003Cstrong>(b)(4)\u003C\u002Fstrong> from opening or the date of expiry and the vials will only be \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your response did not provide justification for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. It is unclear if the stoppers for your stock vials, which are prepared in house, are intended for&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your response states that employees have been instructed to visually inspect stock solution vials. Visual inspection of \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials is not a suitable indicator that the product remains sterile. Your response does not demonstrate how you will prevent contamination when \u003Cstrong>(b)(4)\u003C\u002Fstrong>, with or without use of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, are stored outside of an ISO 5 environment.\u003Cbr>\n\u003Cbr>\n2. Your firm uses \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product vials; however, your response states you are \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which would not be suitable for use in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. It is unclear whether your firm has purchased \u003Cstrong>(b)(4)\u003C\u002Fstrong> for sterilization of the product vials. Your response does not address the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of product vials. You provided no information demonstrating that the current \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycle is adequate. Your response does not address the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> during sterilization or \u003Cstrong>(b)(4)\u003C\u002Fstrong> during \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The use of vials that have not been adequately \u003Cstrong>(b)(4)\u003C\u002Fstrong>, even if adequately sterilized \u003Cstrong>(b)(4)\u003C\u002Fstrong>, is not an acceptable practice.\u003C\u002Fp>\n\n\u003Cp>Please be aware that section 501(a)(2)(A) of the FDCA concerning insanitary conditions applies regardless of whether drug products you compound meet the conditions of section 503A.\u003C\u002Fp>\n\n\u003Cp>Should you continue to compound and distribute drug products that do not meet the conditions of section 503A, the compounding and distribution of such drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the drug CGMP regulations. Before doing so, you must comply with the requirements of section 505 and 502(f)(1) and fully implement corrections that meet the minimum requirements of the CGMP regulations.\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>In addition, it appears you may have been compounding using the bulk drug substance piracetam. Drug products compounded using bulk piracetam are not eligible for the exemptions provided by section 503A(a), because piracetam is not the subject of an applicable USP or NF monograph, not a component of an FDA-approved human drug and does not appear on the 503A bulks list.\u003C\u002Fp>\n\n\u003Cp>Furthermore, it appears that your facility may have produced biological products. Please be advised that federal law does not provide a legal pathway for marketing biological products that have been prepared outside the scope of an approved biologics license application (BLA). Specifically, section 351(a)(1) of the Public Health Service Act (PHS Act) prohibits the introduction into interstate commerce of any biological product unless “a biologics license . . . is in effect for the biological product” (i.e., an approved BLA). Additionally, biological products subject to licensure under section 351 of the PHS Act are not eligible for the exemptions for compounded drugs under sections 503A and 503B of the FDCA. We also note that, as required by the Biologics Price Competition and Innovation Act of 2009, on March 23, 2020, an approved application for a biological product under section 505 of the FDCA was deemed to be a license for the biological product (i.e., an approved BLA) under the PHS Act. This transition affects compounding under sections 503A and 503B of the FDCA because, beginning on March 23, 2020, these biological products that previously could have been submitted in a marketing application under the FD&amp;C Act are subject to licensure under section 351 of the PHS Act and thus are not eligible for the exemptions for compounded drugs under sections 503A and 503B of the FDCA. \u003Cem>See\u003C\u002Fem> \u003Cem>Notice to Compounders: Changes that affect compounding as of March 23, 2020\u003C\u002Fem>\u003Csup>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and section 7002(e)(4) of the Biologics Price Competition and Innovation Act of 2009 for additional information. Although these biological products are not eligible for the exemptions in sections 503A and 503B, FDA issued guidance explaining the conditions under which we do not intend to take action when certain biological products are mixed, diluted, or repackaged in a manner not described in their approved labeling. See Guidance for Industry: Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application (available at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F90986\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F90986\u002Fdownload\u003C\u002Fa>).\u003C\u002Fp>\n\n\u003Cp>In addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b)].\u003C\u002Fp>\n\n\u003Cp>FDA strongly recommends that if you decide to resume production of sterile drugs, your management first undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug processing expertise should assist you in conducting this comprehensive evaluation.\u003C\u002Fp>\n\n\u003Cp>Lastly, during the inspection, investigators noted that your firm may be exporting products to other countries. Please be advised that if a product meets the FDCA’s requirements for sale and distribution in the United States, the FDCA has no additional restrictions on its exportation (i.e., sections 801 and 802 of the FDCA [21 U.S.C. § 381 and 382] do not apply to such exports). However, if the product does not meet FDCA’s domestic marketing requirements and is intended for export then you are required to be in compliance with applicable sections of the FDCA Chapter VIII – Imports and Exports. Furthermore, other federal statutes or regulations administered by other federal agencies (such as the Department of Commerce) may apply. For further information please see FDA’s Guidance for Industry: Exports Under the FDA Export Reform and Enhancement Act of 1996 (available at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fguidance-industry-exports-under-fda-export-reform-and-enhancement-act-1996\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fguidance-industry-exports-under-fda-export-reform-and-enhancement-act-1996\u003C\u002Fa>).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>E. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>If you decide to resume sterile operations, you should take prompt action to correct any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing if you have taken any specific steps to address any violations, or you may inform us that you do not intend to resume production of sterile drugs. If you intend to resume production of sterile drugs in the future, please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. In addition to taking appropriate corrective actions, you should notify this office fifteen (15) working days prior to resuming production of any sterile drugs in the future.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to the Warning Letter Number above (615908). Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Attention: Tina M. Pawlowski, Compliance Officer\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nDivision of Pharmaceutical Quality Operations Division III\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, please contact Tina M. Pawlowski at (313) 393-8217.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Nicholas F. Lyons\u003Cbr>\nActing Program Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations Division III\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> On June 9, 2016, FDA issued a final guidance titled, \u003Cem>Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fem>. This guidance describes FDA’s interim regulatory policy for State-licensed pharmacies, Federal facilities, and licensed physicians that compound human drug products using bulk drug substances that do not otherwise meet the conditions of section 503A(b)(1)(A)(i) while the 503A bulks list is being developed. Specifically, the guidance sets out the conditions under which FDA does not intend to take action against a State-licensed pharmacy, Federal facility, or licensed physician for compounding a drug product using a bulk drug substance that is not the subject of an applicable USP or NF monograph or a component of an FDA-approved drug, until the substance is identified in a final rule as included or not included on the 503A bulks list. These conditions include that the substance may be eligible for inclusion on the 503A bulks list, was nominated with adequate support for FDA to evaluate it, and has not been identified by FDA as a substance that appears to present significant safety risks pending further evaluation. Cerebrolysin, thymosin alpha, thymosin beta, BPC-157, LL-37, pentosan, Selank, and Semax were not nominated for inclusion on the 503A bulks list. For additional information, see the guidance at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM469120.pdf\">http:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM469120.pdf\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> The specific products made by your firm are drugs within the meaning of section 201(g) of the Act, [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) [21 U.S.C. 321(p)] of the FDCA because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Your ineligible drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> In this letter we do not address whether your proposed corrective actions would resolve the CGMP violations noted above.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> Available at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fhuman-drug-compounding\u002Fnotice-compounders-changes-affect-compounding-march-23-2020\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fhuman-drug-compounding\u002Fnotice-compounders-changes-affect-compounding-march-23-2020\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS Next Day\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nLeonard D. Guyer, MD\n\nRecipient Title\n\nFounder and Medical Director\n\nAdvanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine\n\n836 E. 86th Street\n\nIndianapolis, IN 46240-1806\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations Division III\n\nUnited States\n\nWARNING LETTER\n\nWL # 615908\n\nNovember 10, 2021\n\nDear Dr. Guyer:\n\nFrom October 13, 2020, to October 29, 2020, U.S. Food and Drug Administration (FDA) investigators inspected your facility, Advanced Nutriceuticals LLC dba The Guyer Institute of Molecular Medicine located at 836 E. 86th Street, Indianapolis, Indiana 46240. During the inspection, the investigators collected evidence indicating that drug products you produced failed to meet the conditions of section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353a] for exemption from certain provisions of the FDCA. In addition, the investigators noted serious deficiencies in your practices for producing sterile drug products, which put patients at risk.\n\nFDA issued a Form FDA 483 to your firm on October 29, 2020. FDA acknowledges receipt of your facility’s response, dated November 18, 2020. Additionally, FDA acknowledges that your firm voluntarily ceased sterile production while corrective actions are implemented and, on (b)(4), initiated a voluntary recall of all compounded sterile products within expiry due to a lack of sterility assurance. Based on this inspection, it appears that you produced drug products that violate the FDCA.\n\nA. Compounded Drug Products Under the FDCA\n\nSection 503A of the FDCA describes the conditions under which human drug products compounded by a licensed pharmacist in a state licensed pharmacy or a federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].1 Receipt of valid prescriptions for individually-identified patients is one of the conditions for the exemptions under section 503A.\n\nIn addition, for a compounded drug product to qualify for the exemptions under section 503A, bulk drug substances used to compound it must: (I) comply with the standards of an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph, if a monograph exists, and the USP chapter on pharmacy compounding; (II) if such a monograph does not exist, be components of drugs approved by the Secretary; or (III) if such a monograph does not exist and the drug substance is not a component of a drug approved by the Secretary, appear on a list developed by the Secretary through regulation (“503A bulks list”) (section 503A(b)(1)(A)(i) of the FDCA).\n\nB. Failure to Meet the Conditions of Section 503A\n\nDuring the inspection, the FDA investigators collected evidence indicating that drug products produced by your firm failed to meet the conditions of section 503A. For example, the investigators collected evidence indicating:\n\n1. Your firm did not receive valid prescriptions for individually-identified patients for a portion of the drug products you produced, such as your “(b)(4)” products, including Energy Boost.\n\n2. Your firm compounded drug products using (b)(4). Drug products compounded using (b)(4), and (b)(4) are not eligible for the exemptions provided by section 503A(a), because (b)(4), and (b)(4) are not the subject of an applicable USP or NF monograph, are not components of FDA-approved human drugs, and do not appear on the 503A bulks list.2\n\nTherefore, you compounded drug products that do not meet the conditions of section 503A and are not eligible for the exemptions in that section, including the FDA approval requirement of section 505 of the FDCA, the requirement under section 502(f)(1) of the FDCA that labeling bear adequate directions for use, and the requirement of compliance with CGMP under section 501(a)(2)(B) of the FDCA. In the remainder of this letter, we refer to your drug products that do not qualify for exemptions under section 503A as the “ineligible drug products.”\n\nSpecific violations are described below.\n\nC. Violations of the FDCA\n\nAdulterated Drug Products\n\nThe FDA investigators noted that drug products were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigators observed that:\n\n1. Your operator was observed conducting aseptic operations outside of a certified ISO 5 area. The filling of sterile drug products into syringes, which were not for immediate administration to patients, but for shipment to patients across the country, was conducted in the unclassified dispensary area by personnel in street clothes with no gloves donned.\n\n2. Your “IV Hood” used to produce drug products purporting to be sterile is located in an unclassified room. In addition, this hood has not been certified in over two years.\n\n3. Your personnel performing sterile operations have never conducted media fills. Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility.\n\n4. Your operator engaged in aseptic processing while wearing non-sterile gloves, street clothes, and with exposed skin within the ISO 5 aseptic processing area.\n\n5. Your personnel engaged in poor aseptic technique on multiple occasions during the processing of sterile drug products. For example:\n\na. An operator placed their gloved hands outside the ISO 5 work area repeatedly to retrieve supplies without sanitizing their gloved hands before re-entry into the ISO 5 hood.\n\nb. An operator failed to sanitize or change gloves after contact with non-sterile materials (e.g., face mask, trash can) during sterile processing.\n\nc. An operator blocked first air by placing gloved hands directly in line with the sterile filter and open sterile containers.\n\n6. An operator was observed manually stoppering sterile drug vials and touching product contact surfaces during the process.\n\n7. Your firm exposed a stock solution intended to be sterile to worse than ISO 5 air after the stopper had been punctured multiple times. Specifically, the stock solution was stored in an unclassified area for further use after the container closure system had been punctured multiple times, and therefore compromised, throughout the assigned expiry period.\n\n8. Your firm stores unused product vials in non-sterile plastic bags, which are allowed to be reused in sterile production. The vials stored in these bags are not (b)(4). Moreover, your firm’s temperature and time conditions used for (b)(4) of product vials are not known to be (b)(4) microorganisms.\n\n9. Your firm has not conducted environmental monitoring since 2018.\n\n10. Your aseptic processing and surrounding areas had difficult to clean and visibly dirty equipment or surfaces. For example:\n\na. HEPA filters were discolored and\u002For damaged in the ISO 5 cleanroom hood.\n\nb. Your ISO 5 cleanroom workbench was constructed of laminated wood.\n\nc. A heating vent located below the ISO 5 cleanroom hood was visibly dirty and had no filtering device.\n\n11. Your firm handled hazardous drugs without providing adequate containment, segregation, or cleaning of work surfaces and utensils to prevent cross-contamination.\n\nFurthermore, the manufacture of the ineligible drug products is subject to FDA’s CGMP regulations, Title 21, Code of Federal Regulations (CFR), parts 210 and 211. The FDA investigators observed significant CGMP violations at your facility, causing the ineligible drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations included, for example:\n\n1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\n\n2. Your firm failed to ensure that manufacturing personnel wear clothing appropriate to protect drug product from contamination (21 CFR 211.28(a)).\n\n3. Your firm failed to clean and sterilize and process, where indicated by the nature of the drug, container closures to remove pyrogenic properties to assure they are suitable for their intended use (21 CFR 211.94(c)).\n\n4. Your firm failed to establish a system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\n\n5. Your firm failed to have buildings used in the manufacture, processing, packing, or holding of drug products of a suitable size, construction and location to facilitate cleaning, maintenance, and proper operations (21 CFR 211.42(a)).\n\n6. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\n7. Your firm failed to prepare batch production and control records for each batch of drug product that include documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch (21 CFR 211.188(b)).\n\n8. Your firm failed to retest or reexamine components, as appropriate, for identity, strength, quality, and purity and your quality control unit failed to approve or reject components (21 CFR 211.87).\n\nUnder section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\n\nUnapproved New Drug Products\n\nYou do not have any FDA-approved applications on file for the ineligible drug products that you compounded.3 Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. § 331(d)], a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\n\nMisbranded Drug Products\n\nThe ineligible drug products you compounded are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses.4 Accordingly, these ineligible drug products are misbranded under section 502(f)(1) of the FDCA. The introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA. It is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\n\nD. Corrective Actions\n\nWe have reviewed your firm’s response to the Form FDA 483. We acknowledge that your firm voluntarily ceased sterile production while corrective actions are implemented and, on (b)(4), initiated a voluntary recall of all compounded sterile products within expiry due to a lack of sterility assurance.\n\nRegarding your responses related to the insanitary conditions, some of your corrective actions appear adequate. Furthermore, we acknowledge your intention to install new modular cleanrooms in a separate building on your property to be used for sterile operations in the future. However, we cannot fully evaluate the adequacy of the following corrective actions described in your response because you did not include sufficient information or supporting documentation. For example:\n\n1. Your response to multiple observations includes the creation or revision of procedures and\u002For personnel training. None of the pertinent documentation was provided.\n\n2. You committed to the cessation of pre-filling syringes for shipment to patients. Your response states that staff have been counseled and refresher training on proper aseptic technique would be completed, but no documentation related to this was provided.\n\n3. Your response states that (b)(4), but no further details about the kits were provided. It cannot be determined from the available information if the kits (b)(4).\n\n4. Your response states you intend (b)(4) building which will include (b)(4). No additional information or supporting documentation was provided regarding this renovation; no response updates have been received.\n\n5. Your response states your firm has implemented several corrections such as the (b)(4), and (b)(4). No supporting documentation was provided for those corrective actions. No additional information was provided related to the ISO 5 hood with the laminated work surface, which you stated you are (b)(4).\n\n6. Your response states that you plan to (b)(4), but intend to (b)(4). However, no information was provided about the type of equipment and proposed timeline for this corrective action.\n\n7. Your response states that you would (b)(4) which would be more conducive to maneuvering in the cleanroom. It is unclear whether this is referring to (b)(4) to go inside the hood or beside the hood. If inside, dynamic smoke studies have not been provided to evaluate the effect of the (b)(4) on laminar airflow.\n\nIf outside the hood, employees may continue to have issues reaching in and out of the hood to retrieve needed supplies during sterile operations.\n\n8. Your response did not provide sufficient detail for an evaluation of your corrections related to the handling of hazardous drugs to prevent cross contamination.\n\n9. Your response refers to staff members responsible for administering IVs being allowed to (b)(4). It is unclear which staff members this refers to, where this operation is to occur, and whether those employees will also be conducting (b)(4).\n\nYou did not address certain observations related to insanitary conditions, for example:\n\n1. Your response states that (b)(4) building on the property. The response does not address how or if the current ISO 7\u002F8 suite of rooms will be used in the future.\n\n2. Your response states that (b)(4) units to be installed but does not address the (b)(4) monitoring in your current classified areas.\n\n3. Your response did not address the lack of (b)(4) by your operators during aseptic production.\n\n4. Your response failed to address your lack of routine environmental monitoring.\n\n5. Your response did not address what actions, if any, were taken to ensure the IV hood located in the unclassified room is no longer used.\n\n6. Your response did not address the cleaning and mitigation of the visible drug residues on your current shared equipment that was observed during the inspection.\n\nRegarding your responses related to the insanitary conditions, the following corrective actions appear deficient:\n\n1. Your response states that opened vials will (b)(4) from opening or the date of expiry and the vials will only be (b)(4). Your response did not provide justification for (b)(4). It is unclear if the stoppers for your stock vials, which are prepared in house, are intended for (b)(4). Your response states that employees have been instructed to visually inspect stock solution vials. Visual inspection of (b)(4) vials is not a suitable indicator that the product remains sterile. Your response does not demonstrate how you will prevent contamination when (b)(4), with or without use of (b)(4), are stored outside of an ISO 5 environment.\n\n2. Your firm uses (b)(4) drug product vials; however, your response states you are (b)(4), which would not be suitable for use in (b)(4). It is unclear whether your firm has purchased (b)(4) for sterilization of the product vials. Your response does not address the (b)(4) of product vials. You provided no information demonstrating that the current (b)(4) cycle is adequate. Your response does not address the use of (b)(4) during sterilization or (b)(4) during (b)(4). The use of vials that have not been adequately (b)(4), even if adequately sterilized (b)(4), is not an acceptable practice.\n\nPlease be aware that section 501(a)(2)(A) of the FDCA concerning insanitary conditions applies regardless of whether drug products you compound meet the conditions of section 503A.\n\nShould you continue to compound and distribute drug products that do not meet the conditions of section 503A, the compounding and distribution of such drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the drug CGMP regulations. Before doing so, you must comply with the requirements of section 505 and 502(f)(1) and fully implement corrections that meet the minimum requirements of the CGMP regulations.5\n\nIn addition, it appears you may have been compounding using the bulk drug substance piracetam. Drug products compounded using bulk piracetam are not eligible for the exemptions provided by section 503A(a), because piracetam is not the subject of an applicable USP or NF monograph, not a component of an FDA-approved human drug and does not appear on the 503A bulks list.\n\nFurthermore, it appears that your facility may have produced biological products. Please be advised that federal law does not provide a legal pathway for marketing biological products that have been prepared outside the scope of an approved biologics license application (BLA). Specifically, section 351(a)(1) of the Public Health Service Act (PHS Act) prohibits the introduction into interstate commerce of any biological product unless “a biologics license . . . is in effect for the biological product” (i.e., an approved BLA). Additionally, biological products subject to licensure under section 351 of the PHS Act are not eligible for the exemptions for compounded drugs under sections 503A and 503B of the FDCA. We also note that, as required by the Biologics Price Competition and Innovation Act of 2009, on March 23, 2020, an approved application for a biological product under section 505 of the FDCA was deemed to be a license for the biological product (i.e., an approved BLA) under the PHS Act. This transition affects compounding under sections 503A and 503B of the FDCA because, beginning on March 23, 2020, these biological products that previously could have been submitted in a marketing application under the FD&C Act are subject to licensure under section 351 of the PHS Act and thus are not eligible for the exemptions for compounded drugs under sections 503A and 503B of the FDCA. See Notice to Compounders: Changes that affect compounding as of March 23, 20206 and section 7002(e)(4) of the Biologics Price Competition and Innovation Act of 2009 for additional information. Although these biological products are not eligible for the exemptions in sections 503A and 503B, FDA issued guidance explaining the conditions under which we do not intend to take action when certain biological products are mixed, diluted, or repackaged in a manner not described in their approved labeling. See Guidance for Industry: Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application (available at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F90986\u002Fdownload).\n\nIn addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b)].\n\nFDA strongly recommends that if you decide to resume production of sterile drugs, your management first undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug processing expertise should assist you in conducting this comprehensive evaluation.\n\nLastly, during the inspection, investigators noted that your firm may be exporting products to other countries. Please be advised that if a product meets the FDCA’s requirements for sale and distribution in the United States, the FDCA has no additional restrictions on its exportation (i.e., sections 801 and 802 of the FDCA [21 U.S.C. § 381 and 382] do not apply to such exports). However, if the product does not meet FDCA’s domestic marketing requirements and is intended for export then you are required to be in compliance with applicable sections of the FDCA Chapter VIII – Imports and Exports. Furthermore, other federal statutes or regulations administered by other federal agencies (such as the Department of Commerce) may apply. For further information please see FDA’s Guidance for Industry: Exports Under the FDA Export Reform and Enhancement Act of 1996 (available at: https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fguidance-industry-exports-under-fda-export-reform-and-enhancement-act-1996).\n\nE. Conclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nIf you decide to resume sterile operations, you should take prompt action to correct any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing if you have taken any specific steps to address any violations, or you may inform us that you do not intend to resume production of sterile drugs. If you intend to resume production of sterile drugs in the future, please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. In addition to taking appropriate corrective actions, you should notify this office fifteen (15) working days prior to resuming production of any sterile drugs in the future.\n\nYour written notification should refer to the Warning Letter Number above (615908). Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\n\nAttention: Tina M. Pawlowski, Compliance Officer\n\nU.S. Food and Drug Administration\n\nDivision of Pharmaceutical Quality Operations Division III\n\nIf you have questions regarding the contents of this letter, please contact Tina M. Pawlowski at (313) 393-8217.\n\nSincerely,\n\n\u002FS\u002F\n\nNicholas F. Lyons\n\nActing Program Division Director\n\nDivision of Pharmaceutical Quality Operations Division III\n\n______________________\n\n1 We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FDCA.\n\n2 On June 9, 2016, FDA issued a final guidance titled, Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act. This guidance describes FDA’s interim regulatory policy for State-licensed pharmacies, Federal facilities, and licensed physicians that compound human drug products using bulk drug substances that do not otherwise meet the conditions of section 503A(b)(1)(A)(i) while the 503A bulks list is being developed. Specifically, the guidance sets out the conditions under which FDA does not intend to take action against a State-licensed pharmacy, Federal facility, or licensed physician for compounding a drug product using a bulk drug substance that is not the subject of an applicable USP or NF monograph or a component of an FDA-approved drug, until the substance is identified in a final rule as included or not included on the 503A bulks list. These conditions include that the substance may be eligible for inclusion on the 503A bulks list, was nominated with adequate support for FDA to evaluate it, and has not been identified by FDA as a substance that appears to present significant safety risks pending further evaluation. Cerebrolysin, thymosin alpha, thymosin beta, BPC-157, LL-37, pentosan, Selank, and Semax were not nominated for inclusion on the 503A bulks list. For additional information, see the guidance at http:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM469120.pdf.\n\n3 The specific products made by your firm are drugs within the meaning of section 201(g) of the Act, [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) [21 U.S.C. 321(p)] of the FDCA because they are not generally recognized as safe and effective for their labeled uses.\n\n4 Your ineligible drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).\n\n5 In this letter we do not address whether your proposed corrective actions would resolve the CGMP violations noted above.\n\n6 Available at: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fhuman-drug-compounding\u002Fnotice-compounders-changes-affect-compounding-march-23-2020.","Advanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine","advanced-nutriceuticals-llc-dba-guyer-institute-molecular-medicine-615908-11102021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadvanced-nutriceuticals-llc-dba-guyer-institute-molecular-medicine-615908-11102021","2026-10-26T08:07:50.520086+00:00","2021-11-16","615908","2026-03-17","Leonard D. Guyer, MD","2026-08-20T02:26:18.165+00:00","UPS Next Day","2021-11-10",13,{"510k":272,"classification":273,"enforcement":274,"event":275,"event_backfill":276,"pma":277,"warning_letter":278},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]